Certain chemical entities, compositions and methods

By providing IGF-1R inhibitors with specific structures, the abnormal cell division and cancer problems caused by impaired IGF-1R regulation are solved, and the effective regulation of IGF-1R signaling is achieved, reducing the risk of cancer and autoimmune diseases .

CN118974019APending Publication Date: 2024-11-15RITUON PHARMACEUTICALS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380030753.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-10-27
Filing Date
2023-02-03
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Impaired regulation of IGF-1R is related to abnormal cell division, loss of apoptosis regulation, chromosomal instability and increased cancer incidence. The existing treatments targeting IGF-1R have limited effects.

Method used

An inhibitor of IGF-1R, comprising a compound of a specific structure or a pharmaceutically acceptable salt or solvate thereof, is provided for the treatment of cancer, autoimmune disorders and other conditions, modulates cellular signaling by inhibiting IGF-1R activity. .

Benefits of technology

Effectively inhibit IGF-1R activity, potentially reduce the incidence of cancer and autoimmune diseases, and improve the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005061670860000011
    Figure BDA0005061670860000011
  • Figure BDA0005061670860000171
    Figure BDA0005061670860000171
  • Figure BDA0005061670860000173
    Figure BDA0005061670860000173
Patent Text Reader

Abstract

Provided herein are inhibitors of IGF-1R, pharmaceutical compositions comprising the inhibitory compounds, and methods of using the IGF-1R inhibitory compounds for the treatment of disease.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Patent Application No. 63 / 306,944, filed on February 4, 2022, and U.S. Patent Application No. 63 / 419,988, filed on October 27, 2022, each of which is incorporated herein by reference in its entirety. Background Art

[0003] Impaired regulation of IGF-1R has been associated with abnormal cell division, loss of regulation of apoptosis, chromosomal instability, and increased incidence of cancer. Therefore, therapeutics targeting IGF-1R activity are expected to be useful in the treatment of cancer, autoimmune disorders, and other conditions characterized by abnormal IGF-1R pathway signaling. Summary of the invention

[0004] Provided herein are inhibitors of IGF-1R, pharmaceutical compositions comprising the inhibitory compounds, and methods of using the inhibitory compounds for treating disease.

[0005] One embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof having the structure of formula (I):

[0006]

[0007] in,

[0008] X is optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl;

[0009] L is a bond or optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl or optionally substituted heterocyclylalkyl;

[0010] R 2 is an optionally substituted carbocyclic group, an optionally substituted aryl group, an optionally substituted heteroaryl group or an optionally substituted heterocyclic group; wherein the optional substituent of the optionally substituted carbocyclic group, the optionally substituted aryl group, the optionally substituted heteroaryl group or the optionally substituted heterocyclic group is selected from cyano, halo, hydroxy, azido, amino, nitro, -CO 2 H, -S(O)-R 10 、-SR 10 、-S(O) 2 -R 10, optionally substituted C1-C6 alkoxy, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted (heterocyclyl)-O-, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted C2-C6 alkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, -N(R 11 ) 2 、-CO-R 10 , -CO 2 -R 10 、-CON(R 11 ) 2 、-NR 11 CO-R 10 、-NR 11 CO 2 -R 10 、-SO 2 N(R 11 ) 2 、-C(=NR 12 )-N(R 11 ) 2 、-NR 11 CO-N(R 10 ) 2 or -NR 11 SO 2 -N(R 10 ) 2 ;

[0011] X 3 Is N or CR 3 ;

[0012] X 4 Is N or CR 4 ;

[0013] X 5 Is N or CR 5 ;

[0014] X 6 Is N or CR 6 ;

[0015] X 8 Is N or CR 8 ;

[0016] R 3 , R 4 , R 5 , R 6 and R 8 are independently selected from hydrogen, cyano, halo, hydroxy, azido, amino, nitro, -CO 2 H, -S(O)-R 10 、-SR10 、-S(O) 2 -R 10 , optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted C2-C6 alkenyl, optionally substituted heterocyclyl, -N(R 11 ) 2 、-CO-R 10 , -CO 2 -R 10 、-CON(R 11 ) 2 、-NR 11 CO-R 10 、-NR 11 CO 2 -R 10 、-SO 2 N(R 11 ) 2 、-C(=NR 12 )-N(R 11 ) 2 、-NR 11 CO-N(R 10 ) 2 and-NR 11 SO 2 -N(R 10 ) 2 ;

[0017] Each R 10 independently selected from optionally substituted C1-C6 alkyl, optionally substituted C3-C8 carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl and optionally substituted heteroaryl;

[0018] Each R 11 independently selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;

[0019] R 12 is H or optionally substituted C1-C6 alkyl;

[0020] R 9 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 carbocyclyl or optionally substituted C4-C10 carbocyclylalkyl; wherein R 9 and L or R 9 and X may be taken together with any intervening atoms to form an optionally substituted heterocyclyl ring.

[0021] One embodiment provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and at least one pharmaceutically acceptable excipient.

[0022] One embodiment provides a method of treating a disease or condition in a patient in need thereof, the method comprising administering to the patient a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof. Another embodiment provides a method wherein the disease or condition is selected from cancer, autoimmune disease or thyroid eye disease.

[0023] Incorporation by reference

[0024] All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference for the specific purpose identified herein. DETAILED DESCRIPTION

[0025] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an agent" includes a plurality of such agents, reference to "the cell" includes reference to one or more cells (or reference to a plurality of cells) and equivalents thereof known to those skilled in the art, and so forth. When ranges are used herein for physical properties (such as molecular weight) or chemical properties (such as chemical formulae), all combinations and subcombinations of ranges and specific embodiments thereof are intended to be included. When referring to a number or a numerical range, the term "about" means that the number or numerical range referred to is an approximation within the experimental variability (or within the statistical experimental error), and thus, in some cases, the number or numerical range will vary between 1% and 15% of the stated number or numerical range. The term "comprising" (and related terms such as "comprise" or "comprises" or "having" or "including") is not intended to exclude that in certain other embodiments (e.g., embodiments of any composition of matter, composition, method or process, etc. described herein) "consist of" or "consist essentially of" the described features.

[0026] definition

[0027] As used in the specification and the appended claims, the following terms have the following indicated meanings unless indicated to the contrary.

[0028] “Amino” refers to –NH 2 Group.

[0029] "Cyano" refers to a -CN group.

[0030] "Nitro" refers to -NO 2 Group.

[0031] "Oxa" refers to an -O- group.

[0032] "Oxo" refers to a =0 group.

[0033] "Thio" refers to a =S group.

[0034] "Imino" refers to a =NH group.

[0035] "Oximo" refers to a =N-OH group.

[0036] "Hydrazino" refers to =N-NH 2 Group.

[0037] "Alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to fifteen carbon atoms (e.g., C 1 -C 15 In certain embodiments, an alkyl group contains from one to thirteen carbon atoms (e.g., C 1 -C 13 In certain embodiments, an alkyl group contains from one to eight carbon atoms (e.g., C 1 -C 8 In other embodiments, the alkyl group contains from one to five carbon atoms (e.g., C 1 -C 5 In other embodiments, the alkyl group contains from one to four carbon atoms (e.g., C 1 -C 4 In other embodiments, the alkyl group contains from one to three carbon atoms (e.g., C 1 -C 3 In other embodiments, the alkyl group contains one to two carbon atoms (e.g., C 1 -C 2 In other embodiments, the alkyl group contains one carbon atom (e.g., C 1 In other embodiments, the alkyl group contains five to fifteen carbon atoms (e.g., C 5 -C 15 In other embodiments, the alkyl group contains five to eight carbon atoms (e.g., C 5 -C 8 In other embodiments, the alkyl group contains two to five carbon atoms (e.g., C 2 -C 5 In other embodiments, the alkyl group contains three to five carbon atoms (e.g., C 3 -C 5Alkyl). In other embodiments, the alkyl group is selected from methyl, ethyl, 1-propyl (n-propyl), 1-methylethyl (isopropyl), 1-butyl (n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (isobutyl), 1,1-dimethylethyl (tert-butyl), 1-pentyl (n-pentyl). The alkyl group is connected to the rest of the molecule by a single bond. Unless otherwise specifically stated in the specification, the alkyl group is optionally substituted with one or more of the following substituents: halo, cyano, nitro, oxo, thio, imino, oxime, trimethylsilyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a ) 2 、-C(O)R a 、-C(O)OR a 、-C(O)N(R a ) 2 、-N(R a )C(O)OR a 、-OC(O)-N(R a ) 2 、-N(R a )C(O)R a 、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2) and -S(O) t N(R a ) 2 (where t is 1 or 2), where each R a In some embodiments, the alkyl group optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), fluoroalkyl, carbocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), carbocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl) or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl). In certain embodiments, the alkyl group optionally substituted with halogen is haloalkyl. In other embodiments, the alkyl group optionally substituted with fluoroalkyl is -CF3 Group.

[0038] "Alkoxy" refers to a group of the formula -O-alkyl bonded through an oxygen atom, wherein alkyl is an alkyl chain as defined above.

[0039] "Alkenyl" refers to a straight or branched hydrocarbon chain group consisting only of carbon and hydrogen atoms, containing at least one carbon-carbon double bond and having two to twelve carbon atoms. In certain embodiments, alkenyl comprises two to eight carbon atoms. In other embodiments, alkenyl comprises two to four carbon atoms. Alkenyl is connected to the rest of the molecule by a single bond, such as ethenyl (i.e., vinyl (vinyl)), prop-1-enyl (i.e., allyl), but-1-enyl, penta-1-enyl, penta-1,4-dienyl, etc. Unless otherwise specifically stated in the specification, alkenyl groups are optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thio, imino, oxime, trimethylsilyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a ) 2 、-C(O)R a 、-C(O)OR a 、-C(O)N(R a ) 2 、-N(R a )C(O)OR a 、-OC(O)-N(R a ) 2 、-N(R a )C(O)R a 、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2) and -S(O) t N(R a ) 2 (where t is 1 or 2), where R aEach is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), fluoroalkyl, carbocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), carbocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl) or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl).

[0040] "Alkynyl" refers to a straight or branched hydrocarbon chain group consisting only of carbon and hydrogen atoms, containing at least one carbon-carbon triple bond and having two to twelve carbon atoms. In certain embodiments, the alkynyl group comprises two to eight carbon atoms. In other embodiments, the alkynyl group comprises two to six carbon atoms. In other embodiments, the alkynyl group comprises two to four carbon atoms. The alkynyl group is connected to the rest of the molecule by a single bond, such as ethynyl, propynyl, butynyl, pentynyl, hexynyl, etc. Unless otherwise specifically stated in the specification, the alkynyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thio, imino, oxime, trimethylsilyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a ) 2 、-C(O)R a 、-C(O)OR a 、-C(O)N(R a ) 2 、-N(R a )C(O)OR a 、-OC(O)-N(R a ) 2 、-N(R a )C(O)R a 、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2) and -S(O) t N(R a ) 2 (where t is 1 or 2), where each R aand R is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), fluoroalkyl, carbocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), carbocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl) or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl).

[0041] "Alkylene" or "alkylene chain" refers to a straight or branched divalent hydrocarbon chain consisting only of carbon and hydrogen that connects the rest of the molecule to a radical, contains no unsaturation, and has one to twelve carbon atoms, such as methylene, ethylene, propylene, n-butylene, etc. The alkylene chain is connected to the rest of the molecule by a single bond and to the radical by a single bond. The point of attachment of the alkylene chain to the rest of the molecule and to the radical is through one carbon in the alkylene chain or through any two carbons in the chain. In certain embodiments, an alkylene group contains one to eight carbon atoms (e.g., C 1 -C 8 In other embodiments, the alkylene group contains one to five carbon atoms (e.g., C 1 -C 5 In other embodiments, the alkylene group contains one to four carbon atoms (e.g., C 1 -C 4 In other embodiments, the alkylene group contains one to three carbon atoms (e.g., C 1 -C 3 In other embodiments, the alkylene group contains one to two carbon atoms (e.g., C 1 -C 2 In other embodiments, the alkylene group contains one carbon atom (e.g., C 1 In other embodiments, the alkylene group contains five to eight carbon atoms (e.g., C 5 -C 8 In other embodiments, the alkylene group contains two to five carbon atoms (e.g., C 2 -C 5 In other embodiments, the alkylene group contains three to five carbon atoms (e.g., C 3 -C 5Unless stated otherwise specifically in the specification, an alkylene chain is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thio, imino, oxime, trimethylsilyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a ) 2 、-C(O)R a 、-C(O)OR a 、-C(O)N(R a ) 2 、-N(R a )C(O)OR a 、-OC(O)-N(R a ) 2 、-N(R a )C(O)R a 、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2) and -S(O) t N(R a ) 2 (where t is 1 or 2), where each R a and R is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), fluoroalkyl, carbocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), carbocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl) or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl).

[0042] "Alkenylene" or "alkenylene chain" refers to a straight or branched divalent hydrocarbon chain consisting only of carbon and hydrogen that connects the rest of the molecule to a radical, contains at least one carbon-carbon double bond, and has from one to twelve carbon atoms. The alkenylene chain is connected to the rest of the molecule by a single bond and to the radical by a single bond. In certain embodiments, an alkenylene group comprises two to eight carbon atoms (e.g., C 2 -C 8In other embodiments, the alkenylene group contains two to five carbon atoms (e.g., C 2 -C 5 In other embodiments, the alkenylene group contains two to four carbon atoms (e.g., C 2 -C 4 In other embodiments, the alkenylene group contains two to three carbon atoms (e.g., C 2 -C 3 In other embodiments, the alkenylene group contains two carbon atoms (e.g., C 2 In other embodiments, the alkenylene group contains five to eight carbon atoms (e.g., C 5 -C 8 In other embodiments, the alkenylene group contains three to five carbon atoms (e.g., C 3 -C 5 Unless stated otherwise specifically in the specification, an alkenylene chain is optionally substituted with one or more of the following substituents: halo, cyano, nitro, oxo, thio, imino, oxime, trimethylsilyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a ) 2 、-C(O)R a 、-C(O)OR a 、-C(O)N(R a ) 2 、-N(R a )C(O)OR a 、-OC(O)-N(R a ) 2 、-N(R a )C(O)R a 、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2) and -S(O) t N(R a ) 2 (where t is 1 or 2), where each R aand R is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), fluoroalkyl, carbocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), carbocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl) or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl).

[0043] "Alkynylene" or "alkynylene chain" refers to a straight or branched divalent hydrocarbon chain consisting solely of carbon and hydrogen that connects the rest of the molecule to a radical, contains at least one carbon-carbon triple bond, and has from one to twelve carbon atoms. The alkynylene chain is connected to the rest of the molecule by a single bond and to the radical by a single bond. In certain embodiments, an alkynylene group comprises two to eight carbon atoms (e.g., C 2 -C 8 In other embodiments, the alkynylene group contains two to five carbon atoms (e.g., C 2 -C 5 In other embodiments, the alkynylene group contains two to four carbon atoms (e.g., C 2 -C 4 In other embodiments, the alkynylene group contains two to three carbon atoms (e.g., C 2 -C 3 In other embodiments, the alkynylene group contains two carbon atoms (e.g., C 2 In other embodiments, the alkynylene group contains five to eight carbon atoms (e.g., C 5 -C 8 In other embodiments, the alkynylene group contains three to five carbon atoms (e.g., C 3 -C 5 Unless stated otherwise specifically in the specification, an alkynylene chain is optionally substituted with one or more of the following substituents: halo, cyano, nitro, oxo, thio, imino, oxime, trimethylsilyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a ) 2 、-C(O)R a 、-C(O)OR a 、-C(O)N(R a ) 2、-N(R a )C(O)OR a 、-OC(O)-N(R a ) 2 、-N(R a )C(O)R a 、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2) and -S(O) t N(R a ) 2 (where t is 1 or 2), where each R a and R is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), fluoroalkyl, carbocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), carbocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl) or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl).

[0044] "Aryl" refers to a group derived from an aromatic monocyclic or polycyclic hydrocarbon ring system by removing hydrogen atoms from ring carbon atoms. An aromatic monocyclic or polycyclic hydrocarbon ring system contains only hydrogen and carbons of five to eighteen carbon atoms, wherein at least one ring in the ring system is fully unsaturated, i.e., according to Hückel theory, it contains a cyclic, delocalized (4n+2)π-electron system. Ring systems from which aryl groups are derived include, but are not limited to, groups such as benzene, fluorene, indane, indene, tetralin and naphthalene. Unless otherwise specifically stated in the specification, the term "aryl" or the prefix "ar-" (such as in "aralkyl") is intended to include aryl groups optionally substituted by one or more substituents independently selected from the following: optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, halo, cyano, nitro, -R b -OR a , -R b -OC(O)-R a , -R b -OC(O)-OR a , -R b-OC(O)-N(R a ) 2 , -R b -N(R a ) 2 , -R b -C(O)R a , -R b -C(O)OR a , -R b -C(O)N(R a ) 2 , -R b -OR c -C(O)N(R a ) 2 , -R b -N(R a )C(O)OR a , -R b -N(R a )C(O)R a , -R b -N(R a )S(O) t R a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(R a ) 2 (where t is 1 or 2), where each R a R is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), cycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl) or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), each R b are independently a direct bond or a straight or branched alkylene or alkenylene chain, and R c is a straight or branched alkylene or alkenylene chain, and wherein unless otherwise specified, Ra , R b or R c Each of the substituents is unsubstituted.

[0045] "Arylalkyl" refers to a group of the formula -R c -aryl radical, wherein R c is an alkylene chain as defined above, for example methylene, ethylene, etc. The alkylene chain part of the aralkyl group is optionally substituted as described above for alkylene chains. The aryl part of the aralkyl group is optionally substituted as described above for aryl groups.

[0046] "Aralkenyl" refers to a group of the formula -R d -aryl radical, wherein R d is an alkenylene chain as defined above. The aryl part of the aralkenyl group is optionally substituted as described above for aryl groups. The alkenylene chain part of the aralkenyl group is optionally substituted as defined above for alkenylene groups.

[0047] "Arylalkynyl" refers to a group of the formula -R e -aryl radical, wherein R e is an alkynylene chain as defined above. The aryl part of the aralkynyl group is optionally substituted as described above for aryl groups. The alkynylene chain part of the aralkynyl group is optionally substituted as defined above for alkynylene chains.

[0048] "Aralkyloxy" refers to a radical of the formula -OR c -aryl radical, wherein R c is an alkylene chain as defined above, for example methylene, ethylene, etc. The alkylene chain part of the aralkyl group is optionally substituted as described above for alkylene chains. The aryl part of the aralkyl group is optionally substituted as described above for aryl groups.

[0049] "Carbocyclyl" refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon group consisting only of carbon and hydrogen atoms, including condensed rings or bridged ring systems, with three to fifteen carbon atoms. In certain embodiments, the carbocyclyl comprises three to ten carbon atoms. In other embodiments, the carbocyclyl comprises five to seven carbon atoms. The carbocyclyl is connected to the rest of the molecule by a single bond. The carbocyclyl is saturated (i.e., only containing a single C-C bond) or unsaturated (i.e., containing one or more double bonds or triple bonds). Fully saturated carbocyclyl groups are also referred to as "cycloalkyl". Examples of monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. Unsaturated carbocyclyl is also referred to as "cycloalkenyl". Examples of monocyclic cycloalkenyls include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl. Polycyclic carbocyclyl groups include, for example, adamantyl, norbornyl (i.e., bicyclo[2.2.1]heptyl), norbornenyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptyl, etc. Unless otherwise specifically stated in the specification, the term "carbocyclyl" is intended to include carbocyclyl groups optionally substituted by one or more substituents independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, halo, oxo, thio, cyano, nitro, -R b -OR a , -R b -OC(O)-R a , -R b -OC(O)-OR a , -R b -OC(O)-N(R a ) 2 , -R b -N(R a ) 2 , -R b -C(O)R a , -R b -C(O)OR a , -R b -C(O)N(R a ) 2 , -R b -OR c -C(O)N(R a ) 2 , -R b -N(R a )C(O)OR a , -R b -N(R a )C(O)R a , -R b -N(R a )S(O) t R a(where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(R a ) 2 (where t is 1 or 2), where each R a R is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), cycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl) or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), each R b are independently a direct bond or a straight or branched alkylene or alkenylene chain, and R c is a straight or branched alkylene or alkenylene chain, and wherein unless otherwise specified, R a , R b or R c Each of the substituents is unsubstituted.

[0050] "Carbocyclylalkyl" refers to a group of the formula -R c -Carbocyclic group, where R c is an alkylene chain as defined above. The alkylene chain and the carbocyclyl group are optionally substituted as defined above.

[0051] "Carbocyclylalkynyl" refers to a group of the formula -R c -Carbocyclic group, where R c is an alkynylene chain as defined above. The alkynylene chain and the carbocyclyl group are optionally substituted as defined above.

[0052] "Carbocyclylalkoxy" refers to a radical of the formula -OR bonded through an oxygen atom. c -Carbocyclic group, where R c is an alkylene chain as defined above. The alkylene chain and the carbocyclyl group are optionally substituted as defined above.

[0053] "Halo" or "halogen" refers to a bromo, chloro, fluoro, or iodo substituent.

[0054] "Fluoroalkyl" refers to an alkyl group as defined above substituted with one or more fluoro groups as defined above, for example, trifluoromethyl, difluoromethyl, fluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, etc. In some embodiments, the alkyl portion of the fluoroalkyl group is optionally substituted as defined above for an alkyl group.

[0055] "Heterocyclyl" refers to a stable 3- to 18-membered non-aromatic ring group containing two to twelve carbon atoms and one to six heteroatoms selected from nitrogen, oxygen and sulfur. Unless otherwise specifically stated in the specification, the heterocyclyl group is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which optionally includes a fused ring or a bridged ring system. The heteroatoms in the heterocyclyl group are optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heterocyclyl group is partially or completely saturated. The heterocyclyl group is connected to the rest of the molecule through any atom of the ring. Examples of such heterocyclyl groups include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidine, thiazolidinyl, tetrahydrofuranyl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless otherwise specifically stated in the specification, the term "heterocyclyl" is intended to include heterocyclyl groups as defined above, which are optionally substituted by one or more substituents selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, -R b -OR a , -R b -OC(O)-R a , -R b -OC(O)-OR a , -R b -OC(O)-N(R a ) 2 , -R b -N(R a ) 2 , -R b -C(O)R a , -R b -C(O)OR a , -R b -C(O)N(R a ) 2 , -R b -OR c-C(O)N(R a ) 2 , -R b -N(R a )C(O)OR a , -R b -N(R a )C(O)R a , -R b -N(R a )S(O) t R a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(R a ) 2 (where t is 1 or 2), where each R a R is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), cycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl) or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), each R b are independently a direct bond or a straight or branched alkylene or alkenylene chain, and R c is a straight or branched alkylene or alkenylene chain, and wherein unless otherwise specified, R a , R b or R c Each of the substituents is unsubstituted.

[0056] "N-heterocyclyl" or "N-attached heterocyclyl" refers to a heterocyclyl group as defined above containing at least one nitrogen, and wherein the point of attachment of the heterocyclyl group to the rest of the molecule is through the nitrogen atom in the heterocyclyl group. N-heterocyclyl groups are optionally substituted as described above for heterocyclyl groups. Examples of such N-heterocyclyl groups include, but are not limited to, 1-morpholinyl, 1-piperidinyl, 1-piperazinyl, 1-pyrrolidinyl, pyrazolidinyl, imidazolinyl, and imidazolidinyl.

[0057] "C-heterocyclyl" or "C-attached heterocyclyl" refers to a heterocyclyl as defined above containing at least one heteroatom and wherein the point of attachment of the heterocyclyl group to the rest of the molecule is through a carbon atom in the heterocyclyl group. C-heterocyclyl groups are optionally substituted as described above for heterocyclyl groups. Examples of such C-heterocyclyl groups include, but are not limited to, 2-morpholinyl, 2- or 3- or 4-piperidinyl, 2-piperazinyl, 2- or 3-pyrrolidinyl, and the like.

[0058] "Heterocyclylalkyl" refers to a group of the formula -R c -heterocyclic group, wherein R c is an alkylene chain as defined above. If the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl is optionally connected to the alkyl group at the nitrogen atom. The alkylene chain of the heterocyclylalkyl group is optionally substituted as defined above for the alkylene chain. The heterocyclyl moiety of the heterocyclylalkyl group is optionally substituted as defined above for the heterocyclyl group.

[0059] "Heterocyclylalkoxy" refers to a radical of the formula -OR bonded through an oxygen atom. c -heterocyclic group, wherein R c is an alkylene chain as defined above. If the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl is optionally connected to the alkyl group at the nitrogen atom. The alkylene chain of the heterocyclylalkoxy group is optionally substituted as defined above for the alkylene chain. The heterocyclyl moiety of the heterocyclylalkoxy group is optionally substituted as defined above for the heterocyclyl group.

[0060] "Heteroaryl" refers to a group derived from a 3- to 18-membered aromatic ring group containing two to seventeen carbon atoms and one to six heteroatoms selected from nitrogen, oxygen and sulfur. As used herein, a heteroaryl group is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, wherein at least one ring in the ring system is fully unsaturated, i.e., according to Hückel theory, it contains a cyclic, delocalized (4n+2)π-electron system. Heteroaryl includes fused or bridged ring systems. The heteroatoms in the heteroaryl group are optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heteroaryl group is connected to the rest of the molecule through any atom of the ring.Examples of heteroaryl groups include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzofuranyl, benzoxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepyl, benzo[b][1,4]oxazinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyrone, benzofuranyl, benzofuranone, benzothiophenyl (benzothienyl), benzothieno[3,2-d]pyrimidinyl, benzotriazolyl, benzo[4,6]imidazo[ 1,2-a]pyridinyl, carbazolyl, cinnolinyl, cyclopenta[d]pyrimidinyl, 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, 5,6-dihydrobenzo[h]quinazolinyl, 5,6-dihydrobenzo[h]cinnolinyl, 6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazinyl, dibenzofuranyl, dibenzophenylthio, furanyl, furanonyl, furano[3,2-c]pyridinyl, 5,6,7,8,9,10-hexahydrocyclooctano[d]pyrimidinyl, 5,6,7,8,9,10-hexahydrocyclooctano[d]pyridazinyl, 5,6,7,8,9,10-hexahydrocyclooctano[d]pyridazinyl, [d]pyridinyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolyl, isoquinolinyl, indolizinyl, isoxazolyl, 5,8-methano-5,6,7,8-tetrahydroquinazolinyl, naphthyridinyl, 1,6-naphthyridinonyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 5,6,6a,7,8,9,10,10a-octahydrobenzo[h]quinazolinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyrazolo[3,4-d]pyrimidinyl, pyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido [3,4-d]pyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, 5,6,7,8-tetrahydroquinazolinyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, 6,7,8,9-tetrahydro-5Hcyclohepta[4,5]thieno[2,3-d]pyrimidinyl, 5,6,7,8-tetrahydropyrido[4,5-c]pyridazinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-c]pyridinyl, and thiophenol (i.e., thienyl).Unless otherwise specifically stated in the specification, the term "heteroaryl" is intended to include heteroaryl groups as defined above, optionally substituted with one or more substituents selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, halo, optionally substituted fluoroalkyl, optionally substituted haloalkenyl, optionally substituted haloalkynyl, oxo, thioxo, cyano, nitro, -R. b -OR a , -R b -OC(O)-R a , -R b -OC(O)-OR a , -R b -OC(O)-N(R a ) 2 , -R b -N(R a ) 2 , -R b -C(O)R a , -R b -C(O)OR a , -R b -C(O)N(R a ) 2 , -R b -OR c -C(O)N(R a ) 2 , -R b -N(R a )C(O)OR a , -R b -N(R a )C(O)R a , -R b -N(R a )S(O) t R a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(R a ) 2 (where t is 1 or 2), where each R aR is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), cycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl) or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), each R b are independently a direct bond or a straight or branched alkylene or alkenylene chain, and R c is a straight or branched alkylene or alkenylene chain, and wherein unless otherwise specified, R a , R b or R c Each of the substituents is unsubstituted.

[0061] "N-heteroaryl" refers to a heteroaryl group as defined above containing at least one nitrogen, wherein the point of attachment of the heteroaryl group to the rest of the molecule is through the nitrogen atom in the heteroaryl group. N-heteroaryl groups are optionally substituted as described above for heteroaryl groups.

[0062] "C-heteroaryl" refers to a heteroaryl group as defined above, wherein the point of attachment of the heteroaryl group to the rest of the molecule is through a carbon atom in the heteroaryl group. A C-heteroaryl group is optionally substituted as described above for a heteroaryl group.

[0063] "Heteroarylalkyl" refers to a group of the formula -R c -heteroaryl radical, wherein R c is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the heteroaryl is optionally connected to the alkyl group at the nitrogen atom. The alkylene chain of the heteroarylalkyl group is optionally substituted as defined above for the alkylene chain. The heteroaryl moiety of the heteroarylalkyl group is optionally substituted as defined above for the heteroaryl group.

[0064] "Heteroarylalkoxy" refers to a radical of the formula -OR bonded through an oxygen atom. c -heteroaryl radical, wherein R c is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the heteroaryl is optionally connected to the alkyl group at the nitrogen atom. The alkylene chain of the heteroarylalkoxy group is optionally substituted as defined above for the alkylene chain. The heteroaryl moiety of the heteroarylalkoxy group is optionally substituted as defined above for the heteroaryl group.

[0065] In some embodiments, the compounds disclosed herein contain one or more asymmetric centers, thus producing enantiomers, diastereomers and other stereoisomeric forms, which are defined as (R)- or (S)- according to absolute stereochemistry. Unless otherwise indicated, the disclosure is intended to consider all stereoisomeric forms of the compounds disclosed herein. When the compounds described herein contain olefin double bonds, and unless otherwise indicated, the disclosure is intended to include both E and Z geometric isomers (e.g., cis or trans). Similarly, all possible isomers and their racemic and optically pure forms and all tautomeric forms are also intended to be included. The term "geometric isomer" refers to E or Z geometric isomers (e.g., cis or trans) of olefin double bonds. The term "positional isomer" refers to structural isomers around a central ring, such as ortho, meta and para isomers around a benzene ring.

[0066] As used herein, "carboxylic acid bioisostere" refers to a functional group or moiety that exhibits physical, biological, and / or chemical properties similar to a carboxylic acid moiety. Examples of carboxylic acid bioisosteres include, but are not limited to:

[0067]

[0068] wait.

[0069] "Tautomers" refers to molecules in which a proton can move from one atom of a molecule to another atom of the same molecule. In certain embodiments, the compounds described herein exist as tautomers. Where tautomerization is possible, a chemical equilibrium of tautomers will exist. The exact ratio of tautomers depends on several factors, including physical state, temperature, solvent, and pH. Some examples of tautomeric equilibrium include:

[0070]

[0071] In some embodiments, the compounds disclosed herein are used in different isotopically enriched forms, such as 2 H. 3 H. 11 C. 13 C and / or 14 C content. In a specific embodiment, the compound is deuterated at at least one position. Such deuterated forms can be prepared by the methods described in U.S. Patent Nos. 5,846,514 and 6,334,997. As described in U.S. Patent Nos. 5,846,514 and 6,334,997, deuteration can improve metabolic stability and / or efficacy, thereby increasing the duration of drug action.

[0072] Unless otherwise stated, structures depicted herein are intended to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, except for the replacement of hydrogen by deuterium or tritium or the replacement of carbon by 13 C- or 14 Compounds having the present structures other than C-enriched carbon substitutions are within the scope of this disclosure.

[0073] The compounds of the present disclosure optionally contain unnatural proportions of atomic isotopes at one or more atoms that constitute such compounds. For example, the compounds may be labeled with isotopes, such as, for example, deuterium ( 2 H), tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C) Use 2 H. 11 C. 13 C. 14 C. 15 C. 12 N. 13 N. 15 N. 16 N. 16 O. 17 O. 14 F. 15 F. 16 F. 17 F. 18 F. 33 S. 34 S. 35 S. 36 S. 35 Cl, 37 Cl, 79 Br, 81 Br, 125 Isotopic substitutions of I are contemplated. In some embodiments, 18 Isotopic substitution of F is contemplated. All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.

[0074] In certain embodiments, some or all of the compounds disclosed herein 1 H atoms are 2 H atom substitution. Methods for the synthesis of deuterium containing compounds are known in the art and include the following synthetic methods by way of non-limiting example only.

[0075] Deuterium substituted compounds are synthesized using various methods, such as described in: Dean, Dennis C., ed., Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development. [Curr., Pharm. Des., 2000; 6 (10)] 2000, p. 110; George W.; Varma, Rajender S. The Synthesis of Radiolabeled Compounds via Organometallic Intermediates, Tetrahedron, 1989, 45 (21), 6601-21; and Evans, E. Anthony. Synthesis of radiolabeled compounds, J. Radioanal. Chem., 1981, 64 (1-2), 9-32.

[0076] Deuterated starting materials are readily available and are subject to the synthetic methods described herein to provide the synthesis of deuterated compounds. A large number of deuterated reagents and building blocks are commercially available from chemical suppliers such as Aldrich Chemical Co.

[0077] Deuterium transfer reagents suitable for nucleophilic substitution reactions such as iodomethane-d 3 (CD 3 I) is readily available and can be used to transfer deuterium-substituted carbon atoms to reaction substrates under nucleophilic substitution reaction conditions. 3 The use of I is illustrated in the following reaction schemes by way of example only.

[0078]

[0079] Deuterium transfer reagents such as lithium aluminum deuteride (LiAlD 4 ) is used to transfer deuterium to the reaction substrate under reducing conditions. The following reaction scheme only illustrates LiAlD 4 Use of.

[0080]

[0081] Deuterium gas and palladium catalysts are used to reduce unsaturated carbon-carbon bonds and to effect reductive substitution of aromatic carbon-halogen bonds, as illustrated by way of example only in the following reaction schemes.

[0082]

[0083] In one embodiment, the compounds disclosed herein contain one deuterium atom. In another embodiment, the compounds disclosed herein contain two deuterium atoms. In another embodiment, the compounds disclosed herein contain three deuterium atoms. In another embodiment, the compounds disclosed herein contain four deuterium atoms. In another embodiment, the compounds disclosed herein contain five deuterium atoms. In another embodiment, the compounds disclosed herein contain six deuterium atoms. In another embodiment, the compounds disclosed herein contain more than six deuterium atoms. In another embodiment, the compounds disclosed herein are completely substituted with deuterium atoms and do not contain non-exchangeable 1 H hydrogen atom. In one embodiment, the deuterium incorporation level is determined by a synthesis method in which deuterated synthetic building blocks are used as starting materials.

[0084] "Pharmaceutically acceptable salts" include both acid addition salts and base addition salts. Pharmaceutically acceptable salts of any of the IGF-1R inhibitory compounds described herein are intended to encompass any and all pharmaceutically suitable salt forms. Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.

[0085] "Pharmaceutically acceptable acid addition salts" refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphorous acid, and the like. Also included are salts formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, and the like, and include, for example, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Thus, exemplary salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, octanoates, isobutyrates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, methanesulfonates, etc. Also contemplated are salts of amino acids such as arginates, gluconates, and galacturonates (see, e.g., Berge SM et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 66: 1-19 (1997)). In some embodiments, the acid addition salts of basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt according to methods and techniques familiar to those skilled in the art.

[0086] "Pharmaceutically acceptable base addition salts" refer to those salts which retain the biological effectiveness and properties of the free acids and which are not biologically or otherwise undesirable. These salts are prepared by adding inorganic or organic bases to the free acids. In some embodiments, pharmaceutically acceptable base addition salts are formed with metals or amines such as alkali metals and alkaline earth metals or organic amines. Salts derived from inorganic bases include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, and the like. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines (including naturally occurring substituted amines), cyclic amines, and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, N,N-dibenzylethylenediamine, chloroprocaine, hepamine, choline, betaine, ethylenediamine, ethylenedianiline, N-methylglucamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like. See Berge et al., supra.

[0087] "Pharmaceutically acceptable solvate" refers to a composition of matter in the form of a solvent addition. In some embodiments, the solvate contains a stoichiometric or non-stoichiometric amount of a solvent and is formed during preparation with a pharmaceutically acceptable solvent such as water, ethanol, etc. Hydrates are formed when the solvent is water or alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein are conveniently prepared or formed in the processes described herein. The compounds provided herein exist in unsolvated or solvated forms.

[0088] The term "subject" or "patient" includes mammals. Examples of mammals include, but are not limited to, any member of the class Mammalia: humans, non-human primates such as chimpanzees and other apes and monkeys; farm animals such as cattle, horses, sheep, goats, pigs; domestic animals such as rabbits, dogs and cats; experimental animals including rodents such as rats, mice and guinea pigs, etc. In one aspect, the mammal is a human.

[0089] As used herein, "treatment" or "treating" or "palliating" or "ameliorating" are used interchangeably. These terms refer to methods of obtaining beneficial or desired results, including but not limited to therapeutic benefit and / or preventive benefit. "Therapeutic benefit" refers to the eradication or amelioration of the underlying condition being treated. In addition, therapeutic benefit is achieved by eradication or amelioration of one or more physiological symptoms associated with the underlying condition, such that an improvement is observed in the patient, even though the patient still suffers from the underlying condition. In some embodiments, for preventive benefit, the composition is administered to a patient at risk of developing a particular disease, or to a patient reporting one or more physiological symptoms of a disease, even if a diagnosis of the disease has not yet been made.

[0090] IGF-1R tyrosine kinase

[0091] Insulin-like growth factor receptor type 1 (IGF-1R) is a transmembrane class II receptor tyrosine kinase (RTK) belonging to the insulin receptor family and plays a vital role in differentiation, cell growth and cell survival. Signal transduction through IGF-1R is the main pathway responsible for somatic cell growth in mammals during the fetal period, while somatic cell growth in postnatal animals is achieved through the synergistic action of growth hormone (GH) and insulin-like growth factors (IGF1 and IGF2). IGF-1R expression is common in many different cell types. Granular cytoplasmic protein expression is common in human cells, and IGF-1R endocytosis and transport to specific subcellular locations during signal transduction define the nature of specific signal transduction responses, which are critical during normal and pathological cell processes. Dysregulation of IGF-1R signal transduction and function is associated with human diseases, including cancer and growth retardation during development. IGF1 signal transduction continues to have anabolic effects in adulthood, and this signal transduction pathway additionally affects the aging process. Specific developmental functions of IGF-IR have also been elucidated, such as region-specific regulation of axonal growth in medial forebrain regions including the hippocampus and cingulate cortex.

[0092] IGF-1R has been shown to play a key role in cellular transformation events. It is highly overexpressed in a variety of malignant tissues, where it functions as an anti-apoptotic agent by enhancing cell survival. Elevated IGF-1R expression has been associated with transformation in cancers of breast, ovarian, prostate, colon, and lung tissues, as well as in rhabdomyosarcomas, melanomas, and gliomas.

[0093] The IGF-1R gene is located on chromosome 15q26.3. The IGF-1R gene contains 21 exons and spans approximately 100 kb. The promoter region of IGF-1R contains many potential SP1 and AP2 binding sites and thyroid response elements, but no TATA or CCAAT elements. It is expressed as multiple mRNA transcripts, the most abundant of which is 12 kb, followed by several shorter transcripts of 7 kb and 6.4 kb. Of the 12 kb IGF-1R mRNA transcript, 1 kb is the 5'-UTR, 4 kb is the coding sequence, and 7 kb is the 3'-UTR. The protein product of this gene is the insulin-like growth factor 1 (IGF-1) receptor. An alternative human IGF-1R mRNA transcript can be expressed in which a three-base pair (CAG) deletion results in an Arg substitution for Thr898Gly899 eight residues upstream from the start of the transmembrane region of IGF-1R. This CAG- isoform displays reduced internalization and enhanced signaling properties compared to the CAG+ isoform.

[0094] Transcriptional regulation of IGF-1R is controlled by a complex interplay involving DNA-binding and non-DNA-binding transcription factors. Stimulatory nuclear proteins including zinc finger protein Sp1, EWS-WT1, E2F1, Krüppel-like factor-6 (KLF6), and high mobility group A1 (HMGA1) promote IGF-1R expression. Many tumor suppressors, including breast cancer gene-1 (BRCA1), p53, Wilm's tumor protein-1 (WT1), and von Hippel–Lindau gene (VHL), also regulate the IGF-1R locus. Loss of tumor suppressor function can derepress IGF-1R expression, resulting in increased IGF signaling. This impaired regulation of IGF-1R is associated with abnormal cell division, loss of apoptosis regulation, chromosomal instability, and increased cancer incidence. The p53 gene, the most commonly mutated gene in human cancer, functions as a nuclear transcription factor that blocks cell cycle progression and induces apoptosis. Wild-type p53 acts to repress transcriptional activation of the IGF-1R promoter, whereas mutant p53 can have a stimulatory effect on IGF-1R promoter activity. Due to the central role of insulin-like growth factor signaling in cell cycle progression and cell transformation, derepression of the IGF-1R promoter constitutes an important paradigm in tumorigenesis.

[0095] After translation, IGF-1R is a receptor precursor of 1,367 amino acids, including a 30-residue signal peptide that is removed during the translocation of the nascent polypeptide chain. The cleavage of the precursor produces α and β subunits. Two α subunits and two β subunits constitute the IGF-1 receptor. Both α and β subunits are synthesized by a single mRNA precursor. Then, the precursor is glycosylated, proteolytically cleaved, and cross-linked by cysteine ​​bonds to form functional transmembrane αβ chains. After transport to the plasma membrane, the two α chains are located outside the cell, while the β subunits span the membrane and perform intracellular signal transduction under ligand stimulation. The extracellular domain of IGF-1R has an arrangement of two homologous domains (L1 and L2), which are separated by a cysteine-rich furin-like region. Each L domain (L1 spanning residues 1-150 and L2 spanning residues 300-460) consists of five half-leucine-rich repeats and is a member of the leucine-rich repeat superfamily. The C-terminal half of their extracellular domain consists of three fibronectin type 3 repeats and an insertion domain containing an α-β cleavage site. There is a single transmembrane sequence in IGF-1R (residues 906-929). The cytoplasmic portion of IGF-1R consists of a tyrosine kinase catalytic domain (which is flanked by juxtamembrane and C-tail regions) that serves as a binding site for various signaling molecules. The cytoplasmic domain containing the tyrosine kinase domain (residues 930-1337) spans 408 amino acid residues.

[0096] The main feature that distinguishes IGF-1R and its related family members from most other receptor tyrosine kinase families is that they exist on the cell surface as constitutive disulfide-linked dimers and require domain rearrangements rather than receptor oligomerization for cell signaling. Recent studies on signal transduction have shown that ligand-triggered structural changes in the extracellular domain, followed by transmembrane domain closure and dimerization, lead to trans-autophosphorylation and kinase activity of the intracellular segment of IGF-1R. Ligand binding results in conformational changes that bring the most distal ends of the fibronectin type 3 repeats closer together, followed by dimerization of the transmembrane segments within the lipid bilayer. In its basal state, one of the three tyrosines in the activation loop (A-loop), Tyr1162, is bound in the active site but cannot be cis-phosphorylated because part of the A-loop interferes with the ATP-binding site and the catalytic Asp1150 is not properly positioned to coordinate MgATP. Upon activation, Tyr1162, Tyr1158, and Tyr1163 are trans-autophosphorylated by the kinase domain of the second monomer. Thus, in the basal state, Tyr1162 competes with the adjacent β-chain for binding to the active site, but is not cis-phosphorylated due to steric constraints that prevent simultaneous binding of Tyr1162 and MgATP. Autophosphorylation of the three tyrosines in the A-loop results in a dramatic change in conformation, activating the kinase domain.

[0097] Three ligands have been identified as mediating signaling through IGF-1R. These ligands are insulin-like growth factor (IGF1), insulin-like growth factor 2 (IGF2), and insulin. IGF-1R binds its endogenous ligands in the following order of affinity: IGF1 with the highest affinity, IGF2 with lower affinity, and insulin with weak affinity. The biological activity of IGF1 and IGF2 is regulated by a family of six IGF binding proteins. These binding proteins regulate the transport and bioavailability of IGFs and also compete with IGFs for binding to IGF-1R. Two ligand binding sites are present in the extracellular portion of each αβ dimer of IGF-1R. The IGF-1R extracellular domain is autoinhibitory and ligand binding releases this autoinhibition and brings the TM domains together to allow autophosphorylation and subsequent activation of the kinase domain. IGF2 is the major growth factor required for early development, while IGF1 is required for maximal growth. After birth, IGF1 is secreted primarily by the liver in response to stimulation from GH, but can also be expressed by other cell types. IGF1 regulates normal physiology and is known to promote cancer progression by inhibiting apoptosis and stimulating cell proliferation. Unlike most growth factors, whose biological activity is primarily regulated by release from secretory granules, serum concentrations of both IGF1 and IGF2 in circulation and tissues far exceed those required for maximum cell stimulation. More than 99% of circulating IGFs are bound to IGFBPs, most of which form a 150-kDa complex with IGFBP-3 and the acid-labile subunit (ALS). This complex extends the serum half-life of IGF1 from approximately 10 minutes to 15 hours and helps to tightly regulate IGF bioavailability at the cellular level. Because IGF has a greater binding affinity to IGFBPs than to IGF-1R, IGFBPs competitively inhibit IGF / IGF-1R binding and signaling. Local proteases can cleave IGFBPs into fragments with lower binding affinity, thereby releasing IGF to bind to IGF-1R.

[0098] In leukemia and malignant solid tumors, the IGF pathway is disrupted in various ways during cell transformation and tumor metastasis. Genetic risk factors (including those that affect the expression of IGF-1R, IGF1, IGF2 and IGFBP) contribute to the risk of developing into a tumor. As mentioned above, the expression of IGF-1R is strictly regulated and is often de-repressed due to the loss of activity of various tumor suppressor pathways. Another type of indirect participation of the IGF pathway in cancer progression involves the interaction between the IGF pathway and other hormones. Estrogen in breast cancer and androgen in prostate cancer have been shown to enhance IGF-1R signal transduction. IGF signal transduction also has a direct contribution to cancer progression, because the activated pathway involves enhanced cell survival and proliferation, as well as the ability to escape cell cycle arrest and apoptosis mechanisms, which usually serve to stop the effect of such abnormal cells.

[0099] IGF-1R activation and intracellular signaling pathways

[0100] The life cycle of human cells is strictly regulated by intracellular and extracellular signals, which together control cell proliferation, cell senescence and apoptosis. When the sum of growth stimulatory and inhibitory signals is favorable for proliferation, cells enter mitosis. For example, circulating IGF1 and IGF2 bind to IGF-1R and trigger a signal transduction cascade, which leads to increased proliferation and enhanced survival of IGF-responsive cells. This signal transduction is the core of tumorigenesis and involves downstream effector mechanisms to mediate the effects of signal transduction initiation.

[0101] Ligand binding to IGF-1R activates receptor kinases, leading to receptor autophosphorylation and tyrosine phosphorylation of multiple substrates. These substrates include insulin receptor substrates (IRS1 / 2), Src homology and collagen (Shc) adaptor proteins, and 14-3-3 proteins. Phosphorylation of IRS1 and IRS2 proteins leads to the activation of two major signaling pathways: the PI3K-AKT / PKB pathway and the Ras-MAPK pathway.

[0102] Activation of the MAPK pathway leads to increased cell proliferation, whereas activation of the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), which in turn activates several downstream substrates, including the protein AKT / PKB. AKT phosphorylation can enhance protein synthesis through mTOR activation and trigger the anti-apoptotic effects of IGF-1R through phosphorylation and inactivation of BAD (a pro-apoptotic member of the BCL2 family). In an alternative pathway for activating the PI3K pathway, a different regulatory subunit of PI3K (PIK3R3) binds to the IGR1R and insulin receptor (INSR) via its SH2 domain in a kinase-dependent manner, providing a means by which these two receptors can regulate the PI3K pathway.

[0103] In parallel with PI3K driven signaling, recruitment of Grb2 / SOS via phosphorylated IRS1 or phosphorylated Shc family members leads to recruitment of Ras and activation of the ras-MAPK pathway. The ras / MAPK pathway has many demonstrated involvement points in mediating mitogenic, differentiation, and migration signals. The mitogenic activity of IGF-1R is mediated through Ras and the PI3K-AKT pathway and results in upregulation of cyclin D1 and its binding partner CDK4. This results in phosphorylation of the retinoblastoma protein, release of the E2F transcription factor, and expression of downstream target genes such as cyclin E, a key regulator of entry into the S phase. Other pathways involved in cell proliferation are also regulated by IGF-1R activation. IGF-1R pathway activation has been shown to downregulate the cell cycle inhibitor p27 kip1 、p57 kip2 and PTEN.

[0104] In addition to these two major signaling pathways (PI3K-AKT / PKB and Ras-MAPK), IGF-1R also signals through the Janus kinase / signal transducer and activator of transcription pathway (JAK / STAT). Phosphorylation of JAK proteins can lead to phosphorylation and subsequent activation of signal transducer and activator of transcription (STAT) proteins. The JAK / STAT pathway activates gene transcription and can be responsible for transforming activity. Specific activation of STAT3 has been shown to be regularly involved in the transforming activity of IGF-1R. JNK kinases have also been shown to be activated by IGF-1R.

[0105] Further integration of signal transduction pathways is demonstrated by the multiple ways in which the IGF-1R and epidermal growth factor receptor (EGFR) pathways interact. IGF-1R and EGFR directly interact with each other and can heterodimerize. IGF-1R and EGFR can also mediate the availability of ligands for each other. Indirect interactions between the IGF-1R and EGFR pathways involve the utilization of shared G protein-coupled receptors or other downstream signaling molecules.

[0106] It was once believed that cell surface receptor tyrosine kinases terminate their signal transduction when they are internalized. However, it is now generally accepted that internalized receptors, including IGF-1R, can signal from endosomes and intracellular membrane compartments. In addition, they can also regulate gene transcription by translocation to the nucleus. Although the details of the mechanisms that determine the subcellular localization of IGF-1R or its compartmentalization with other signaling proteins are not completely clear, it has been suggested that IGF-1R trafficking within cells is regulated in a cell type-specific manner and that cell-specific signals can affect the recruitment and activation of effector proteins. Therefore, cell-specific IGF-1R trafficking, compartmentalization, and subcellular localization can define how cells respond to extracellular stimuli.

[0107] IGF-1R inhibitors

[0108] Forced overexpression of IGF-1R leads to malignant transformation of cultured cells and elevated IGF-1R levels observed in various human tumor types. Downregulation of IGF-1R levels can reverse the transformed phenotype of tumor cells and can sensitize them to apoptosis in vivo.

[0109] Several kinase inhibitors and blocking monoclonal antibodies that inhibit ligand binding and signal transduction have been developed and tested. Examples of human monoclonal antibodies that bind to IGF-1R include: cixutumumab, ganitumab, teprotumumab, figitumumab, dalotuzumab, and R1507. Several clinical trials, including one involving subjects with metastatic pancreatic cancer, have demonstrated that ganitumab is largely ineffective in improving survival. Teprotumumab, sold under the brand name Tepezza, is another human monoclonal antibody that binds to IGF-1R. Tepezza has been approved for the treatment of thyroid eye disease (TED), an autoimmune disorder characterized by proptosis. For this condition, Tepezza has been shown to reduce inflammation, thereby preventing muscle and fat tissue remodeling, and thereby leading to the prevention of expansion of tissue behind the eye. Although Tepezza has been shown to be effective in treating TED, teprotumumab has shown little efficacy in a phase 1 trial for treating malignancies. In fact, these monoclonal antibody inhibitors of IGF-1R have been largely unsuccessful in clinical trials, which may be related to how the internalization, subcellular localization, and signaling of IGF-1R are controlled in normal and cancer cells.

[0110] In view of the failure of clinical trials of antibodies targeting IGF-1R as cancer treatments, it is reasonable to refocus on potential small molecule inhibitors of IGF-1R. One such small molecule inhibitor is OSI-906, a dual IGF-1R / INSR kinase inhibitor. When administered orally once daily, OSI-906 effectively and selectively inhibits the autophosphorylation of both human IGF-1R and IR, exhibits in vitro antiproliferative effects in various tumor cell lines, and shows strong in vivo antitumor efficacy in IGF-1R-driven xenograft models. Unfortunately, a Phase 3 study testing the effectiveness of OSI-906 (Linsitinib) in the treatment of adrenocortical carcinoma concluded that Linsitinib did not increase overall survival. Effective therapeutic targeting of IGF-1R that leads to improved cancer survival is a huge unmet need.

[0111] IGF-1R kinase inhibitory compounds

[0112] In one aspect, provided herein is an IGF-1R inhibitory compound.

[0113] One embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof having the structure of formula (I):

[0114]

[0115] in,

[0116] X is optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl;

[0117] L is a bond or optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl or optionally substituted heterocyclylalkyl;

[0118] R 2 is an optionally substituted carbocyclic group, an optionally substituted aryl group, an optionally substituted heteroaryl group or an optionally substituted heterocyclic group; wherein the optional substituent of the optionally substituted carbocyclic group, the optionally substituted aryl group, the optionally substituted heteroaryl group or the optionally substituted heterocyclic group is selected from cyano, halo, hydroxy, azido, amino, nitro, -CO 2 H, -S(O)-R 10 、-SR 10 、-S(O) 2 -R 10 , optionally substituted C1-C6 alkoxy, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted (heterocyclyl)-O-, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted C2-C6 alkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, -N(R 11 ) 2 、-CO-R 10 , -CO 2 -R 10 、-CON(R 11 ) 2 、-NR 11 CO-R 10 、-NR 11 CO 2 -R 10 、-SO 2 N(R 11 ) 2 、-C(=NR 12 )-N(R 11 ) 2 、-NR 11 CO-N(R 10 ) 2 or -NR11 SO 2 -N(R 10 ) 2 ;

[0119] X 3 Is N or CR 3 ;

[0120] X 4 Is N or CR 4 ;

[0121] X 5 Is N or CR 5 ;

[0122] X 6 Is N or CR 6 ;

[0123] X 8 Is N or CR 8 ;

[0124] R 3 , R 4 , R 5 , R 6 and R 8 are independently selected from hydrogen, cyano, halo, hydroxy, azido, amino, nitro, -CO 2 H, -S(O)-R 10 、-SR 10 、-S(O) 2 -R 10 , optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted C2-C6 alkenyl, optionally substituted heterocyclyl, -N(R 11 ) 2 、-CO-R 10 , -CO 2 -R 10 、-CON(R 11 ) 2 、-NR 11 CO-R 10 、-NR 11 CO 2 -R 10 、-SO 2 N(R 11 ) 2 、-C(=NR 12 )-N(R 11 ) 2 、-NR 11 CO-N(R 10 ) 2 and-NR11 SO 2 -N(R 10 ) 2 ;

[0125] Each R 10 independently selected from optionally substituted C1-C6 alkyl, optionally substituted C3-C8 carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl and optionally substituted heteroaryl;

[0126] Each R 11 independently selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;

[0127] R 12 is H or optionally substituted C1-C6 alkyl;

[0128] R 9 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 carbocyclyl or optionally substituted C4-C10 carbocyclylalkyl; wherein R 9 and L or R 9 and X may be taken together with any intervening atoms to form an optionally substituted heterocyclyl ring.

[0129] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X 3 is N and X 4 Yes CR 4 .

[0130] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X 3 Yes CR 3 And X 4 It is N.

[0131] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X 3 Yes CR 3 And X 4 Yes CR 4 .

[0132] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein L is a bond. Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X is an optionally substituted C3-C7 cycloalkyl. Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X is an optionally substituted C4 cycloalkyl. Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X is an optionally substituted heterocyclyl. Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X is an optionally substituted piperidine or pyrrolidine. Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X is an optionally substituted piperidin-4-yl. Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X is an optionally substituted C1-C8 alkyl.

[0133] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein L is an optionally substituted cycloalkyl. Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X is an optionally substituted C3-C7 cycloalkyl. Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X is an optionally substituted heterocyclyl. Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X is an optionally substituted C1-C8 alkyl. Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X is an optionally substituted C4-C10 cycloalkylalkyl. Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X is an optionally substituted heterocyclylalkyl.

[0134] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 It's H.

[0135] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R 4 is H. Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R 4 is an optionally substituted C1-C4 alkoxy group.

[0136] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X 8 It is N.

[0137] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X 8 Yes CR 8 Another embodiment provides the compound or a pharmaceutically acceptable salt or solvate thereof, wherein R 8 is H. Another embodiment provides the compound or a pharmaceutically acceptable salt or solvate thereof, wherein R 8 Another embodiment provides the compound or a pharmaceutically acceptable salt or solvate thereof, wherein R 8 It's F.

[0138] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R 9 It's H.

[0139] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is an optionally substituted aryl group.

[0140] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 Another embodiment provides the compound or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 Another embodiment provides the compound or a pharmaceutically acceptable salt or solvate thereof, R 2 It is 2-fluorophenyl.

[0141] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is an optionally substituted pyridine.

[0142] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X 6 It is N.

[0143] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X 6 Yes CR 6 Another embodiment provides the compound or a pharmaceutically acceptable salt or solvate thereof, wherein R 6 It's H.

[0144] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X5 It is N.

[0145] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X 5 Yes CR 5 Another embodiment provides the compound or a pharmaceutically acceptable salt or solvate thereof, wherein R 5 It's H.

[0146] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X 5 Yes CR 5 And X 6 Yes CR 6 Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X 5 is CH and X 6 It is CH.

[0147] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X 5 Yes CR 5 , X 6 Yes CR 6 And X 8 Yes CR 8 Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X 5 It is CH, X 6 is CH and X 8 It's CF.

[0148] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X 3 Yes CR 3 And X 4 Yes CR 4 Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X 3 is CH and X 4 Yes CR 4 , where R 4 Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X 3 is CH and X 4 It is C-OCH 3 .

[0149] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X 3 Yes CR 3 , X 4 Yes CR 4 , X 5 Yes CR 5 , X 6 Yes CR 6 And X 8 Yes CR 8 Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, X 3 It is CH, X 4 It is C-OCH 3 , X 5 It is CH, X 6 is CH and X 8 It's CF.

[0150] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is phenyl substituted by at least one halogen, X 3 Yes CR 3 , X 4 Yes CR 4 , X 5 Yes CR 5 , X 6 Yes CR 6 And X 8 Yes CR 8 Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is phenyl substituted by at least one halogen, X 3 It is CH, X 4 It is C-OCH 3 , X 5 It is CH, X 6 is CH and X 8 Another embodiment provides the compound or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 It is 2-fluorophenyl.

[0151] Another embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein -LX is

[0152] One embodiment provides an IGF-1R inhibitory compound or a pharmaceutically acceptable salt or solvate thereof having the structure shown in Table 1A.

[0153] Table 1A

[0154]

[0155]

[0156]

[0157]

[0158]

[0159]

[0160]

[0161]

[0162]

[0163] Another embodiment provides an IGF-1R inhibitory compound, or a pharmaceutically acceptable salt or solvate thereof, as provided in Table 1B.

[0164] Table 1B

[0165]

[0166]

[0167] Preparation of compounds

[0168] The compounds used in the synthetic chemistry reactions described herein are prepared according to organic synthesis techniques known to those skilled in the art, starting from commercially available chemicals and / or from compounds described in the chemical literature. “Commercially available chemicals” were obtained from standard commercial sources, including Acros Organics (Pittsburgh, PA), Aldrich Chemical (Milwaukee, WI, including Sigma Chemical and Fluka), Apin Chemicals Ltd. (Milton Park, UK), Avocado Research (Lancashire, UK), BDH Inc. (Toronto, Canada), Bionet (Cornwall, UK), Chemservice Inc. (West Chester, PA), Crescent Chemical Co. (Hauppauge, NY), Eastman Organic Chemicals, Eastman Kodak Company (Rochester, NY), Fisher Scientific Co. (Pittsburgh, PA), Fisons Chemicals (Leicestershire, UK), Frontier Scientific (Logan, UT), ICN Biomedicals, Inc. (Costa Mesa, CA), Key Organics (Cornwall, UK), Lancaster Synthesis (Windham, NH), Maybridge Chemical Co. Ltd. (Cornwall, UK), Parish Chemical Co. (Orem, UT), Pfaltz & Bauer, Inc. (Waterbury, CN), Polyorganix (Houston, TX), Pierce Chemical Co. (Rockford, IL), Riedel de Haen AG (Hanover, Germany), Spectrum Quality Product, Inc. (New Brunswick, NJ), TCI America (Portland, OR), Trans World Chemicals, Inc. (Rockville, MD), and Wako Chemicals USA, Inc. (Richmond, VA).

[0169] Suitable reference books and papers detailing the synthesis of reactants that can be used to prepare the compounds described herein, or providing references to articles describing such preparations, include, for example, "Synthetic Organic Chemistry", John Wiley & Sons, Inc., New York; SR Sandler et al., "Organic Functional Group Preparations," 2nd edition, Academic Press, New York, 1983; H O House, "Modern Synthetic Reactions," 2nd edition, WA Benjamin, Inc. Menlo Park, Calif. 1972; TL Gilchrist, "Heterocyclic Chemistry," 2nd edition, John Wiley & Sons, New York, 1992; J. March, "Advanced Organic Chemistry: Reactions, Mechanisms and Structure," 4th edition, Wiley-Interscience, New York, 1992. Other suitable reference books and papers that detail the synthesis of reactants that can be used to prepare the compounds described herein or provide references to articles describing the preparations include, for example, Fuhrhop, J. and henzlin G. "Organic Synthesis: Concepts, Methods, Starting Materials", 2nd Revised and Expanded Edition (1994) John Wiley & Sons ISBN: 3-527-29074-5; Hoffman, RV "Organic Chemistry, An Intermediate Text" (1996) Oxford University Press, ISBN 0-19-509618-5; Larock, RC "Comprehensive Organic Transformations: A Guide to Functional Group Preparations" 2nd Edition (1999) Wiley-VCH, ISBN: 0-471-19031-4; March, J. "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure" 4th Edition (1992) John Wiley & Sons, ISBN: 0-471-60180-2; Otera, J.(Editor) "Modern Carbonyl Chemistry" (2000) Wiley-VCH, ISBN: 3-527-29871-1; Patai, S. "Patai's 1992Guide to the Chemistry of Functional Groups" (1992) Interscience ISBN: 0-471-93022-9; Solomons, TWG "Organic Chemistry" 7th edition (2000) John Wiley & Sons, ISBN: 0-471-19095-0; Stowell, JC, "Intermediate Organic Chemistry" 2nd edition (1993) Wiley-Interscience, ISBN: 0-471-57456-2; "Industrial Organic Chemicals: Starting Materials and Intermediates: An Ullmann's Encyclopedia"(1999)John Wiley & Sons, ISBN: 3-527-29645-X, 8 volumes; "Organic Reactions" (1942-2000) John Wiley & Sons, more than 55 volumes; and "Chemistry of Functional Groups" John Wiley & Sons, 73 volumes. .

[0170] Specific and similar reactants are optionally identified by an index of known chemicals prepared by the Chemical Abstract Service of the American Chemical Society, which is available in most public and university libraries and through online databases (contact the American Chemical Society, Washington, DC for more details). Chemicals known but not commercially available in the catalog are optionally prepared by custom chemical synthesis agencies, many of which provide custom synthesis services. A reference for the preparation and selection of pharmaceutical salts of the compounds described herein is P. H. Stahl & C. G. Wermuth "Handbook of Pharmaceutical Salts", Verlag Helvetica Chimica Acta, Zurich, 2002.

[0171] Pharmaceutical composition

[0172] In certain embodiments, the IGF-1R inhibitory compounds described herein are administered as a pure chemical. In other embodiments, the IGF-1R inhibitory compounds described herein are combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, a physiologically suitable (or acceptable) excipient, or a physiologically suitable (or acceptable) carrier), which is selected based on the selected route of administration and standard pharmaceutical practice as described, for example, in Remington: The Science and Practice of Pharmacy (Gennaro, 21st Edition Mack Pub. Co., Easton, PA (2005)).

[0173] Provided herein are pharmaceutical compositions comprising at least one IGF-1R inhibitory compound described herein, or a stereoisomer, pharmaceutically acceptable salt, hydrate or solvate thereof, and one or more pharmaceutically acceptable carriers. A carrier (or excipient) is acceptable or suitable if it is compatible with the other ingredients of the composition and is not deleterious to the recipient (i.e., subject or patient) of the composition.

[0174] One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

[0175] One embodiment provides a method for preparing a pharmaceutical composition, which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof with a pharmaceutically acceptable carrier.

[0176] In certain embodiments, the IGF-1R inhibitory compound as described in Formula (I) or a pharmaceutically acceptable salt or solvate thereof is substantially pure in that it contains less than about 5%, or less than about 2%, or less than about 1%, or less than about 0.5%, or less than about 0.1% of other small organic molecules, such as unreacted intermediates or synthesis by-products produced in one or more steps of the synthesis method.

[0177] One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Table 1A or Table 1B or a pharmaceutically acceptable salt or solvate thereof.

[0178] One embodiment provides a method for preparing a pharmaceutical composition, comprising mixing a compound of Table 1A or Table 1B or a pharmaceutically acceptable salt or solvate thereof with a pharmaceutically acceptable carrier.

[0179] In certain embodiments, the IGF-1R inhibitory compound as described in Table 1A or Table 1B, or a pharmaceutically acceptable salt or solvate thereof, is substantially pure in that it contains less than about 5%, or less than about 2%, or less than about 1%, or less than about 0.5%, or less than about 0.1% of other small organic molecules, such as unreacted intermediates or synthesis by-products produced in one or more steps of the synthesis method.

[0180] Suitable oral dosage forms include, for example, tablets, pills, sachets, or capsules of hard or soft gelatin, methylcellulose, or other suitable materials that are easily dissolved in the digestive tract. In some embodiments, suitable non-toxic solid carriers are used, including, for example, pharmaceutical grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, etc. (see, for example, Remington: The Science and Practice of Pharmacy (Gennaro, 21st Edition Mack Pub. Co., Easton, PA (2005)).

[0181] In some embodiments, the IGF-1R inhibitory compound as described in Formula (I) or Table 1A or Table 1B, or a pharmaceutically acceptable salt or solvate thereof, is formulated for administration by injection. In some cases, the injection formulation is an aqueous formulation. In some cases, the injection formulation is a non-aqueous formulation. In some cases, the injection formulation is an oil-based formulation, such as sesame oil, etc.

[0182] The dosage of the composition comprising at least one IGF-1R inhibitory compound as described herein varies depending on the condition of the subject or patient (eg, human). In some embodiments, these factors include general health, age, and other factors.

[0183] The pharmaceutical composition is applied in a manner suitable for the disease to be treated (or prevented). Suitable dosage and suitable duration and frequency of application will be determined by factors such as the patient's condition, the type and severity of the patient's disease, the specific form of the active ingredient and the method of administration. Typically, suitable dosage and treatment regimen provide a composition of the amount sufficient to provide treatment and / or prevention benefits (e.g., improved clinical outcomes, such as more frequent complete or partial remissions, or longer disease-free and / or overall survival, or mitigation of symptom severity). Optimal dose is typically determined using experimental models and / or clinical trials. Optimal dose depends on the patient's body mass, body weight or blood volume.

[0184] Oral dosages are generally from about 1.0 mg to about 1000 mg, one to four times a day or more.

[0185] Treatment

[0186] One embodiment provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of the human or animal body.

[0187] One embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in a method for treating cancer or a neoplastic disease.

[0188] One embodiment provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable excipient for use in a method for treating cancer or a tumor disease.

[0189] One embodiment provides a use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for treating cancer or tumor diseases.

[0190] In some embodiments, a method of treating cancer in a patient in need thereof is provided, comprising administering to the patient a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a method of treating cancer in a patient in need thereof is provided, comprising administering to the patient a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable excipient.

[0191] One embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in a method for treating an autoimmune disease.

[0192] One embodiment provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable excipient for use in a method for treating an autoimmune disease.

[0193] One embodiment provides a use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for treating an autoimmune disease.

[0194] In some embodiments, a method of treating an autoimmune disease in a patient in need thereof is provided, comprising administering to the patient a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a method of treating an autoimmune disease in a patient in need thereof is provided, comprising administering to the patient a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable excipient.

[0195] One embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in a method of treating thyroid eye disease.

[0196] One embodiment provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable excipient for use in a method for treating thyroid eye disease.

[0197] One embodiment provides a use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for treating thyroid eye disease.

[0198] In some embodiments, a method of treating thyroid eye disease in a patient in need thereof is provided, comprising administering to the patient a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a method of treating thyroid eye disease in a patient in need thereof is provided, comprising administering to the patient a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable excipient.

[0199] One embodiment provides a compound of Table 1A or Table 1B, or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of the human or animal body.

[0200] One embodiment provides a compound of Table 1A or Table 1B, or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treating cancer or a neoplastic disease.

[0201] One embodiment provides a pharmaceutical composition comprising a compound of Table 1A or Table 1B or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable excipient for use in a method of treating cancer or a neoplastic disease.

[0202] One embodiment provides a use of a compound of Table 1A or Table 1B or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for treating cancer or a tumor disease.

[0203] In some embodiments, a method of treating cancer in a patient in need thereof is provided, comprising administering to the patient a compound of Table 1A or Table 1B, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a method of treating cancer in a patient in need thereof is provided, comprising administering to the patient a pharmaceutical composition comprising a compound of Table 1A or Table 1B, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

[0204] One embodiment provides a compound of Table 1A or Table 1B, or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treating an autoimmune disease.

[0205] One embodiment provides a pharmaceutical composition comprising a compound of Table 1A or Table 1B or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable excipient for use in a method of treating an autoimmune disease.

[0206] One embodiment provides a use of a compound of Table 1A or Table 1B or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for treating an autoimmune disease.

[0207] In some embodiments, a method of treating an autoimmune disease in a patient in need thereof is provided, comprising administering to the patient a compound of Table 1A or Table 1B, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a method of treating an autoimmune disease in a patient in need thereof is provided, comprising administering to the patient a pharmaceutical composition comprising a compound of Table 1A or Table 1B, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

[0208] One embodiment provides a compound of Table 1A or Table 1B, or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treating thyroid eye disease.

[0209] One embodiment provides a pharmaceutical composition comprising a compound of Table 1A or Table 1B, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient for use in a method of treating thyroid eye disease.

[0210] One embodiment provides use of a compound of Table 1A or Table 1B or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for treating thyroid eye disease.

[0211] In some embodiments, a method of treating thyroid eye disease in a patient in need thereof is provided, comprising administering to the patient a compound of Table 1A or Table 1B, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a method of treating thyroid eye disease in a patient in need thereof is provided, comprising administering to the patient a pharmaceutical composition comprising a compound of Table 1A or Table 1B, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

[0212] Provided herein are methods wherein the pharmaceutical composition is administered orally. Provided herein are methods wherein the pharmaceutical composition is administered by injection.

[0213] One embodiment provides a method of inhibiting an IGF-1R enzyme comprising contacting the IGF-1R enzyme with a compound of Formula (I) or Table 1A or Table 1B. Another embodiment provides a method of inhibiting an IGF-1R enzyme, wherein the IGF-1R enzyme is contacted in an in vivo environment. Another embodiment provides a method of inhibiting an IGF-1R enzyme, wherein the IGF-1R enzyme is contacted in an in vitro environment.

[0214] Other embodiments and uses will be apparent to those skilled in the art in light of this disclosure.The following examples are provided merely as illustrations of various embodiments and should not be construed as limiting the invention in any way.

[0215] Example

[0216] I. Chemical Synthesis

[0217] In some embodiments, the IGF-1R inhibitory compounds disclosed herein are synthesized according to the following examples. As used below and throughout the description of the present invention, unless otherwise indicated, the following abbreviations should be understood to have the following meanings:

[0218] ℃ Celsius

[0219] δ H Chemical shift downfield of tetramethylsilane in parts per million

[0220] DCM Dichloromethane (CH 2 Cl 2 )

[0221] DMF Dimethylformamide

[0222] DMSO Dimethyl sulfoxide

[0223] EA Ethyl acetate

[0224] ESI Electrospray ionization

[0225] Et Ethyl

[0226] g

[0227] h hour

[0228] HPLC High Performance Liquid Chromatography

[0229] Hz Hertz

[0230] J Coupling constant (NMR spectroscopy)

[0231] LCMS Liquid chromatography mass spectrometry

[0232] μ micro

[0233] m multiple peak (spectrum); meter; millimeter

[0234] M Moore

[0235] M + Ions of the parent molecule

[0236] Me Methyl

[0237] MHz Megahertz

[0238] min

[0239] mol mole; molecular (measured in mol wt)

[0240] mL milliliters

[0241] MS

[0242] nm nanometer

[0243] NMR Nuclear Magnetic Resonance

[0244] pH The electrical potential of hydrogen; a measure of the acidity or alkalinity of an aqueous solution

[0245] PE Petroleum Ether

[0246] RT Room temperature

[0247] s singlet (spectrum)

[0248] t triplet (spectrum)

[0249] T Temperature

[0250] TFA Trifluoroacetic acid

[0251] THF Tetrahydrofuran

[0252] Example 1: Preparation of 5-amino-1-(3-oxocyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide

[0253]

[0254] 7-Bromoquinoline (20 g, 96.6 mmol, 1.0 eq), DPPP (8.0 g, 19.3 mmol, 0.2 eq) and Pd(OAc) were added. 2To a solution of (2.1 g, 9.7 mmol, 0.1 eq) in DMSO / MeOH (300 mL / 300 mL) was added TEA (40 mL, 289.8 mmol, 3.0 eq). The mixture was stirred at 120 °C for 15 h under CO (5 atm) and then concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give quinoline-7-carboxylic acid methyl ester (16.4 g, 91.1%) as a yellow solid. LRMS (M+H + )m / z: calculated: 188.1, found: 188.0.

[0255]

[0256] To a stirred solution of quinoline-7-carboxylic acid methyl ester (16.4 g, 87.7 mmol, 1.0 eq) in DCM (300 mL) was added m-CPBA (22.7 g, 131.6 mmol, 1.5 eq) at 25° C. The mixture was stirred at 25° C. for 2 h, then poured into ice and the mixture was quenched by the addition of saturated Na 2 CO 3 The aqueous solution was adjusted to pH 13 and extracted with DCM (500 mL x 3). The combined organic layers were dried over sodium sulfate and concentrated in vacuo to give 7-(methoxycarbonyl)quinoline 1-oxide (17.5 g, 98.3%) as a yellow oil. LRMS (M+H + )m / z: calculated: 204.1, found: 204.1.

[0257]

[0258] To a solution of 7-(methoxycarbonyl)quinoline 1-oxide (17.5 g, 86.2 mmol, 1.0 equiv) in DCM (500 mL) was added POBr at -78 °C. 3 (32.1 g, 112.1 mmol, 1.3 eq) and DMF (3.3 mL, 43.1 mmol, 0.5 eq). The mixture was stirred at 25 °C for 2 h, then poured into ice and stirred by adding saturated Na 2 CO 3 The aqueous solution was adjusted to pH 13 and extracted with DCM (500 mL x 3). The combined organic layers were dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give methyl 2-bromoquinoline-7-carboxylate (17.2 g, 75.4%) as a yellow solid. LRMS (M+H + )m / z: calculated: 266.0, found: 266.0. 1H NMR (DMSO-d 6 ,400MHz)δ8.50(s,1H),8.45(d,1H),8.12-8.21(m,2H),8.86(d,1H),3.95(s,3H).

[0259]

[0260] To a solution of methyl 2-bromoquinoline-7-carboxylate (17.2 g, 64.7 mmol, 1.0 equiv) in dioxane (300 mL) were added phenylboronic acid (15.8 g, 129.3 mmol, 2.00 equiv), Pd(PPh 3 ) 4 (7.5 g, 6.4 mmol, 0.1 eq.). The mixture was stirred at 120 °C for 1 h, then concentrated in vacuo and diluted with water (100 mL), and extracted with EtOAc (150 mL x 2). The combined organic layers were washed with brine (150 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give methyl 2-phenylquinoline-7-carboxylate (8.8 g, 50.2%) as a white solid. LRMS (M+H + )m / z: calculated: 264.1, found: 264.1.

[0261]

[0262] To methyl 2-phenylquinoline-7-carboxylate (8.8 g, 33.5 mmol, 1.0 equiv) was dissolved in MeOH (100 mL) and H 2 To the solution in 4% 4-nitropropene (2% ethyl acetate) (30 mL) was added NaOH (2.0 g, 50.2 mmol, 1.5 eq). The mixture was stirred at 80 °C for 15 h, then concentrated in vacuo and diluted with water (60 mL). 37% HCl was added to adjust to pH 2. The resulting mixture was stirred for 5 min, filtered and concentrated in vacuo to give 2-phenylquinoline-7-carboxylic acid (7.8 g, 93.9%) as a white solid. LRMS (M+H + )m / z: calculated: 250.1, found: 250.0.

[0263]

[0264] To a solution of 2-phenylquinoline-7-carboxylic acid (2.1 g, 8.4 mmol, 1.0 eq.) in DCM (100 mL) was added (COCl) at -78 °C. 2(3.6 mL, 42.1 mmol, 5.0 equiv) and DMF (5 drops). The mixture was stirred at room temperature for 7 h and then concentrated in vacuo to give 2-phenylquinoline-7-carbonyl chloride as a yellow solid (2.6 g, about 100.0%). LRMS (M+H + ) m / z: Calculated: 264.1, found: 264.1 in MeOH.

[0265]

[0266] In an ice bath, malononitrile (247.1 mg, 3.70 mmol, 1.0 equiv) and DIEA (1.8 mL, 11.20 mmol, 3.0 equiv) were added to a solution of 2-phenylquinoline-7-carbonyl chloride (1.0 g, 3.7 mmol, 1.0 equiv) in THF (100 mL). The mixture was stirred at room temperature for 3 h, then concentrated and diluted with water (20 mL). The resulting mixture was extracted with EtOAc (50 mL X 2). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH=50 / 1, v / v) to give 2-(hydroxy(2-phenylquinoline-7-yl)methylene)malononitrile as a yellow oil (600 mg, 67.5%). LRMS (M+H + )m / z: calculated: 298.1, found: 298.0.

[0267]

[0268] To a solution of 2-(hydroxy(2-phenylquinolin-7-yl)methylene)malononitrile (500 mg, 1.70 mmol, 1.0 equiv) in THF (30 mL) was added Me 2 SO 4 The mixture was stirred at 80 ° C for 3 h, then concentrated in vacuo, diluted with water (20 mL) and extracted with EtOAc (50 mL×2). The combined organic layer was washed with brine (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 2-(methoxy(2-phenylquinolin-7-yl)methylene)malononitrile as a yellow oil (450 mg, 94.2%). LRMS (M+H + )m / z: calculated: 312.1, found: 312.1.

[0269]

[0270] To a solution of 2-(methoxy(2-phenylquinolin-7-yl)methylene)malononitrile (450 mg, 1.80 mmol, 1.0 equiv) in EtOH (30 mL) was added hydrazine hydrate (0.9 mL, 18.00 mmol, 10.0 equiv). The mixture was stirred at 90 °C for 2 h, then concentrated in vacuo and diluted with water (20 mL). The resulting mixture was stirred for 5 min and filtered. The solid was dried to give 5-amino-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile as a white solid (456 mg, 100.0%). LRMS (M+H + )m / z: calculated: 312.1, found: 312.1.

[0271]

[0272] 5-Amino-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (150 mg, 0.48 mmol, 1.0 equiv) was stirred in H 3 PO 4 The solution in 2% ethanol (10 mL) was stirred at 120 °C for 1 h. The reaction mixture was diluted with water (20 mL). Na 2 CO 3 To adjust the pH to 12-13. The mixture was extracted with EtOAc (50 mL x 2). The combined organic layers were washed with brine (50 mL) and dried over anhydrous sodium sulfate and concentrated to give 5-amino-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide as a white solid (132 mg, 88.0%). LRMS (M+H + )m / z: calculated: 330.1, found: 330.1.

[0273]

[0274] To a solution of 5-amino-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide (60 mg, 0.18 mmol, 1.0 equiv) in DMSO (20 mL) were added 3-bromocyclobutane-1-one (1.7 mg, 0.72 mmol, 4.0 equiv) and K 2 CO 3(75 mg, 0.54 mmol, 3.0 equivalents). The mixture was stirred at 100 ° C for 2h, then diluted with water (50 mL) and extracted with EtOAc (50 mL × 3). The combined organic layer was washed with brine (30 mL × 2) and concentrated in vacuo. The resulting residue was purified by preparative HPLC to give 5-amino-1-(3-oxocyclobutyl)-3-(2-phenylquinoline-7-yl)-1H-pyrazole-4-carboxamide as a white solid (1.0 mg, 1.6%). LRMS (M+H + )m / z: calculated: 398.2, found: 398.0. 1 H NMR(400MHz,DMSO)δ8.61(s,1H),8.40(d,1H),8.29(d,2H),8.04-8.10(m,2H),7.86 (d,1H),7.49-7.58(m,3H),4.26-4.28(m,1H),2.60-2.67(m,2H),2.32-2.34(m,2H).

[0275] Example 2: Preparation of 5-amino-3-(2-phenylquinolin-7-yl)-1-(piperidin-4-yl)-1H-pyrazole-4-carboxamide

[0276]

[0277] To a solution of 5-amino-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide (260 mg, 0.8 mmol, 1.0 equiv) in DMF (20 mL) were added tert-butyl 4-bromopiperidine-1-carboxylate (1.3 g, 4.8 mmol, 6.0 equiv) and Cs 2 CO 3 The mixture was stirred at 80 ° C for 24 h, then diluted with water (20 mL), extracted with EtOAc (50 mL × 2). The combined organic layer was washed with brine (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (PE / EA = 1 / 1, v / v) to give 4- (5-amino-4-carbamoyl-3- (2-phenylquinoline-7-yl) -1H-pyrazol-1-yl) piperidine-1-carboxylic acid tert-butyl ester as a yellow oil (240 mg, 94.2%), LRMS (M + H + )m / z: calculated: 513.3, found: 513.3.

[0278]

[0279] To a solution of tert-butyl 4-(5-amino-4-carbamoyl-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (220 mg, 0.5 mmol, 1.0 equiv) in DCM (5 mL) was added 1 M HCl / EA (5 mL). The mixture was stirred at room temperature for 3 h, then concentrated, and the resulting residue was purified by preparative HPLC to give 5-amino-3-(2-phenylquinolin-7-yl)-1-(piperidin-4-yl)-1H-pyrazole-4-carboxamide (2.1 mg, 1.2%) as a white solid, LRMS (M+H + )m / z: calculated: 413.2, found: 413.2, 1 H NMR(400MHz,DMSO)δ8.49(d,1H),8.28-8.48(m,4H),8.16-8.19(m,2H),8.04(d,1H),7.76(dd,1H) ,7.51-7.59(m,4H),6.33(s,2H),4.31-4.35(m,1H),3.23(d,2H),2.78(t,2H),1.92-2.21(m,4H).

[0280] Example 3: Preparation of 4-(5-amino-4-carbamoyl-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)piperidine-1-carboxamide

[0281]

[0282] To a solution of 5-amino-3-(2-phenylquinolin-7-yl)-1-(piperidin-4-yl)-1H-pyrazole-4-carboxamide (37 mg, 0.09 mmol, 1.0 equiv) in DCM (5 mL) was added TEA (0.1 mL, 0.72 mmol, 8.0 equiv) and trimethylsilyl isocyanate (20.7 mg, 0.18 mmol, 2.0 equiv) at 0° C. The reaction mixture was stirred at room temperature for 16 h and then heated to room temperature in saturated NaHCO 3 The product was added into 4- (5-amino-4-carbamoyl-3- (2-phenylquinoline-7-yl) -1H-pyrazol-1-yl) piperidine -1- carboxamide (9.6 mg, 23.4%) as a white solid. LRMS (M+H) + )m / z: calculated: 456.2, found: 456.1. 1 H NMR (DMSO-d6 ,400MHz)δ8.56(d,1H),8.28-8.30(m,2H),8.23(s,1H),8.19(d,1H),8.06(d,1H),7.80(dd,1H) ,7.53-7.61(m,3H),4.34-4.39(m,1H),4.07-4.11(m,2H),2.77-2.85(m,2H),1.83-1.89(m,4H).

[0283] Example 4: Preparation of methyl 4-(5-amino-4-carbamoyl-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate

[0284]

[0285] 5-amino-3-(2-phenylquinolin-7-yl)-1-(piperidin-4-yl)-1H-pyrazole-4-carboxamide (70 mg, 0.2 mmol, 1.0 equiv) and NaHCO 3 (44.7 mg, 0.5 mmol, 3.0 equiv) in MeCN (6.0 mL) and H 2 To the solution in 2% CO (2.0 mL), methyl chloroformate (18.9 mg, 0.2 mmol, 1.0 equiv) was added. The mixture was stirred at room temperature for 5 h and then quenched by H 2 The product was quenched with 4-(5-amino-4-carbamoyl-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid methyl ester as a white solid (17.0 mg. 21.3%). LRMS (M+H + )m / z: calculated: 471.2, found: 471.1. 1 H NMR (DMSO-d 6 ,400MHz)δ8.48(d,1H),8.29-8.31(m,2H),8.17(d,2H),8.03(d,1H),7.76(d,1H),7.51-7.59(m,3H), 6.35(s,2H),4.38-4.22(m,1H),4.11-4.13(m,2H),3.65(s,3H),2.94-2.95(m,2H),1.86-1.91(m,4H).

[0286] Example 5: Preparation of 5-amino-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide

[0287]

[0288] MeMgBr (3M, 85.2 mL, 255.7 mmol, 1.5 eq) was added dropwise to a solution of 3-(benzyloxy)cyclobutanone (30 g, 170.5 mmol, 1.0 eq) in THF (300 mL) at -78 °C. The mixture was stirred at -78 °C for 1 h and then washed with NH 4 The CI aqueous solution (500mL) is quenched. The aqueous layer is extracted with ethyl acetate (150mL×3). The combined organic layer is washed with brine (300mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue is purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to obtain 3-(benzyloxy)-1-methylcyclobutane-1-ol (30.3g, 92.6%) as a yellow oil. 1 H NMR (DMSO-d 6 ,400MHz)δ7.27-7.36(m,5H),4.97(s,1H),4.34(s,2H),3.64-3.68(m,1H),2.22-2.28(m,2H),1.91-1.96(m,2H),1.15(s,3H).

[0289]

[0290] A mixture of 3-benzyloxy-1-methyl-cyclobutanol (30.3 g, 157.8 mmol, 1.0 equiv) and Pd / C (10 wt%, 10 g) in MeOH (500 mL) was stirred under hydrogen (1 atm) at room temperature for 16 h, then filtered and concentrated in vacuo to give 1-methylcyclobutane-1,3-diol (16 g, ca. 100%) as a yellow oil. 1 H NMR (DMSO-d 6 ,400MHz) δ4.87(d,1H),4.81(s,1H),3.69-3.71(m,1H),2.16-2.22(m,2H),1.84-1.89(m,2H),1.13(s,3H).

[0291]

[0292] A mixture of 1-methylcyclobutane-1,3-diol (16 g, 156.9 mmol, 1.0 equiv) and IBX (87.8 g, 313.7 mmol, 2.0 equiv) in MeCN (200 mL) was stirred at 80 °C for 15 h, then filtered and concentrated in vacuo to give 3-(benzyloxy)cyclobutanone (10 g, 64.1%) as a yellow oil. 1 H NMR (DMSO-d 6 ,400MHz) δ5.49(s,1H),2.98(s,4H),1.48(s,3H).

[0293]

[0294] To a stirred solution of 3-hydroxy-3-methylcyclobutane-1-one (10 g, 100.0 mmol, 1.0 equiv) in MeOH (200 mL) was added BocNHNH 2 (15.8 g, 120.0 mmol, 1.2 eq) and AcOH (0.5 mL, 8.3 mmol, 0.1 eq). The reaction mixture was stirred at room temperature for 3 h, and then NaBH 3 CN (12.6g, 200.0mol, 2.0 equivalents). The reaction mixture was stirred at room temperature for 2h, then at 80°C for 18h, cooled to room temperature and concentrated in vacuo, and the resulting residue was diluted with EtOAc (200mL), washed with water (200mL) and brine (200mL). The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was purified by preparative HPLC to give tert-butyl 2-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)hydrazine-1-carboxylate (4.8g, 22.2%) and tert-butyl 2-((1r, 3r)-3-hydroxy-3-methylcyclobutyl)hydrazine-1-carboxylate (3.6g, 16.6%) as a colorless oil. tert-butyl 2-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)hydrazine-1-carboxylate: 1 H NMR (DMSO-d 6 ,400MHz)δ8.15(s,1H),4.78(s,1H),4.32-4.34(m,1H),2.95-3.01(m,1H),1.94-1.99(m,2H),1.79-1.84(m,2H),1.38(s,9H),1.15(s,3H). LRMS(M+H + )m / z: calculated value: 217.1, found value: 217.1. tert-Butyl 2-((1r,3r)-3-hydroxy-3-methylcyclobutyl)hydrazine-1-carboxylate: 1 H NMR (DMSO-d6 ,400MHz)δ8.17(s,1H),4.67(s,1H),4.35-4.37(m,1H),3.44-3.46(m,1H),1.93-1.99(m,2H),1.67-1.76(m,2H),1.38(s,9H),1.25(s,3H). LRMS(M+H + )m / z: calculated: 217.1, found: 217.1.

[0295]

[0296] To a stirred solution of tert-butyl 2-((1s,3s)-3-hydroxy-3-methylcyclobutyl)hydrazine-1-carboxylate (1.5 g, 6.9 mmol, 1.0 equiv) in DCM (10 mL) was added HCl (4 N, 10 mL) in dioxane. The reaction was stirred at 30 °C for 30 min, then the mixture was concentrated in vacuo to give (1s,3s)-3-hydrazino-1-methylcyclobutane-1-ol (1.2 g, ca. 100%) as a white solid. LRMS (M+H + )m / z: calculated: 117.1, found: 117.1.

[0297]

[0298] To a solution of 2-(methoxy(2-phenylquinolin-7-yl)methylene)malononitrile (2.1 g, 6.9 mmol, 1.0 equiv) and (1s, 3s)-3-hydrazino-1-methylcyclobutane-1-ol (1.2 g, 10.3 mmol, 1.5 equiv) in EtOH (50 mL) was added TEA (7.6 mL, 55.2 mmol, 8.0 equiv) at room temperature. The reaction mixture was stirred at 90 ° C for 2 h, then the mixture was concentrated in vacuo and purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 5-amino-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (1.7 g, 62.9%) as a yellow solid. LRMS (M+H + )m / z: calculated: 395.2, found: 396.3.

[0299]

[0300] At room temperature, 5-amino-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (1.7 g, 4.3 mmol, 1.0 equiv) and K 2 CO3 To a stirred solution of DMSO (1.8 g, 12.9 mmol, 3.0 equiv) was added H 2 O 2 (30%, 9.8 g, 86.1 mmol, 20.0 equiv). After the addition was complete, the reaction mixture was stirred at 60 ° C for 1 h. Water (80 mL) was added and the mixture was extracted with EtOAc (200 mL). The organic layer was washed with brine (100 mL), dried over anhydrous sodium sulfate and purified by preparative HPLC to give 5-amino-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-3-(2-phenylquinoline-7-yl)-1H-pyrazole-4-carboxamide (1050.2 mg, 61.8%) as a white solid. LRMS (M+H + )m / z: calculated: 414.2, found: 414.1. 1 H NMR (DMSO-d 6 ,400MHz)δ8.50(d,1H),8.30(d,2H),8.21(s,1H),8.18(d,1H),8.05(d,1H),7.78(dd,1H),7.49-7.59(m, 3H),6.31(brs,2H),5.19(brs,1H),4.42-4.51(m,1H),2.59-2.65(m,2H),2.36-2.42(m,2H),1.35(s,3H).

[0301] Example 6: Preparation of 5-amino-1-((1r,3r)-3-hydroxy-3-methylcyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide

[0302]

[0303] To a solution of 2-(methoxy(2-phenylquinolin-7-yl)methylene)malononitrile (268.1 mg, 0.86 mmol, 1.0 eq) and 3-hydrazino-1-methylcyclobutane-1-ol (150 mg, 1.3 mmol, 1.5 eq) in EtOH (50 mL) was added TEA (1.0 mL, 6.9 mmol, 8.0 eq) at room temperature. The reaction mixture was stirred at 90 °C for 2 h and then concentrated in vacuo. The resulting residue was purified by reverse phase chromatography, eluting with (MeCN in water, from 10% to 70%) to give 5-amino-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (55 mg, 16.2%) and 5-amino-1-((1r, 3r)-3-hydroxy-3-methylcyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (60 mg, 17.6%) as yellow solids. They were confirmed by NOESY. 5-amino-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile, 1 H NMR (DMSO-d 6 ,400MHz)δ8.54(s,1H),8.48(d,1H),8.28-8.31(m,2H),8.17(d,1H),8.09(s,2H),7.49-7.59(m,3H ),6.80(s,2H),5.28(s,1H),4.45-4.50(m,1H),2.60-2.66(m,2H),2.39-2.44(m,2H),1.34(s,3H). LRMS(M+H + )m / z: calculated value: 396.2, found value: 396.3. 5-amino-1-((1r,3r)-3-hydroxy-3-methylcyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile, 1 H NMR (DMSO-d 6 ,400MHz)δ8.53(s,1H),8.48(d,1H),8.28-8.31(m,2H),8.17(d,1H),8.09(s,2H),7.50-7.60(m,3H ),6.77(s,2H),5.03(s,1H),4.94-4.99(m,1H),2.54-2.58(m,2H),2.43-2.49(m,2H),1.41(s,3H). LRMS(M+H + )m / z: calculated: 396.2, found: 396.3.

[0304]

[0305] At room temperature, 5-amino-1-((1r,3r)-3-hydroxy-3-methylcyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (60 mg, 0.15 mmol, 1.0 equiv) and K 2 CO 3 To a stirred solution of (62.9 mg, 0.46 mmol, 3.0 equiv) in DMSO (30 mL) was added H 2 O 2 (30%, 344.3mg, 3.0mmol, 20.0 equivalents). After the addition was completed, the reaction mixture was stirred at 60 ° C for 2h. Water (20mL) was added and the mixture was extracted with EtOAc (50mL X3). The combined organic layer was washed with brine (30mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was purified by preparative HPLC to give 5-amino-1-((1r, 3r)-3-hydroxy-3-methylcyclobutyl)-3-(2-phenylquinoline-7-yl)-1H-pyrazole-4-carboxamide (5.7mg, 9.5%) as a white solid. LRMS (M+H + )m / z: calculated: 414.2, found: 414.1. 1 H NMR (DMSO-d 6 ,400MHz)δ8.49(d,1H),8.29-8.32(m,2H),8.16-8.20(m,2H),8.05(d,1H),7.78(dd,1H),7.49- 7.59(m,3H),6.28(s,2H),4.93-4.97(m,1H),2.54-2.56(m,2H),2.39-2.45(m,2H),1.36(s,3H).

[0306] Example 7: Preparation of 5-amino-3-(2-phenylquinolin-7-yl)-1-(piperidin-4-yl)-1H-pyrazole-4-carboxamide

[0307]

[0308] To a solution of 5-amino-3-(2-phenylquinolin-7-yl)-1-(piperidin-4-yl)-1H-pyrazole-4-carboxamide (20 mg, 0.05 mmol, 1.0 equiv) in MeOH (10 mL) was added HCHO (37%, 0.24 mL, 0.05 mmol, 1.0 equiv), AcOH (1 drop) and NaBH 3CN (9.5 mg, 0.15 mmol, 3.0 equiv). The mixture was stirred at room temperature for 18 h and then diluted with water (10 mL). Na 2 CO 3 To adjust to pH 10-11. The mixture was extracted with EtOAc (20 mL x 2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate and concentrated in vacuo. The resulting residue was purified by preparative HPLC to give 5-amino-1-(1-methylpiperidin-4-yl)-3-(2-phenylquinoline-7-yl)-1H-pyrazole-4-carboxamide (1.9 mg, 9.2%) as a white solid. LCMS (M+H + )m / z: calculated: 427.2, found: 427.3, 1 H NMR (400MHz, CD 3 OD)δ8.40(d,1H),8.01(d,1H),8.05(d,2H),8.01(d,2H)7.75(d,1H),7.40-7.45(m ,3H),4.58(s,3H),3.18-3.22(m,2H),2.47(s,3H),2.31-2.35(m,2H),2.04(d,2H).

[0309] Example 8: Preparation of 5-amino-1-(1-(2-hydroxyethyl)piperidin-4-yl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide

[0310]

[0311] To a solution of 5-amino-3-(2-phenylquinolin-7-yl)-1-(piperidin-4-yl)-1H-pyrazole-4-carboxamide (20 mg, 0.049 mmol, 1.0 equiv) in MeCN (8 mL) were added 2-bromoethane-1-ol (8 mg, 0.064 mmol, 1.3 equiv) and Cs 2 CO 3 (32 mg, 0.098 mmol, 2 equiv.). The mixture was stirred at 80 ° C for 15 h, then diluted with water (50 mL) and extracted with EtOAc (20 mL × 2). The combined organic layer was washed with water (20 mL) and brine (20 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was purified by preparative HPLC to give 5-amino-1-(1-(2-hydroxyethyl)piperidin-4-yl)-3-(2-phenylquinoline-7-yl)-1H-pyrazole-4-carboxamide as a white solid (2.7 mg, 12.2%). LRMS (M+H +)m / z: calculated: 457.2, found: 457.1. 1 H NMR (DMSO-d 6 ,400MHz)δ8.48(d,1H),8.28-8.30(m,2H),8.15-8.18(m,2H),8.03(d,1H),7.57-7.78(dd,1H),7.49-7.59(m,3H),6.3 0(s,2H),4.39(s,1H),4.13-4.18(m,1H),3.51(s,2H),3.00(d,2H),2.44(t,2H),1.99-2.17(m,4H),1.80-1.83(m,2H).

[0312] Example 9: Preparation of 5-amino-1-((1s, 3s)-3-hydroxycyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide and 5-amino-1-((1r, 3r)-3-hydroxycyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide

[0313]

[0314] To a solution of 3-(benzyloxy)cyclobutane-1-one (2.0 g, 11.40 mmol, 1.0 equiv) in hexanes (100 mL) was added NH 2 -NH 2 The mixture was stirred at 80 ° C for 3 h and then concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give tert-butyl 2-(3-(benzyloxy)cyclobutylene)hydrazine-1-carboxylate as a yellow oil (2.4 g, 90.2%), LRMS (M+H + )m / z: calculated: 291.2, found: 291.1.

[0315]

[0316] To a solution of tert-butyl 2-(3-(benzyloxy)cyclobutylidene)hydrazine-1-carboxylate (2.0 g, 6.9 mmol, 1.0 equiv) in THF (100 mL) was added BH 3 (1M, 22 mL, 22.00 mmol, 3.0 equiv). The mixture was stirred at room temperature for 15 h and then washed with saturated NH 4The mixture was quenched with Cl aqueous solution and extracted with EtOAc (200 mL x 2). The combined organic layers were washed with brine (200 mL) and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give tert-butyl 2-((1s, 3s)-3-(benzyloxy)cyclobutyl)hydrazine-1-carboxylate (2.1 g, about 100%) as a colorless oil, LRMS (M+H + )m / z: calculated: 293.2, found: 293.1.

[0317]

[0318] To a stirred solution of tert-butyl 2-((1s,3s)-3-(benzyloxy)cyclobutyl)hydrazine-1-carboxylate (2.4 g, 10.30 mmol, 1.0 equiv) in DCM (80 mL) was added 4N HCl / dioxane (50 mL). The reaction was stirred at 30 °C for 30 min and then concentrated in vacuo to give ((1s,3s)-3-(benzyloxy)cyclobutyl)hydrazine (2.1 g, ca. 100.0%). LRMS (M+H + )m / z: calculated: 193.1, found: 193.0.

[0319]

[0320] To a solution of ((1s,3s)-3-(benzyloxy)cyclobutyl)hydrazine (500 mg, 2.60 mmol, 1.0 eq) in EtOH (30 mL) was added 2-(methoxy(2-phenylquinolin-7-yl)methylene)malononitrile (1.2 g, 3.9 mmol, 1.5 eq) and TEA (5.4 mL, 39.1 mmol, 15.0 eq). The mixture was stirred at 90 °C for 2 h, then concentrated, diluted with water (20 mL), and extracted with EtOAc (50 mL x 2). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 5-amino-1-((1s,3s)-3-(benzyloxy)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (450 mg, 36.8%) as a yellow solid. LRMS (M+H + )m / z: calculated: 472.2, found: 472.2.

[0321]

[0322] 5-Amino-1-((1s,3s)-3-(benzyloxy)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (450 mg, 0.95 mmol, 1.0 equiv) was stirred in H 2 SO 4 The solution in 4% NaOH (10 mL) was stirred at room temperature for 5 h and then poured into ice. 2 CO 3 The mixture was stirred for 2 hours at room temperature for 3 hours to adjust to pH = 12-13. The aqueous layer was concentrated in vacuo and the resulting residue was triturated with DCM / MeOH (1 / 1, 300 mL) and filtered. The organic layer was concentrated in vacuo and the resulting residue was purified by preparative HPLC to give 5-amino-1-((1s, 3s)-3-hydroxycyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide as a white solid (250 mg, 65.8%), LRMS (M+H + )m / z: calculated: 400.2, found: 400.3. 1 H NMR (400 MHz, DMSO-d 6 )δ8.49(d,1H),8.40-8.33(m,2H),8.22(d,1H),8.17(d,1H),8.05(d,1H),7.83 (dd,1H),7.49-7.59(m,3H),6.26(s,2H),4.33-4.49(m,2H),2.57-2.76(m,4H).

[0323] Example 10: Preparation of 1-(1-acetylpiperidin-4-yl)-5-amino-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide

[0324]

[0325] 5-amino-3-(2-phenylquinolin-7-yl)-1-(piperidin-4-yl)-1H-pyrazole-4-carboxamide (25 mg, 0.06 mmol, 1.0 equiv) was added to a precipitate in MeCN / H 2 O (1 / 1, 5 mL) was added with NaHCO 3 (15 mg, 0.18 mmol, 3.0 equiv) and (CH 3 CO) 2The mixture was stirred at room temperature for 3 hours, then concentrated in vacuo and diluted with water (10 mL), and extracted with EtOAc (20 mL × 2). The combined organic layer was washed with brine (50 mL) and dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was purified by preparative HPLC to give 1-(1-acetylpiperidin-4-yl)-5-amino-3-(2-phenylquinoline-7-yl)-1H-pyrazole-4-carboxamide (22 mg, 78.5%) as a white solid. LRMS (M+H + )m / z: calculated: 455.2, found: 455.1. 1 H NMR (400 MHz, DMSO-d 6 )δ8.48(d,1H),8.29(d,2H),8.15-8.19(m,2H),8.03(d,1H),7.76(d,1H),7.51-7.59(m,3H),6.35(s,2H),4 .42-4.54(m,2H),3.95-3.99(m,1H),3.17-3.33(m,1H),2.50-2.71(m,1H),1.98(s,3H),1.75-1.96(m,4H).

[0326] Example 11: Preparation of ethyl (1s, 3s)-3-(5-amino-4-carbamoyl-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)cyclobutane-1-carboxylate

[0327]

[0328] To a solution of ethyl 3-oxocyclobutane-1-carboxylate (20.0 g, 140.8 mmol, 1.0 equiv) in hexane (200 mL) was added tert-butyl hydrazinecarboxylate (22.3 g, 169.0 mmol, 1.2 equiv) at room temperature. The compound was stirred at 80 ° C for 2 h and then concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (PE / EA=2 / 1, v / v) to give tert-butyl 2-(3-(ethoxycarbonyl)cyclobutylene)hydrazine-1-carboxylate (32 g, 88.9%) as a white solid. LRMS (M+H + )m / z: calculated: 257.1, found: 257.0.

[0329]

[0330] At room temperature, tert-butyl 2-(3-(ethoxycarbonyl)cyclobutylidene)hydrazine-1-carboxylate (27 g 105.5 mmol, 1.0 equiv) and NaBH 3CN (13.3g, 210.9mmol, 2.0 equivalents) was added to a stirred solution of MeOH (100mL) / THF (200mL) with AcOH (3mL, 50mmol, 0.5 equivalents). The reaction mixture was stirred at 70°C for 18, then cooled to room temperature and concentrated in vacuo. The resulting residue was diluted with EtOAc (200mL), washed with water (200mL) and brine (200mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH=40:1, v / v) to give tert-butyl 2-(3-(ethoxycarbonyl)cyclobutyl)hydrazine-1-carboxylate (27.3g, about 100%) as a white solid. LRMS (M+H + )m / z: calculated: 259.2, found: 259.1.

[0331]

[0332] To a stirred solution of tert-butyl 2-(3-(ethoxycarbonyl)cyclobutyl)hydrazine-1-carboxylate (27.3 g, 105.8 mmol, 1.0 equiv) in DCM (80 mL) was added HCl in dioxane (4 N, 30 mL). The reaction was stirred at 30 °C for 30 min and then concentrated in vacuo to give ethyl 3-hydrazinocyclobutane-1-carboxylate as a white solid (23.1 g, ca. 100%). LRMS (M+H + )m / z: calculated: 159.1, found: 159.0.

[0333]

[0334] To a solution of 2-(methoxy(2-phenylquinolin-7-yl)methylene)malononitrile (2 g, 6.4 mmol, 1.0 eq) and ethyl 3-hydrazinocyclobutane-1-carboxylate (1.5 g, 9.6 mmol, 1.5 eq) in EtOH (30 mL) was added TEA (7.1 mL, 51.4 mmol, 8.0 eq) at room temperature. The reaction mixture was stirred at 90 °C for 2 h and then concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (PE / EA=2 / 1, v / v) to give ethyl (1s,3s)-3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)cyclobutane-1-carboxylate (900 mg, 32.1%) and ethyl (1r,3s)-3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)cyclobutane-1-carboxylate (830 mg, 29.6%) as white solids. Ethyl (1s,3s)-3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)cyclobutane-1-carboxylate: 1 HNMR (DMSO-d 6 ,400MHz)δ8.53(s,1H),8.49(d,1H),8.30(d,2H),8.18(d,1H),8.05-8.10(m,2H),7.50-7.59(m,3H),6.85(s ,2H),4.77-4.81(m,1H),4.13(q,2H),2.95-2.99(m,1H),2.73-2.80(m,2H),2.64-2.69(m,2H),1.22(t,3H). LRMS(M+H + )m / z: calculated value: 438.2, found value: 438.1. (1r,3s)-3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)cyclobutane-1-carboxylic acid ethyl ester: 1 H NMR (DMSO-d 6 ,400MHz)δ8.56(s,1H),8.49(d,1H),8.30(d,2H),8.18(d,1H),8.07-8.13(m,2H),7.51-7.60(m,3H),6.85(s ,2H),5.02-5.06(m,1H),4.15(q,2H),3.23-3.28(m,1H),2.84-2.91(m,2H),2.61-2.68(m,2H),1.25(t,3H). LRMS(M+H + )m / z: calculated: 438.2, found: 438.1.

[0335]

[0336] (1s,3s)-3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)cyclobutane-1-carboxylic acid ethyl ester (25 mg, 0.057 mmol, 1.0 equiv) was dissolved in concentrated H 2 SO 4 The solution in (3mL) was stirred at 25 ° C for 15h, then adjusted to pH 8 with saturated sodium carbonate solution and extracted with EtOAc (30mL×2). The combined organic layer was washed with brine (20mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was purified by preparative HPLC to give (1s, 3s)-3-(5-amino-4-carbamoyl-3-(2-phenylquinoline-7-yl)-1H-pyrazol-1-yl)cyclobutane-1-carboxylic acid ethyl ester as a white solid (8.5mg, 32.6%). LRMS (M+H + )m / z: calculated: 456.2, found: 456.1. 1 H NMR (DMSO-d 6 ,400MHz)δ8.50(d,1H),8.29-8.31(m,2H),8.17-8.20(m,2H),8.06(d,1H),7.75-7.78(dd,1H),7.50-7.59(m,3H),6.3 1(s,2H),4.76-4.80(m,1H),4.06-4.12(m,2H),2.94-2.98(m,1H),2.70-2.77(m,2H),2.58-2.65(m,2H),1.23(s,3H).

[0337] Example 12: Preparation of 5-amino-1-((1s,3s)-3-(morpholinomethyl)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide

[0338]

[0339] To a stirred solution of (1s,3s)-3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)cyclobutane-1-carboxylic acid ethyl ester (2.0 g, 4.6 mmol, 1.0 equiv) in anhydrous THF (20 mL) was added DIBAL-H (1 N, 9.2 mL, 9.2 mmol, 2.0 equiv) in hexanes under ice bath. The reaction was stirred at 0°C for 2 h and then washed with saturated NH 4Cl aqueous solution (20.0mL) was quenched and extracted with EtOAc (50mL x 3). The combined organic layer was dried over sodium sulfate and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (PE / EtOAc=1 / 1, v / v) to give 5-amino-1-((1s, 3s)-3-(hydroxymethyl)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile as a light yellow oil (600mg, 33.3%). LRMS (M+H + )m / z: calculated: 396.2, found: 396.1.

[0340]

[0341] To a stirred solution of 5-amino-1-((1s,3s)-3-(hydroxymethyl)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (600 mg, 1.5 mmol, 1.0 eq) and DMAP (366.6 mg, 3.0 mmol, 2.0 eq) in DCM (30 mL) was added TsCl (438.6 mg, 2.3 mmol, 1.5 eq) portionwise. The reaction mixture was stirred at 35 °C for 1 h and then quenched by H 2 O (20.0mL) quenched and extracted by EtOAc (50mL x 3). The combined organic layer was dried over sodium sulfate and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (PE / EtOAc=2 / 1, v / v) to give ((1s, 3s)-3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)cyclobutyl)4-methylbenzenesulfonic acid methyl ester as a light yellow solid (800mg, 95.9%). LRMS (M+H + )m / z: calculated: 550.2, found: 550.3.

[0342]

[0343] A solution of methyl ((1s,3s)-3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)cyclobutyl)4-methylbenzenesulfonate (800 mg, 1.5 mmol, 1.0 equiv) and morpholine (652.5 mg, 7.5 mmol, 5.0 equiv) in DMA (10.0 mL) was stirred at 100 °C for 4 h and then heated by H 2O (100.0mL) quenched and extracted by DCM / MeOH (10 / 1, 50mL x 3). The combined organic layer was dried over sodium sulfate and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH = 10 / 1, v / v) to give 5-amino-1- ((1s, 3s) -3- (morpholinomethyl) cyclobutyl) -3- (2-phenylquinolin-7-yl) -1H- pyrazole-4-carbonitrile as a light yellow oil (600mg, 88.6%). LRMS (M + H + )m / z: calculated: 465.2, found: 465.1.

[0344]

[0345] 5-Amino-1-((1s,3s)-3-(morpholinomethyl)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (400 mg, 0.9 mmol, 1.0 equiv) was stirred in H 2 SO 4 The mixture in 4% paraformaldehyde (1 mL) was stirred at room temperature for 12 h and then heated to 400 °C. 2 O (20.0 mL) and the mixture was washed with saturated Na 2 CO 3 The aqueous solution was adjusted to pH 8.0 and then extracted by DCM: MeOH (10: 1, 50 mL x 3). The combined organic layer was dried over sodium sulfate and concentrated in vacuo. The resulting residue was purified by reverse phase chromatography, eluted with an aqueous solution of MeCN (10% to 70%) to give 5-amino-1-((1s, 3s)-3-(morpholinomethyl)cyclobutyl)-3-(2-phenylquinoline-7-yl)-1H-pyrazole-4-carboxamide as a white solid (301.5 mg, 72.5%). LRMS (M+H + )m / z: calculated: 483.2, found: 483.1. 1 H NMR (MeOD-d 4 ,400MHz)δ9.22(d,1H),8.72(s,1H),8.17-8.44(m,5H),7.77-7.81(m,3H),4.03-4.07(m 2H),3.83-4.03(m,3H),3.41-3.50(m,5H),3.18-3.30(m,3H),2.70-2.82(m,2H),2.62(s,1H).

[0346] Example 13: Preparation of 5-amino-1-((1r,3r)-3-(morpholinomethyl)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide

[0347]

[0348] In N 2 To a solution of (1r,3r)-3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)cyclobutane-1-carboxylic acid ethyl ester (530 mg, 1.2 mmol, 1.0 equiv) in DCM (15 mL) was added DIBAL-H (1 M, 1.5 mL, 1.5 mmol, 1.2 equiv) dropwise at -78 °C over a period of 10 min. The reaction mixture was stirred at -70 °C for 30 min, then quenched with water (5 mL) at 0 °C and filtered. The combined organic layers were washed with brine (15 mL), dried over sodium sulfate, filtered and concentrated in vacuo to give 5-amino-1-((1r,3r)-3-formylcyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (471 mg, about 100%) as a white solid. LRMS(M+H + )m / z: calculated: 394.2, found: 394.1.

[0349]

[0350] To a solution of 5-amino-1-((1r,3r)-3-formylcyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (200 mg, 0.51 mmol, 1.0 equiv) in MeOH (20 mL) was added NaBH(OAc) 3 (161.8 mg, 0.76 mmol, 1.5 eq), AcOH (15.3 mg, 0.25 mmol, 0.5 eq) and morpholine (66.4 mg, 0.76 mmol, 1.5 eq) were added and the mixture was stirred at 20 °C for 3 h, then quenched with water and MeOH was removed in vacuo. The resulting residue was washed with H 2 The mixture was diluted with 4-nitropropene (20 mL), extracted with EtOAc (50 mL), and the combined organic layers were dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to afford 5-amino-1-((1r, 3r)-3-(morpholinomethyl)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (150 mg, 63.5%) as a white solid.

[0351]

[0352] 5-Amino-1-((1r,3r)-3-(morpholinomethyl)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (150 mg, 0.32 mmol, 1.0 equiv) was added to 98% sulfuric acid (3 mL) at room temperature. The mixture was stirred for 1 h and then slowly poured into ice. The mixture was washed with saturated NaHCO 3 The aqueous solution was adjusted to pH 7 and extracted with ethyl acetate (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was purified by preparative HPLC to give 5-amino-1-((1r, 3r)-3-(morpholinomethyl)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide (60.2 mg, 38.7%) as a white solid. LRMS (M+H + )m / z: calculated: 483.2, found: 483.1. 1 H NMR (DMSO-d 6 ,400MHz)δ8.50(d,1H),8.29-8.32(m,2H),8.22(s,1H),8.18(d,1H),8.06(d,1H),7.80(dd,1H),7.52-7.60(m,3H), 6.28(s,2H),4.96-5.00(m,1H),3.58(t,4H),2.63-2.68(m,2H),2.50-2.52(m,3H),2.36-2.39(m,4H),2.16(t,2H).

[0353] Example 14: Preparation of 5-amino-1-((1r,3r)-3-(azetidin-1-ylmethyl)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide

[0354]

[0355] To a solution of 5-amino-1-((1r,3r)-3-formylcyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (70 mg, 0.18 mmol, 1.0 equiv) in DCM (20 mL) was added NaBH(OAc) 3 (56.6 mg, 0.27 mmol, 1.5 eq), AcOH (5.3 mg, 0.09 mmol, 0.5 eq) and azetidine (15.2 mg, 0.27 mmol, 1.5 eq). The mixture was stirred at 20 °C for 3 h, then quenched with water and concentrated in vacuo. The resulting residue was washed with H 2O (20mL) was diluted and extracted with EtOAc (50mL). The combined organic layer was washed with brine (20mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (PE / EA = 1 / 1, v / v) to obtain 5-amino-1- ((1r, 3r) -3- (azetidin-1-ylmethyl) cyclobutyl) -3- (2-phenylquinolin-7-yl) -1H- pyrazole-4-carbonitrile (20 mg, 63.5%) as a yellow solid. LRMS (M + H + )m / z: calculated: 435.2, found: 435.1.

[0356]

[0357] 5-Amino-1-((1r,3r)-3-(azetidin-1-ylmethyl)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (20 mg, 0.32 mmol, 1.0 equiv) was added to 98% sulfuric acid (3 mL) and the mixture was stirred at room temperature for 3 h, then slowly poured into ice and concentrated by adding saturated NaHCO 3 The mixture was stirred for 2 hours at 4 ℃ for 10 minutes at 4 ℃ for 30 minutes. The mixture was stirred for 2 hours ... + )m / z: calculated: 453.2, found: 453.1. 1 H NMR (CD 3 OD,400MHz)δ8.46(d,1H),8.32(s,1H),8.16(d,2H),8.06(dd,2H),7.76-7.80(m,1H),7.50 -7,58(m,3H),4.86-4.90(m,1H),3.31-3.35(m,5H),2.70-2.80(m,4H),2.11-2.28(m,4H).

[0358] Example 15: Preparation of 5-amino-3-(2-phenylquinolin-7-yl)-1-((1s,3s)-3-(piperazin-1-ylmethyl)cyclobutyl)-1H-pyrazole-4-carboxamide

[0359]

[0360] A solution of methyl ((1s,3s)-3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)cyclobutyl)4-methylbenzenesulfonate (40 mg, 0.07 mmol, 1.0 equiv) and tert-butyl piperazine-1-carboxylate (651.0 mg, 3.5 mmol, 5.0 equiv) in DMA (5.0 mL) was stirred at 100 °C for 4 h and then heated to room temperature by H 2 O (50.0mL) quenched and extracted by DCM: MeOH (10: 1, 20mL x 3). The combined organic layer was dried over sodium sulfate and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH=10 / 1, v / v) to give tert-butyl 4-(((1s, 3s)-3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)cyclobutyl)methyl)piperazine-1-carboxylate as a light yellow oil (20 mg, 48.8%). LRMS (M+H + )m / z: calculated: 564.3, found: 564.4.

[0361]

[0362] Tert-butyl 4-(((1s,3s)-3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)cyclobutyl)methyl)piperazine-1-carboxylate (20 mg, 0.04 mmol, 1.0 equiv) was dissolved in concentrated H 2 SO 4 The mixture in 4% paraformaldehyde (1.0 mL) was stirred at room temperature for 12 h and then purified by H 2 O (20.0 mL). Then, saturated Na 2 CO 3 The aqueous solution was adjusted to pH 8.0. The mixture was extracted by DCM / MeOH (10 / 1, 50 mL x 3). The combined organic layers were dried over sodium sulfate and concentrated in vacuo. The resulting residue was purified by preparative HPLC to give 5-amino-3-(2-phenylquinolin-7-yl)-1-((1s, 3s)-3-(piperazine-1-ylmethyl)cyclobutyl)-1H-pyrazole-4-carboxamide as a white solid (1.9 mg, 11.2%). LRMS (M+H + )m / z: calculated: 482.3, found: 482.2. 1 H NMR (DMSO-d 6,400MHz)δ8.50(d,1H),8.31(d,2H),8.17-8.19(m,2H),8.06(d,1H),7.77(d,1H),7.52-7.59(m,3H),6.2 6(s,2H),4.66-4-70(m,1H),2.67-2.72(m,4H),2.39-2.50(m,3H),2.19-2.31(m,5H),2.18-2.19(m,3H).

[0363] Example 16: Preparation of 5-amino-3-(2-phenylquinolin-7-yl)-1-((1r,3r)-3-(piperazin-1-ylmethyl)cyclobutyl)-1H-pyrazole-4-carboxamide

[0364]

[0365] To a solution of 5-amino-1-((1r,3r)-3-formylcyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (140 mg, 0.36 mmol, 1.0 equiv) in DCM (20 mL) was added NaBH(OAc) 3 (113.2 mg, 0.53 mmol, 1.5 eq), AcOH (10.7 mg, 0.18 mmol, 0.5 eq) and tert-butyl piperazine-1-carboxylate (99.4 mg, 0.53 mmol, 1.5 eq). The mixture was stirred at 20 °C for 3 h, then quenched with water and concentrated in vacuo. The resulting residue was washed with H 2 O (20mL) and extracted with EtOAc (50mL). The combined organic layers were washed with brine (20mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was purified by column chromatography (SiO 2 , PE / EA=1 / 1, v / v) to obtain tert-butyl 4-(((1r,3r)-3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)cyclobutyl)methyl)piperazine-1-carboxylate (30 mg, 15.0%) as a yellow solid. LRMS (M+H + )m / z: calculated value: 564.3, found value: 564.2.

[0366]

[0367] tert-Butyl 4-(((1r,3r)-3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)cyclobutyl)methyl)piperazine-1-carboxylate (30 mg, 0.053 mmol, 1.0 equiv) was added to concentrated H 2SO 4 (3 mL) and the mixture was stirred for 3 h, then slowly poured into ice and concentrated by adding saturated NaHCO 3 The mixture was stirred for 2 hours at 4 ℃ for 10 minutes at 4 ℃ for 2 hours. The mixture was stirred for 2 hours at 4 ℃ for 3 hours at 4 ℃ for 10 minutes ... + )m / z: calculated: 482.3, found: 482.2. 1 H NMR (CD 3 OD,400MHz)δ8.79(d,1H),8.46(s,1H),8.21(d,2H),8.14-8.17(m,2H),8.00(d,1H),7.64-7.66(m ,3H),4.86-4.95(m,1H),3.47(brs,4H),3.24-3.31(m,4H),2.86-2.91(m,3H),2.44-2.47(m,2H).

[0368] Example 17: Preparation of (1s, 3s)-3-(5-amino-4-carbamoyl-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)cyclobutane-1-carboxylic acid

[0369]

[0370] To (1s,3s)-3-(5-amino-4-carbamoyl-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)cyclobutane-1-carboxylic acid ethyl ester (70 mg, 0.15 mmol, 1.0 equiv) was added MeOH / H 2 To the solution in 4% 4-nitropropene (2-nitropropene)-1H-pyrazol-1-yl)-1H-pyrazol-1-yl)-cyclobutane-1-carboxylic acid was added LiOH (10.8 mg, 0.45 mmol, 3.0 equiv). The mixture was stirred at 50 ° C for 1 h and then concentrated in vacuo. The mixture was adjusted to pH 5 with 37% HCl, the solid was filtered and further purified by preparative HPLC to give (1s, 3s)-3-(5-amino-4-carbamoyl-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)cyclobutane-1-carboxylic acid as a white solid (24.0 mg, 36.5%). LCMS (M+H+) m / z: calculated: 428.2, found: 428.1. 1 H NMR (DMSO-d 6,400MHz)δ8.49(d,1H),8.29-8.31(m,2H),8.16-8.19(m,2H),8.05(d,1H),7.76-7.78(dd,1 H),7.51-7.58(m,3H),6.37(s,2H),4.71-4.75(m,1H),2.69-2.78(m,3H),2.54-2.57(m,2H).

[0371] Example 18: Preparation of 5-amino-1-((1s,3s)-3-(azetidin-1-ylmethyl)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide

[0372]

[0373] A solution of methyl ((1s,3s)-3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)cyclobutyl)4-methylbenzenesulfonate (140 mg, 0.27 mmol, 1.0 equiv) and azetidine (145 mg, 2.7 mmol, 10.0 equiv) in DMA (5.0 mL) was stirred at 100 °C for 4 h and then heated to room temperature by H 2 O (20.0mL) quenched and extracted by DCM / MeOH (10 / 1, 20mL x 3). The combined organic layer was dried over sodium sulfate and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH = 10 / 1, v / v) to give 5-amino-1- ((1s, 3s) -3- (azetidin-1-ylmethyl) cyclobutyl) -3- (2-phenylquinolin-7-yl) -1H- pyrazole-4-carbonitrile as a yellow solid (50 mg, 45.2%). LRMS (M + H + )m / z: calculated: 435.2, found: 435.1.

[0374]

[0375] 5-Amino-1-((1s,3s)-3-(azetidin-1-ylmethyl)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (20 mg, 0.04 mmol, 1.0 equiv) was stirred in H 2 SO 4 The mixture in 4% paraformaldehyde (2.0 mL) was stirred at room temperature for 12 h and then purified by H 2 O (20.0 mL) and quenched by adding saturated Na 2 CO 3The aqueous solution was adjusted to pH = 8.0. The mixture was extracted by DCM / MeOH (10 / 1, 30mL × 3). The combined organic layer was dried over sodium sulfate and concentrated in vacuo. The resulting residue was purified by reverse phase chromatography, eluted with an aqueous solution of MeCN (from 10% to 80%) to give 5-amino-1-((1s, 3s)-3-(azetidin-1-ylmethyl)cyclobutyl)-3-(2-phenylquinoline-7-yl)-1H-pyrazole-4-carboxamide as a white solid (1.1 mg, 5.2%). LRMS (M + H + )m / z: calculated: 453.2, found: 453.2. 1 H NMR (DMSO-d 6 ,400MHz)δ8.50(d,1H),8.29-8.31(m,2H),8.17-8.20(m,2H),8.07(d,1H),7.77(d,1H),7.52-7.59(m,3H), 6.27(s,2H),4.67-4.71(m,1H),2.67-2.68(m,1H),2.33-2.38(m,6H),2.21-2.25(m,3H),1.98-2.08(m,3H).

[0376] Example 19: Preparation of 5-amino-1-((1s,3s)-3-((4-methylpiperazin-1-yl)methyl)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide

[0377]

[0378] A solution of methyl ((1s,3s)-3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)cyclobutyl)4-methylbenzenesulfonate (130 mg, 0.24 mmol, 1.0 equiv) and 1-methylpiperazine (118.4 mg, 1.2 mmol, 5.0 equiv) in DMA (5.0 mL) was stirred at 100 °C for 4 h and then heated to room temperature by H 2 O (50.0mL) quenched and extracted by DCM / MeOH (10 / 1, 20mL x 3). The combined organic layer was dried over sodium sulfate and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH = 10 / 1, v / v) to give 5-amino-1- ((1s, 3s) -3- ((4-methylpiperazine-1-yl) methyl) cyclobutyl) -3- (2-phenylquinolin-7-yl) -1H- pyrazole-4-carbonitrile as a light yellow oil (90 mg, 79.6%). LRMS (M + H +)m / z: calculated: 478.3, found: 478.4.

[0379]

[0380] 5-Amino-1-((1s,3s)-3-((4-methylpiperazin-1-yl)methyl)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (40 mg, 0.08 mmol, 1.0 equiv) was dissolved in concentrated H 2 SO 4 The mixture in 4% paraformaldehyde (1.0 mL) was stirred at room temperature for 12 h and then purified by H 2 O (20.0 mL) and the mixture was washed with saturated Na 2 CO 3 The aqueous solution was adjusted to pH 8.0. The mixture was extracted by DCM: MeOH (10: 1, 50 mL x 3). The combined organic layers were dried over sodium sulfate and concentrated in vacuo. The resulting residue was purified by preparative HPLC to give 5-amino-1-((1s, 3s)-3-((4-methylpiperazine-1-yl)methyl)cyclobutyl)-3-(2-phenylquinoline-7-yl)-1H-pyrazole-4-carboxamide as a white solid (21.7 mg, 52.3%). LRMS (M+H + )m / z: calculated: 496.3, found: 496.3. 1 H NMR (DMSO-d 6 ,400MHz)δ8.50(d,1H),8.30-8.32(m,2H),8.17-8.19(m,2H),8.06(d,1H),7.77(d,1H),7.52-7.59(m,3H ),6.26(s,2H),4.69-4.71(m,1H),2.49-2.51(m,3H),2.36-2.42(m,7H),2.13-2.35(m,5H),2.14(s,3H).

[0381] Example 20: Preparation of ethyl (1r,3r)-3-(5-amino-4-carbamoyl-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)-1-methylcyclobutane-1-carboxylate

[0382]

[0383] To a solution of 1-methyl-3-oxocyclobutane-1-carboxylic acid ethyl ester (5.0 g, 32.1 mmol, 1.0 equiv) in hexane (80 mL) was added tert-butyl hydrazinecarboxylate (5.1 g, 38.4 mmol, 1.2 equiv) at room temperature. The mixture was stirred at 80 ° C for 2 h and then concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (PE / EA=2 / 1, v / v) to give tert-butyl 2-(3-(ethoxycarbonyl)-3-methylcyclobutylene)hydrazine-1-carboxylate (5 g, 58.1%) as a white solid. LRMS (M+H + )m / z: calculated: 271.2, found: 271.1.

[0384]

[0385] At room temperature, tert-butyl 2-(3-(ethoxycarbonyl)-3-methylcyclobutylidene)hydrazine-1-carboxylate (5 g 18.4 mmol, 1.0 equiv) and NaBH 3 To a stirred solution of CN (2.3 g, 36.7 mmol, 2.0 equiv.) in MeOH (50 mL) / THF (50 mL), AcOH (0.6 mL, 9.2 mmol, 0.5 equiv.) was added. The reaction mixture was stirred at 70 ° C for 16 h, then cooled to room temperature and concentrated in vacuo. The resulting residue was diluted with EtOAc (200 mL), washed with water (200 mL) and brine (200 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH=40:1, v / v) to give tert-butyl 2-(3-(ethoxycarbonyl)-3-methylcyclobutyl)hydrazine-1-carboxylate (4.9 g, about 100%) as a white solid. LRMS (M+H + )m / z: calculated: 273.2, found: 273.1.

[0386]

[0387] To a stirred solution of tert-butyl 2-(3-(ethoxycarbonyl)-3-methylcyclobutyl)hydrazine-1-carboxylate (4.9 g, 18.0 mmol, 1.0 equiv) in DCM (30 mL) was added 4N HCl / dioxane (30 mL). The reaction was stirred at 30 °C for 30 min and then concentrated in vacuo to give ethyl 3-hydrazino-1-methylcyclobutane-1-carboxylate (4 g, ca. 100%) as a white solid. LRMS (M+H + )m / z: calculated: 173.1, found: 173.0.

[0388]

[0389] To a solution of 2-(methoxy(2-phenylquinolin-7-yl)methylene)malononitrile (3.0 g, 9.7 mmol, 1.0 equiv) and ethyl 3-hydrazino-1-methylcyclobutane-1-carboxylate (2.5 g, 14.5 mmol, 1.5 equiv) in EtOH (30 mL) was added TEA (10.7 mL, 77.5 mmol, 8.0 equiv) at room temperature. The reaction mixture was stirred at 90 °C for 2 h and then concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (PE / EA=2 / 1, v / v) to give (1s, 3s)-3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)-1-methylcyclobutane-1-carboxylic acid ethyl ester (45 mg, 1.1%) and (1r, 3r)-3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)-1-methylcyclobutane-1-carboxylic acid ethyl ester (600 mg, 13.9%) as white solids. (1s, 3s)-3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)-1-methylcyclobutane-1-carboxylic acid ethyl ester: 1 H NMR (DMSO-d 6 ,400MHz)δ8.54(s,1H),8.50(d,1H),8.30-8.32(m,2H),8.19(d,1H),8.05-8.12(m,2H),7.51-7.61(m,3H),6 .88(s,2H),4.99-5.04(m,1H),4.16(q,2H),2.93-2.98(m,2H),2.31-2.37(m,2H),1.48(s,3H),1.26(t,3H). LRMS(M+H + )m / z: calculated value: 452.2, found value: 452.1. (1r,3r)-3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)-1-methylcyclobutane-1-carboxylic acid ethyl ester: 1 H NMR (DMSO-d 6 ,400MHz)δ8.56(s,1H),8.50(d,1H),8.29-8.32(m,2H),8.19(d,1H),8.11-8.12(m,2H),7.53-7.61(m,3H),6 .85(s,2H),4.88-4.93(m,1H),4.18(q,2H),2.86-2.93(m,2H),2.55-2.61(m,2H),1.50(s,3H),1.26(t,3H). LRMS(M+H +)m / z: calculated: 452.2, found: 452.1.

[0390]

[0391] Ethyl (1r,3r)-3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)-1-methylcyclobutane-1-carboxylate (100 mg, 0.22 mmol, 1.0 equiv) was added to concentrated H 2 SO 4 (5 mL), and the mixture was stirred for 2 h, then slowly poured into ice and concentrated by adding saturated NaHCO 3 The solution was adjusted to pH 7 and extracted with ethyl acetate (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was purified by preparative HPLC to give (1r, 3r)-3-(5-amino-4-carbamoyl-3-(2-phenylquinoline-7-yl)-1H-pyrazol-1-yl)-1-methylcyclobutane-1-carboxylic acid ethyl ester (23.8 mg, 23.1%) as a white solid. LRMS (M+H + )m / z: calculated: 470.2, found: 470.2. 1 H NMR (DMSO-d 6 ,400MHz)δ8.50(d,1H),8.30(d,2H),8.22(s,1H),8.18(d,1H),8.06(d,1H),7.79(dd,1H),7.51-7.59(m,3H), 6.31(s,2H),4.85-4.90(m,1H),4.17(q,2H),2.83-2.89(m,2H),2.52-2.58(m,2H),1.44(s,3H),1.26(t,3H).

[0392] Example 21: Preparation of 5-amino-1-((1r,3r)-3-((4-methylpiperazin-1-yl)methyl)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide

[0393]

[0394] To a solution of 5-amino-1-((1r,3r)-3-formylcyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (160 mg, 0.41 mmol, 1.0 equiv) and 1-methylpiperazine (48.8 mg, 0.49 mmol, 1.2 equiv) in DCE (35 mL) was added NaBH(OAc)3 (172 mg, 0.81 mmol, 2.0 equiv.). The mixture was stirred at 25 ° C for 3 h and then concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (PE / EA = 20 / 1, v / v) to give 5-amino-1- ((1r, 3r) -3- ((4-methylpiperazine-1-yl) methyl) cyclobutyl) -3- (2-phenylquinolin-7-yl) -1H- pyrazole-4-carbonitrile as a yellow solid (110 mg, 56.6%). LRMS (M + H + )m / z: calculated: 474.3, found: 474.2.

[0395]

[0396] 5-Amino-1-((1r,3r)-3-((4-methylpiperazin-1-yl)methyl)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (110 mg, 0.23 mmol, 1.0 equiv) was dissolved in concentrated H 2 SO 4 The solution in (3mL) was stirred at 25 ° C for 15h, and then adjusted to pH = 8 by adding saturated aqueous sodium carbonate solution. The mixture was extracted with EtOAc (30mL X 2). The combined organic layer was washed with brine (20mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was purified by preparative HPLC to give 5-amino-1-((1r, 3r)-3-((4-methylpiperazine-1-yl)methyl)cyclobutyl)-3-(2-phenylquinoline-7-yl)-1H-pyrazole-4-carboxamide as a white solid (26.4mg, 23.2%). LRMS (M+H + )m / z: calculated: 496.3, found: 496.3. 1 H NMR (DMSO-d 6 ,400MHz)δ8.49(d,1H),8.29-8.31,(m,2H),8.16-8.21,(m,2H),8.05(d,1H),7.79(dd,1H),7.49-7.59(m,3H) ,6.26(s,2H),4.94-4.98(m,1H),2.63-2.65(m,2H),2.48-2.49,(m,4H),2.24-2.37(m,7H),2.11-2.15(m,5H).

[0397] Example 22: Preparation of (1r, 3r)-3-(5-amino-4-carbamoyl-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)-1-methylcyclobutane-1-carboxylic acid

[0398]

[0399] Ethyl (1r,3r)-3-(5-amino-4-carbamoyl-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)-1-methylcyclobutane-1-carboxylate (22 mg, 0.046 mmol, 1.0 equiv) and LiOH (1.5 mg, 0.07 mmol, 1.5 equiv) were stirred in MeOH / H 2 The solution in 20 mL / 5 mL was stirred at 30 ° C for 5 h, then adjusted to pH 5 with 37% HCl and concentrated in vacuo. The resulting residue was purified by preparative HPLC to give (1r, 3r)-3-(5-amino-4-carbamoyl-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)-1-methylcyclobutane-1-carboxylic acid (14.4 mg, 70.0%) as a yellow solid. LRMS (M+H + )m / z: calculated: 442.2, found: 442.1. 1 H NMR (DMSO-d 6 ,400MHz)δ8.50(d,1H),8.30(d,2H),8.21(s,1H),8.17(d,1H),8.06(d,1H),7.79(dd,1H),7.49- 7.60(m,3H),6.28(s,2H),4.82-4.87(m,1H),2.74-2.80(m,2H),2.27-2.32(m,2H),1.30(s,3H).

[0400] Example 23: Preparation of 5-amino-1-(3-morpholinocyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide

[0401]

[0402] Under ice bath, 5-amino-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (400 mg, 1.3 mmol, 1.0 equiv) and K 2 CO 3 To a stirred mixture of 3-bromocyclobutane-1-one (107.6 mg, 0.8 mmol, 0.6 eq) in DMF (5.0 mL) was added 3-bromocyclobutane-1-one (211.6 mg, 1.4 mmol, 1.1 eq). The mixture was stirred at room temperature for 4 h and then heated to room temperature by H 2The product was quenched with 4% paraformaldehyde (200 mg, 40.0 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were dried over sodium sulfate and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (PE / EtOAc=2 / 1, v / v) to give 5-amino-1-(3-oxocyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile as a light yellow oil (200 mg, 41.1%). LRMS (M+H + )m / z: calculated: 380.1, found: 380.1.

[0403]

[0404] To a stirred solution of 5-amino-1-(3-oxocyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (200 mg, 0.5 mmol, 1.0 equiv), AcOH (45.0 mg, 0.8 mmol, 1.5 equiv) and morpholine (130.5 mg, 1.5 mmol, 3.0 equiv) in DCM (5 mL) was added NaBH 3 CN (64 mg, 1.0 mmol, 2.0 equiv). The reaction was stirred at room temperature for 4 h and then quenched by H 2 The mixture was quenched with 4-nitropropene (20.0 mL) and extracted with DCM / MeOH (10 / 1, 30 mL x 3). The combined organic layers were dried over sodium sulfate and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH=10 / 1, v / v) to give 5-amino-1-(3-morpholinocyclobutyl)-3-(2-phenylquinoline-7-yl)-1H-pyrazole-4-carbonitrile as a light yellow solid (100 mg, 42.2%). LRMS (M+H + )m / z: calculated: 451.2, found: 451.2.

[0405]

[0406] 5-Amino-1-(3-morpholinocyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (100 mg, 0.2 mmol, 1.0 equiv) was dissolved in concentrated H 2 SO 4 The mixture was stirred at room temperature for 12 h and then washed with H 2 O (20.0 mL) and the mixture was washed with saturated Na 2 CO 3The aqueous solution was adjusted to pH 8.0. The mixture was extracted by DCM / MeOH (10 / 1, 20 mL x 3). The combined organic layer was dried over sodium sulfate and concentrated in vacuo. The resulting residue was purified by preparative HPLC to give 5-amino-1-(3-morpholinocyclobutyl)-3-(2-phenylquinoline-7-yl)-1H-pyrazole-4-carboxamide as a white solid (61.4 mg, 59.0%). LRMS (M+H + )m / z: calculated: 469.2, found: 469.1. 1 H NMR (DMSO-d 6 ,400MHz)δ8.50(d,1H),8.30-8.31(m,2H),8.17-8.19(m,2H),8.06(d,1H),7.77(m,1H),7.52-7.6 0(m,3H),6.30-6.32(s,2H),4.55-4.59(m,1H),3.58(d,4H),2.50-2.51(m,3H),2.30-2.39(m,6H).

[0407] Example 24: Preparation of 5-amino-1-isopropyl-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide

[0408]

[0409] To a stirred solution of 2-(methoxy(2-phenylquinolin-7-yl)methylene)malononitrile (550 mg, 1.8 mmol, 1.0 eq) and TEA (545.4 mg, 5.4 mmol, 3.0 eq) in EtOH (10.0 mL) was added isopropylhydrazine hydrochloride (396 mg, 3.6 mmol, 2.0 eq). The mixture was stirred at reflux for 2 h and then heated to 400 °C by H 2 The product was quenched with 4-nitropropane-2-yl-1H-pyrazole-4-carbonitrile (20.0 mL) and extracted with DCM / MeOH (10 / 1, 30 mL×3). The combined organic layers were concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH=10 / 1, v / v) to give 5-amino-1-isopropyl-3-(2-phenylquinoline-7-yl)-1H-pyrazole-4-carbonitrile as a light yellow solid (450.0 mg, 72.1%). LRMS (M+H + )m / z: calculated: 354.2, found: 354.2.

[0410]

[0411] 5-Amino-1-isopropyl-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (200 mg, 0.57 mmol, 1.0 equiv) was stirred in H 2 SO 4 The mixture in 4% paraformaldehyde (1 mL) was stirred at room temperature for 12 h and then heated to 400 °C. 2 O (20.0 mL) and the mixture was washed with saturated Na 2 CO 3 The aqueous solution was adjusted to pH 8.0 and then extracted by DCM / MeOH (10 / 1, 30 mL x 3). The combined organic layers were dried over sodium sulfate and concentrated in vacuo. The resulting residue was purified by preparative HPLC to give 5-amino-1-isopropyl-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide as a white solid (94.4 mg, 45.0%). LRMS (M+H + )m / z: calculated: 372.2, found: 372.1. 1 H NMR (DMSO-d 6 ,400MHz)δ8.48-8.50(d,1H),8.23(d,2H),8.16-8.18(m,2H),8.04(d,1H),7.7 7(d,1H),7.51-7.59(m,3H),6.28(s,2H),4.52-4.55(m,1H),1.38-1.40(m,6H).

[0412] Example 25: Preparation of 5-amino-3-(2-phenylquinolin-7-yl)-1-(3-(piperazin-1-yl)cyclobutyl)-1H-pyrazole-4-carboxamide

[0413]

[0414] To a solution of 5-amino-1-(3-oxocyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (100 mg, 0.26 mmol, 1.0 equiv) in DCM (20 mL) was added NaBH 3 CN (24.9 mg, 0.40 mmol, 1.5 eq), AcOH (23.7 mg, 0.40 mmol, 1.5 eq) and tert-butyl piperazine-1-carboxylate (147.2 mg, 0.79 mmol, 3.0 eq). The mixture was stirred at 20 °C for 3 h, then quenched with water and concentrated in vacuo. The resulting residue was purified by HPLC. 2 O (20mL) and extracted with EtOAc (50mL). The combined organic layers were washed with brine (20mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was purified by column chromatography (SiO2 , PE / EA=1 / 1, v / v) to obtain tert-butyl 4-(3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)cyclobutyl)piperazine-1-carboxylate (60 mg, 41.3%) as a yellow solid. LRMS (M+H + )m / z: calculated: 550.3, found: 550.2.

[0415]

[0416] Tert-butyl 4-(3-(5-amino-4-cyano-3-(2-phenylquinolin-7-yl)-1H-pyrazol-1-yl)cyclobutyl)piperazine-1-carboxylate (60 mg, 0.11 mmol, 1.0 equiv) was added to concentrated H 2 SO 4 The mixture was stirred at room temperature for 3 h, then slowly poured into ice and concentrated by adding saturated NaHCO 3 (aqueous solution) was adjusted to pH 7 and extracted with ethyl acetate (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was purified by preparative HPLC to give 5-amino-3-(2-phenylquinolin-7-yl)-1-(3-(piperazin-1-yl)cyclobutyl)-1H-pyrazole-4-carboxamide (21.9 mg, 43.1%) as a white solid. LRMS (M+H + )m / z: calculated: 468.2, found: 468.1. 1 H NMR (DMSO-d 6 ,400MHz)δ8.50(d,1H),8.31(d,2H),8.19(s,1H),8.18(d,1H),8.05(d,1H),7.77(dd,1H),7.49-7. 59(m,3H),6.31(s,2H),4.53-4.57(m,1H),2.63-2.68(m,4H),2.33-2.49(m,5H),2.19-2.22(m,4H).

[0417] Example 26: Preparation of 5-amino-1-(3-(4-methylpiperazin-1-yl)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide

[0418]

[0419] To a solution of 5-amino-1-(3-oxocyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (100 mg, 0.26 mmol, 1.0 equiv) in DCM (20 mL) was added NaBH 3 CN (24.9 mg, 0.40 mmol, 1.5 eq), AcOH (23.7 mg, 0.40 mmol, 1.5 eq) and 1-methylpiperazine (79.1 mg, 0.79 mmol, 3.0 eq). The mixture was stirred at 30 °C for 3 h, then quenched with water and concentrated in vacuo. The resulting residue was purified by HPLC. 2 The mixture was diluted with 4% ethyl acetate (20 mL) and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (20 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (SiO 2 , PE / EA=1 / 1, v / v) to obtain 5-amino-1-(3-(4-methylpiperazin-1-yl)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (70 mg, 57.3%) as a yellow solid. LRMS (M+H + )m / z: calculated: 464.2, found: 464.1.

[0420]

[0421] 5-Amino-1-(3-(4-methylpiperazin-1-yl)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (60 mg, 0.11 mmol, 1.0 equiv) was added to concentrated H 2 SO 4 (5 mL) and the mixture was stirred at room temperature for 3 h, then slowly poured into ice and washed with saturated NaHCO 3 The mixture was stirred for 2 hours at 4 ℃ for 10 minutes. The mixture was stirred for 2 hours at 4 ℃ for 3 ... + )m / z: calculated: 482.3, found: 482.2. 1 H NMR (DMSO-d 6,400MHz)δ8.50(d,1H),8.30(d,2H),8.19(s,1H),8.18(d,1H),8.04(d,1H),7.77(dd,1H),7.49- 7.59(m,3H),6.31(s,2H),4.51-4.60(m,1H),2.50-2.52(m,2H),2.31-2.41(m,11H),2.14(s,3H).

[0422] Example 27: Preparation of 5-amino-1-(3-(azetidin-1-yl)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide

[0423]

[0424] To a stirred solution of 5-amino-1-(3-oxocyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (200 mg, 0.5 mmol, 1.0 equiv), AcOH (45.0 mg, 0.8 mmol, 1.5 equiv) and azetidine (85.5 mg, 1.5 mmol, 3.0 equiv) in DCM (5 mL) was added NaBH 3 CN (64 mg, 1.0 mmol, 2.0 equiv). The reaction was stirred at room temperature for 4 h and then quenched by H 2 O (20.0mL) was quenched and the mixture was extracted by DCM / MeOH (10 / 1, 30mL x 3). The combined organic layer was dried over sodium sulfate and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH = 10 / 1, v / v) to give 5-amino-1- (3- (azetidin-1-yl) cyclobutyl) -3- (2-phenylquinolin-7-yl) -1H- pyrazole-4-carbonitrile as a light yellow oil (50mg, 22.5%). LRMS (M + H + )m / z: calculated: 421.2, found: 421.2.

[0425]

[0426] 5-Amino-1-(3-(azetidin-1-yl)cyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (50 mg, 0.1 mmol, 1.0 equiv) was dissolved in concentrated H 2 SO 4 The mixture of 2-nitropropene (1.0 mL) was stirred at room temperature for 12 h and then purified by H 2 O (20.0 mL) and the mixture was washed with saturated Na 2 CO3 The aqueous solution was adjusted to pH 8.0. The mixture was extracted by DCM / MeOH (10 / 1, 20 mL x 3). The combined organic layers were dried over sodium sulfate and concentrated in vacuo. The resulting residue was purified by preparative HPLC to give 5-amino-1-(3-(azetidin-1-yl)cyclobutyl)-3-(2-phenylquinoline-7-yl)-1H-pyrazole-4-carboxamide as a white solid (3.6 mg, 6.9%). LRMS (M+H + )m / z: calculated: 439.2, found: 439.1. 1 HNMR (DMSO-d 6 ,400MHz)δ8.51(d,1H),8.29-8.31(m,2H),8.17-8.20(m,2H),8.06(d,1H),7.78(dd,1H),7.52-7.59(m,3H),6.30(s,2 H),4.50-4.55(m,1H),3.27-3.32(m,3H),3.18-3.19(m,1H),2.67-2.68(m,1H),2.33-2.46(m,4H),1.93-1.97(m,2H).

[0427] Example 28: Preparation of 5-amino-3-(8-fluoro-2-phenylquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide

[0428]

[0429] A solution of 3-bromo-2-fluoroaniline (10 g, 52.9 mmol, 1.0 eq) and benzaldehyde (257 g, 2.40 mol, 1.2 eq) in toluene (1.5 L) was stirred at 150 °C for 16 h. The reaction mixture was concentrated to dryness in vacuo to give N-(3-bromo-2-fluorophenyl)-1-phenylmethanimine (7.5 g, 51.3%) as a yellow oil, which was used in the next step without further purification. LRMS (M+H + )m / z: calculated: 278.0, found: 278.0. 1 H NMR (DMSO-d 6 ,400MHz)δ8.68(s,1H),7.95-7.98(m,2H),7.52-7.62(m,4H),7.32(t,1H),7.20(t,1H).

[0430]

[0431] A solution of N-(3-bromo-2-fluorophenyl)-1-phenylmethanimine (7 g, 25.2 mmol, 1.0 equiv) and ethoxyethylene (9.1 g, 125.9 mol, 5.0 equiv) in TFE (100 mL) was stirred at 35 °C for 16 h. The reaction mixture was concentrated in vacuo and purified by column chromatography on silica gel (PE / EA=10 / 1, v / v) to give 7-bromo-8-fluoro-2-phenyl-1,2-dihydroquinoline (2.8 g, 37.8%) as a yellow solid. LRMS (M+H + )m / z: calculated: 304.0, found: 304.0.

[0432]

[0433] 7-Bromo-8-fluoro-2-phenyl-1,2-dihydroquinoline (2.8 g, 9.5 mmol, 1.0 equiv) and MnO 2 A suspension of (16.5 g, 190.1 mol, 5.0 equiv) in DCM (50 mL) was stirred at 35 °C for 12 h. The reaction mixture was filtered, and the filtrate was concentrated in vacuo and purified by column chromatography on silica gel (PE / EA=10 / 1, v / v) to give 7-bromo-8-fluoro-2-phenylquinoline (1.2 g, 42.8%) as a yellow solid. LRMS (M+H + )m / z: calculated: 302.0, found: 302.0.

[0434]

[0435] To 7-bromo-8-fluoro-2-phenylquinoline (500 mg, 1.7 mmol, 1.0 eq), DPPP (136.4 mg, 0.33 mmol, 0.2 eq) and Pd(OAc) was added. 2 To a solution of 1,4-difluoro-2-phenylquinoline-7-carboxylic acid (37.1 mg, 0.16 mmol, 0.1 eq.) in DMSO / MeOH (300 mL / 300 mL) was added TEA (40 mL, 289.8 mmol, 3.0 eq.). The mixture was stirred at 80 °C for 15 h under CO (1 atm) and then concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give 8-fluoro-2-phenylquinoline-7-carboxylic acid methyl ester (100 mg, 21.5%) as a yellow oil. LRMS (M+H + )m / z: calculated: 282.1, found: 282.1.

[0436]

[0437] To methyl 8-fluoro-2-phenylquinoline-7-carboxylate (100 mg, 0.36 mmol, 1.0 equiv) was dissolved in MeOH (30 mL) and H 2 To the solution in 4% 4-nitropropane-2-ol (5 mL) was added NaOH (21.4 mg, 0.53 mmol, 1.5 eq). The mixture was stirred at 50 °C for 5 h, then concentrated in vacuo and diluted with water (20 mL), and 37% HCl was added to adjust to pH 2. The resulting mixture was stirred for 5 min, filtered and concentrated in vacuo to give 8-fluoro-2-phenylquinoline-7-carboxylic acid (80 mg, 84.2%) as a white solid, LRMS (M+H + )m / z: calculated: 268.1, found: 268.1.

[0438]

[0439] To a solution of 8-fluoro-2-phenylquinoline-7-carboxylic acid (80 mg, 0.30 mmol, 1.0 equiv) in DCM (10 mL) was added (COCl) at -78 °C. 2 (0.13 mL, 1.5 mmol, 5.0 equiv) and DMF (1 drop). The mixture was stirred at room temperature for 1 h and then concentrated in vacuo to give 8-fluoro-2-phenylquinoline-7-carbonyl chloride as a yellow solid (95 mg, ca. 100.0%), LRMS (M+H + ) m / z: Calculated: 282.1, found: 282.1 in MeOH.

[0440]

[0441] In an ice bath, malononitrile (22.0 mg, 0.33 mmol, 1.0 equiv) and DIEA (0.2 mL, 1.0 mmol, 3.0 equiv) were added to a solution of 8-fluoro-2-phenylquinoline-7-carbonyl chloride (95 mg, 0.33 mmol, 1.0 equiv) in THF (10 mL). The mixture was stirred at room temperature for 3 h, then concentrated in vacuo and diluted with water (20 mL). The resulting mixture was extracted with EtOAc (50 mL×2). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH=50 / 1, v / v) to give 2-(8-fluoro-2-phenylquinoline-7-carbonyl) malononitrile as a yellow oil (60 mg, 54.5%), LRMS (M+H + )m / z: calculated: 316.1, found: 316.1.

[0442]

[0443] To a solution of 2-(8-fluoro-2-phenylquinoline-7-carbonyl)malononitrile (60 mg, 0.19 mmol, 1.0 equiv) in THF (10 mL) was added MeOH at room temperature. 2 SO 4 To the mixture was added 4-((8-fluoro-2-phenylquinoline-7-yl)-2-nitropropane-2-yl)-1 ... + )m / z: calculated: 330.1, found: 330.1.

[0444]

[0445] To a solution of 2-((8-fluoro-2-phenylquinolin-7-yl)(methoxy)methylene)malononitrile (40 mg, 0.12 mmol, 1.0 equiv) and (1s, 3s)-3-hydrazino-1-methylcyclobutane-1-ol (21.2 mg, 0.18 mmol, 1.5 equiv) in EtOH (20 mL) was added TEA (0.2 mL, 0.97 mmol, 8.0 equiv) at room temperature. The reaction mixture was stirred at 90 °C for 2 h, then the mixture was concentrated in vacuo and purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 5-amino-3-(8-fluoro-2-phenylquinolin-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (30 mg, 60.0%) as a yellow solid. LRMS (M+H + )m / z: calculated: 414.2, found: 414.2.

[0446]

[0447] At room temperature, 5-amino-3-(8-fluoro-2-phenylquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (30 mg, 0.07 mmol, 1.0 equiv) and K 2 CO 3To a stirred solution of (30.1 mg, 0.22 mmol, 3.0 equiv) in DMSO (10 mL) was added H 2 O 2 (30%, 164.7 mg, 1.5 mmol, 20.0 equiv). After the addition was complete, the reaction mixture was stirred at 60 ° C for 1 h. Water (20 mL) was added and the mixture was extracted with EtOAc (50 mL). The organic layer was washed with brine (100 mL), dried over anhydrous sodium sulfate and purified by preparative HPLC to give 5-amino-3-(8-fluoro-2-phenylquinoline-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide (5.4 mg, 17.2%) as a white solid. LRMS (M+H + )m / z: calculated: 432.2, found: 432.1. 1 H NMR (DMSO-d 6 ,400MHz)δ8.57(d,1H),8.27-8.33(m,3H),7.89(d,1H),7.51-7.63(m,4H),6.32(s,2H ),5.18(s,1H),4.45-4.50(m,1H),2.55-2.61(m,2H),2.36-2.41(m,2H),1.34(s,3H).

[0448] Example 29: Preparation of 5-amino-1-(oxetane-3-yl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide

[0449]

[0450] At 0°C, 5-amino-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (400 mg, 1.3 mmol, 1.0 equiv) and K 2 CO 3 3-iodooxetane (260.3 mg, 1.4 mmol, 1.1 eq.) (107.6 mg, 0.8 mmol, 0.6 eq.) was added to the stirred mixture in DMF (5.0 mL). The mixture was stirred at 35 °C for 4 h and then quenched by H 2The product was quenched with 4% paraformaldehyde (20.0 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were dried over sodium sulfate and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (PE / EA=2 / 1, v / v) to give 5-amino-1-(oxetane-3-yl)-3-(2-phenylquinoline-7-yl)-1H-pyrazole-4-carbonitrile as a yellow oil (220 mg, 46.6%). LRMS (M+H + )m / z: calculated: 368.1, found: 368.1.

[0451]

[0452] At room temperature, 5-amino-1-(oxetan-3-yl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (30 mg, 0.22 mmol, 1.0 equiv) and K 2 CO 3 To a stirred solution of (90.2 mg, 0.65 mmol, 3.0 equiv) in DMSO (10 mL) was added H 2 O 2 (30%, 494.1 mg, 4.4 mmol, 20.0 equiv). After the addition was complete, the reaction mixture was stirred at 60 ° C for 2 h. Water (20 mL) was added and the mixture was extracted with EtOAc (50 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate and purified by preparative HPLC to give 5-amino-1-(oxetane-3-yl)-3-(2-phenylquinoline-7-yl)-1H-pyrazole-4-carboxamide (15.4 mg, 18.3%) as a white solid. LRMS (M+H + )m / z: calculated: 386.2, found: 386.0. 1 H NMR (DMSO-d 6 ,400MHz)δ8.51(d,1H),8.29-8.32(m,2H),8.25(s,1H),8.19(d,1H),8.07(d,1H),7.82(dd,1H ),7.50-7.60(m,3H),6.35(s,2H),6.05(brs,1H),5.58-5.62(m,1H),5.01(t,2H),4.88(t,2H).

[0453] Example 30: Preparation of 5-amino-1-(3,3-difluorocyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide

[0454]

[0455] 5-Amino-1-(3-oxocyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (250 mg, 0.66 mmol, 1.0 eq) was dissolved in DCM (30 mL) and cooled to 0 ° C. DAST (531.0 mg, 3.3 mmol, 5.0 eq) was added dropwise and the reaction mixture was stirred at 35 ° C for 1 h. The reaction mixture was quenched with water, neutralized to pH 7 by saturated aqueous sodium bicarbonate solution and extracted with DCM (30 mL × 3). The organic layer was washed with brine (50 mL), dried over sodium sulfate and concentrated to give a crude residue. The crude residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give 5-amino-1-(3,3-difluorocyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (160 mg, 60.6%) as a yellow solid. LRMS (M+H + )m / z: calculated: 402.1, found: 402.0.

[0456]

[0457] 5-Amino-1-(3,3-difluorocyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (80 mg, 0.20 mmol, 1.0 equiv) was added to concentrated H 2 SO 4 (5 mL) and the mixture was then stirred at 35 °C for 12 h, then slowly poured into ice and washed with saturated NaHCO 3 (aqueous solution) was adjusted to pH 7 and extracted with ethyl acetate (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was purified by preparative HPLC to give 5-amino-1-(3,3-difluorocyclobutyl)-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide (45.2 mg, 53.5%) as a white solid. LRMS (M+H + )m / z: calculated: 420.2, found: 420.0. 1 H NMR (DMSO-d 6 ,400MHz)δ8.50(d,1H),8.29-8.32(m,2H),8.22(s,1H),8.18(d,1H),8.06(d,1H),7 .78(dd,1H),7.49-7.59(m,3H),6.44(s,2H),4.87-4.92(m,1H),3.06-3.25(m,4H).

[0458] Example 31: Preparation of 2-(2-phenylquinolin-7-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3,6-dicarboxamide

[0459]

[0460] To a solution of 5-amino-3-(2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (120 mg, 0.39 mmol, 1.0 eq) in EtOH (10 mL) was added ethyl 2-formyl-3-oxopropanoate (61.1 mg, 0.42 mmol, 1.1 eq) and HOAc (5 drops). After stirring at 25 °C for 16 h, the mixture was filtered and washed with H 2 O (10 mL) and dried in vacuo to give ethyl 3-cyano-2-(2-phenylquinolin-7-yl)pyrazolo[1,5-a]pyrimidine-6-carboxylate (130 mg, 81.2%) as a yellow solid. LRMS (M+H + )m / z: calculated: 420.1, found: 420.0.

[0461]

[0462] Ethyl 3-cyano-2-(2-phenylquinolin-7-yl)pyrazolo[1,5-a]pyrimidine-6-carboxylate (130 mg, 0.31 mmol, 1.0 equiv) was added to concentrated H 2 SO 4 (5 mL) and the mixture was then stirred at 25 °C for 3 h, then slowly poured into ice and washed with saturated NaHCO 3 The solution was adjusted to pH 7 and extracted with ethyl acetate (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give ethyl 3-carbamoyl-2-(2-phenylquinolin-7-yl)pyrazolo[1,5-a]pyrimidine-6-carboxylate (90 mg, 66.6%) as a yellow solid. LRMS (M+H + )m / z: calculated: 438.1, found: 438.0.

[0463]

[0464] 3-Carbamoyl-2-(2-phenylquinolin-7-yl)pyrazolo[1,5-a]pyrimidine-6-carboxylic acid ethyl ester (75 mg, 0.17 mmol, 1.0 equiv) was added to concentrated HCl (15 mL), and the mixture was stirred at 50 °C for 15 h. The reaction mixture was concentrated in vacuo to give 3-carbamoyl-2-(2-phenylquinolin-7-yl)pyrazolo[1,5-a]pyrimidine-6-carboxylic acid (40 mg, 57.1%) as a yellow solid. LRMS (M+H + )m / z: calculated: 410.1, found: 410.0.

[0465]

[0466] To 3-carbamoyl-2-(2-phenylquinolin-7-yl)pyrazolo[1,5-a]pyrimidine-6-carboxylic acid (40 mg, 0.10 mmol, 1.0 equiv), NH 4 To a solution of Cl (52.8 mg, 1.0 mmol, 10.0 equiv) and HATU (55.7 mg, 0.15 mmol, 1.5 equiv) in DMF (10 mL) was added DIEA (63.1 mg, 0.50 mmol, 5.0 equiv), and the mixture was stirred at room temperature for 1 h. The mixture was diluted with water (50 mL), extracted with DCM (50 mL X 2) and washed with water (50 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 2-(2-phenylquinolin-7-yl)pyrazolo[1,5-a]pyrimidine-3,6-dicarboxamide as a yellow solid (15 mg, 37.5%). LRMS (M+H + )m / z: calculated: 409.1, found: 409.0.

[0467]

[0468] To a solution of 2-(2-phenylquinolin-7-yl)pyrazolo[1,5-a]pyrimidine-3,6-dicarboxamide (15 mg, 0.037 mmol, 1.0 equiv) in DCM (5 mL) was added NaBH 4 (14.0 mg, 0.37 mmol, 10.0 equiv). After stirring at room temperature for 16 h, the mixture was partitioned between DCM / MeOH (50 mL / 3 mL) and brine (30 mL). The organic layer was washed with Na 2 SO 4The resulting residue was purified by preparative HPLC to give 2-(2-phenylquinolin-7-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3,6-dicarboxamide (5.1 mg, 34.0%) as a white solid. LRMS (M+H + )m / z: calculated: 413.2, found: 413.1. 1 H NMR (DMSO-d 6 ,400MHz)δ8.48(d,1H),8.28-8.31(m,2H),8.20(s,1H),8.17(d,1H),8.03(d,1H),7.77(dd,1H) ,7.51-7.59(m,3H),4.20-4.25(m,1H),4.06-4.12(m,1H),3.46-3.57(m,2H),2.96-2.99(m,1H).

[0469] Example 32: Preparation of 5-amino-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-3-(4-methoxy-2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide

[0470]

[0471] To 7-bromo-4-methoxyquinoline (34 g, 143.4 mmol, 1.0 eq), DPPP (11.8 g, 28.7 mmol, 0.2 eq) and Pd(OAc) was added. 2 (3.2g, 14.3mmol, 0.1 eq.) TEA (59.5mL, 430.4mmol, 3.0 eq.) was added to a solution of DMSO / MeOH (1000mL / 500mL). The mixture was stirred at 80°C for 15h under CO (1atm) and then concentrated under vacuum. The resulting residue was added to water (300mL) and the mixture was extracted with EtOAc (550mL X 3). The organic layer was washed with brine (300mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give 4-methoxyquinoline-7-carboxylic acid methyl ester (21.2g, 67.8%) as a yellow oil. LRMS (M+H + )m / z: calculated: 218.1, found: 218.1.

[0472]

[0473] To a solution of methyl 4-methoxyquinoline-7-carboxylate (21.2 g, 97.6 mmol, 1.0 eq) in DCM (300 mL) was added m-CPBA (42.1 g, 244.2 mmol, 2.5 eq) at room temperature. The mixture was stirred at room temperature for 12 h, then poured into ice and washed with saturated Na 2 CO 3 The aqueous solution was adjusted to pH 13 and extracted with DCM (500 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under vacuum to give 4-methoxy-7-(methoxycarbonyl)quinoline 1-oxide (15.2 g, 66.8%) as a yellow oil. LRMS (M+H + )m / z: calculated: 234.1, found: 234.2.

[0474]

[0475] 4-Methoxy-7-(methoxycarbonyl)quinoline 1-oxide (15.2 g, 65.2 mmol, 1.0 equivalent), POBr 3 A mixture of 1,2-dihydro-1,4-dihydro-2-nitropropene (28.1 g, 97.8 mmol, 1.5 eq.) and DMF (2.4 g, 32.6 mmol, 0.5 eq.) in DCM (500 mL) was stirred for 15 h, then the mixture was cooled to room temperature and poured into ice, washed with Na 2 CO 3 The aqueous solution was adjusted to pH 12-13. The aqueous layer was extracted with EtOAc (300 mL x 2). The combined organic layers were washed with brine (200 mL), dried over anhydrous sodium sulfate and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=2 / 1, v / v) to give methyl 2-bromo-4-methoxyquinoline-7-carboxylate (8.6 g, 44.8%) as a yellow solid. LRMS (M+H + )m / z: calculated: 296.0, found: 297.1.

[0476]

[0477] To a solution of methyl 2-bromo-4-methoxyquinoline-7-carboxylate (8.6 g, 29.0 mmol, 1.0 eq) in dioxane (300 mL) were added phenylboronic acid (7.1 g, 58.1 mmol, 2.0 eq), Pd(PPh 3 ) 4 (3.4 g, 2.9 mmol, 0.1 eq) and Cs 2 CO 3(18.9 g, 58.0 mmol, 2.0 equiv.). The mixture was stirred at 120 ° C for 15 h, then concentrated under vacuum, diluted with water (100 mL) and extracted with EtOAc (150 mL × 2). The combined organic layer was washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give 4-methoxy-2-phenylquinoline-7-carboxylic acid methyl ester (11 g, about 100%) as a white solid. LRMS (M+H + )m / z: calculated: 294.1, found: 294.1.

[0478]

[0479] To methyl 4-methoxy-2-phenylquinoline-7-carboxylate (11 g, 37.5 mmol, 1.0 equiv) was dissolved in MeOH (300 mL) and H 2 To the solution in 4% 4-nitropropene (50 mL) was added NaOH (2.3 g, 56.3 mmol, 1.5 eq). The mixture was stirred at 50 °C for 5 h, then concentrated under vacuum and diluted with water (100 mL). 37% HCl was added to adjust to pH 2. The resulting mixture was stirred for 5 min, filtered and dried to give 4-methoxy-2-phenylquinoline-7-carboxylic acid (10 g, 95%) as a white solid, LRMS (M+H + )m / z: calculated: 280.1, found: 280.1.

[0480]

[0481] To a solution of 4-methoxy-2-phenylquinoline-7-carboxylic acid (10 g, 35.8 mmol, 1.0 equiv) in DCM (100 mL) was added (COCl) at -78 °C. 2 (9.1 mL, 107.5 mmol, 3.0 equiv). The mixture was stirred at room temperature for 1 h and then concentrated under vacuum to give 4-methoxy-2-phenylquinoline-7-carbonyl chloride as a yellow solid (12.5 g, ca. 100.0%), LRMS (M+H + ) m / z: Calculated: 294.1, found: 294.1 in MeOH.

[0482]

[0483] In an ice bath, malononitrile (2.8 g, 41.9 mmol, 1.0 equiv) and DIEA (21.9 mL, 125.8 mmol, 3.0 equiv) were added to a solution of 4-methoxy-2-phenylquinoline-7-carbonyl chloride (12.5 g, 41.9 mmol, 1.0 equiv) in THF (200 mL). The mixture was stirred at room temperature for 3 h, then concentrated under vacuum and diluted with water (200 mL). The resulting mixture was extracted with EtOAc (300 mL X 2). The combined organic layers were washed with brine (300 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH=50 / 1, v / v) to give 2-(4-methoxy-2-phenylquinoline-7-carbonyl) malononitrile as a yellow oil (11.6 g, 84%), LRMS (M+H + )m / z: calculated: 328.1, found: 328.1.

[0484]

[0485] To a solution of 2-(4-methoxy-2-phenylquinoline-7-carbonyl)malononitrile (11.6 g, 35.3 mmol, 1.0 equiv) in THF (100 mL) was added MeOH at room temperature. 2 SO 4 The mixture was stirred at 80 ° C for 3 h, then concentrated under vacuum, diluted with water (200 mL) and extracted with EtOAc (500 mL × 2). The combined organic layer was washed with brine (500 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 2-(methoxy(4-methoxy-2-phenylquinolin-7-yl)methylene)malononitrile as a yellow oil (4.8 g, 34%), LRMS (M+H + )m / z: calculated: 342.1, found: 342.1.

[0486]

[0487] At room temperature, 2-(methoxy(4-methoxy-2-phenylquinolin-7-yl)methylene)malononitrile (800 mg, 2.3 mmol, 1.0 equiv) and (1s, 3s)-3-hydrazino-1-methylcyclobutane-1-ol (408.2 mg, 3.5 mmol, 1.5 equiv) were added to a solution of MeOH (50 mL) with TEA (2.6 mL, 18.7 mmol, 8.0 equiv). The mixture was stirred at 90 ° C for 2 h, and then the mixture was concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 5-amino-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-3-(4-methoxy-2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (800 mg, 80.0%) as a yellow solid. LRMS(M+H + )m / z: calculated: 426.2, found: 426.2.

[0488]

[0489] At room temperature, 5-amino-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-3-(4-methoxy-2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (800 mg, 1.9 mmol, 1.0 equiv) and K 2 CO 3 To a stirred solution of (779.3 mg, 5.6 mmol, 3.0 equiv) in DMSO (50 mL) was added H 2 O 2 (30%, 3.0 mL, 37.6 mmol, 20.0 equiv). After the addition was complete, the reaction mixture was stirred at 60 ° C for 2 h. The mixture was diluted with water (50 mL) and extracted with EtOAc (50 mL × 2). The combined organic layer was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered, concentrated under vacuum and purified by preparative HPLC to give 5-amino-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-3-(4-methoxy-2-phenylquinoline-7-yl)-1H-pyrazole-4-carboxamide (464.2 mg, 56%) as a white solid. LRMS (M+H + )m / z: calculated: 444.2, found: 444.2. 1 H NMR (DMSO-d 6,400MHz)δ8.31(d,2H),8.17(d,1H),8.14(s,1H),7.15(dd,1H),7.48-7.57(m,4H),6.30(s,2H), 5.20(s,1H),4.44-4.49(m,1H),4.19(s,3H),2.59-2.64(m,2H),2.36-2.41(m,2H),1.34(s,3H).

[0490] Example 33: Preparation of 5-amino-3-(4-ethoxy-8-fluoro-2-phenylquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide

[0491]

[0492] At room temperature, 3-oxo-3-phenylpropionic acid ethyl ester (25.4g, 132.2mmol, 1.0 equivalent) was added to a solution of 3-bromo-2-fluoroaniline (25.0g, 132.2mmol, 1.0 equivalent) in toluene (300mL). The mixture was stirred at 120 ° C for 15h. The mixture was cooled to room temperature and diluted with PE (500mL). The precipitate was filtered and dried under vacuum to give 3-((3-bromo-2-fluorophenyl)imino)-3-phenylpropionic acid (7g, 15.9%) as a yellow solid. LRMS (M+H + )m / z: calculated: 336.0, found: 336.1.

[0493]

[0494] 3-((3-bromo-2-fluorophenyl)imino)-3-phenylpropanoic acid (15 g, 44.6 mmol, 1.0 equiv) and Ph 2 A mixture of 1,2-dihydro-2-nitro-1-oxadiazole (2,4-dole-4-nitropropene) and 1,4-dihydro-2-nitro-1-oxadiazole (2,4-dole-4-nitropropene) was stirred at 240 °C for 1 h. The mixture was cooled to room temperature and diluted with PE (200 mL). The precipitate was filtered and dried to give 7-bromo-8-fluoro-2-phenylquinolin-4(1H)-one (3 g, 21.1%) as a brown solid. LRMS (M+H + )m / z: calculated: 318.0, found: 318.1.

[0495]

[0496] To a solution of 1-bromo-8-fluoro-2-phenylquinolin-4(1H)-one (8 g, 25.2 mmol, 1.0 equiv) in MeCN (120 mL) was added POBr 3(14.4 g, 50 mmol, 2.0 equiv.). The mixture was stirred at 100°C for 2 h. The mixture was then cooled to room temperature, poured into ice, and washed with saturated Na 2 CO 3 The aqueous solution was adjusted to pH 13 and extracted with DCM (500 mL x 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give 4,7-dibromo-8-fluoro-2-phenylquinoline (6 g, 62.3%) as a yellow solid. LRMS (M+H + )m / z: calculated: 381.9, found: 381.9.

[0497]

[0498] A mixture of 4,7-dibromo-8-fluoro-2-(2-fluorophenyl)quinoline (970 mg, 2.4 mmol, 1.0 eq.), EtONa (216.0 mg, 3.2 mmol, 1.3 eq.) and EtOH (30 mL) was stirred at reflux for 15 h. The mixture was concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=2 / 1, v / v) to give 7-bromo-4-ethoxy-8-fluoro-2-phenylquinoline (420 mg, 51%) as a yellow solid. LRMS (M+H + )m / z: calculated: 346.0, found: 346.0.

[0499]

[0500] To 7-bromo-4-ethoxy-8-fluoro-2-phenylquinoline (420 mg, 1.2 mmol, 1.0 eq), DPPP (200.0 mg, 0.49 mmol, 0.4 eq) and Pd(OAc) was added. 2 (54.3mg, 0.24mmol, 0.2 eq) TEA (0.9mL, 6.1mmol, 5.0 eq) was added to a solution of DMSO / MeOH (100mL / 100mL). The mixture was stirred at 80°C for 1h under CO (1atm), then the reaction mixture was diluted with water (500mL) and extracted with EtOAc (200mL X 3). The combined organic layers were washed with brine (300mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 4-ethoxy-8-fluoro-2-phenylquinoline-7-carboxylic acid methyl ester (420mg, about 100%) as a yellow solid. LRMS (M+H +)m / z: calculated: 326.1, found: 326.1.

[0501]

[0502] To methyl 4-ethoxy-8-fluoro-2-phenylquinoline-7-carboxylate (420 mg, 1.3 mmol, 1.0 equiv) was dissolved in MeOH (30 mL) and H 2 To a solution of 4-ethoxy-8-fluoro-2-phenylquinoline-7-carboxylic acid (349 mg, 87%) in 4% HCl (3 mL) was added NaOH (77.5 mg, 1.9 mmol, 1.5 eq). The mixture was stirred at 80 °C for 15 h, then concentrated under vacuum and diluted with water (10 mL), and adjusted to pH = 2 with 37% aqueous HCl. The resulting mixture was stirred for 5 min, filtered and dried under vacuum to give 4-ethoxy-8-fluoro-2-phenylquinoline-7-carboxylic acid (349 mg, 87%) as a white solid, LRMS (M+H + )m / z: calculated: 312.1, found: 312.1.

[0503]

[0504] To a solution of 4-ethoxy-8-fluoro-2-phenylquinoline-7-carboxylic acid (349 mg, 1.1 mmol, 1.0 equiv) in DCM (30 mL) was added (COCl) at -78 °C. 2 (0.5 mL, 5.6 mmol, 5.0 equiv) and DMF (2 drops). The mixture was stirred at room temperature for 7 h and then concentrated under vacuum to give 4-ethoxy-8-fluoro-2-phenylquinoline-7-carbonyl chloride as a yellow solid (550 mg, about 100.0%), which was used directly in the next step. LRMS (M+H + )m / z: calculated: 326.1, found: 326.1.

[0505]

[0506] To a solution of 4-ethoxy-8-fluoro-2-phenylquinoline-7-carbonyl chloride (550 mg, 1.7 mmol, 1.0 equiv) in THF (70 mL) was added malononitrile (110 mg, 1.7 mmol, 1.0 equiv) and DIEA (0.9 mL, 5 mmol, 3.0 equiv). The mixture was stirred at room temperature for 2 h, then concentrated and diluted with water (100 mL). The resulting mixture was extracted with EtOAc (150 mL X 2). The combined organic layers were washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH=50 / 1, v / v) to give 2-(4-ethoxy-8-fluoro-2-phenylquinoline-7-carbonyl) malononitrile as a yellow oil (320 mg, 79%), LRMS (M+H + )m / z: calculated: 360.1, found: 360.0.

[0507]

[0508] To a solution of 2-(4-ethoxy-8-fluoro-2-phenylquinoline-7-carbonyl)malononitrile (320 mg, 0.90 mmol, 1.0 equiv) in THF (50 mL) was added Me 2 SO 4 The mixture was stirred at 80 ° C for 3 h, then concentrated under vacuum and diluted with water (100 mL), extracted with EtOAc (150 mL × 2). The combined organic layer was washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 2-((4-ethoxy-8-fluoro-2-phenylquinoline-7-yl)(methoxy)methylene)malononitrile as a yellow oil (110 mg, 33%), LRMS (M+H + )m / z: calculated: 374.1, found: 374.1.

[0509]

[0510] To a solution of 2-((4-ethoxy-8-fluoro-2-phenylquinolin-7-yl)(methoxy)methylene)malononitrile (110 mg, 0.29 mmol, 1.0 equiv) and (1s,3s)-3-hydrazino-1-methylcyclobutane-1-ol (41.1 mg, 0.35 mmol, 1.2 equiv) in MeOH (50 mL) was added TEA (0.33 mL, 2.4 mmol, 8.0 equiv) at room temperature. The reaction mixture was stirred at 80 °C for 2 h and then concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=2 / 1, v / v) to give 5-amino-3-(4-ethoxy-8-fluoro-2-phenylquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (40 mg, 30%) as a yellow solid, LRMS (M+H + )m / z: calculated: 458.2, found: 458.2.

[0511]

[0512] To a stirred solution of 5-amino-3-(4-ethoxy-8-fluoro-2-phenylquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (30 mg, 0.065 mmol, 1.0 equiv) in DMSO (20 mL) was added K 2 CO 3 (45.3 mg, 0.33 mmol, 5.0 equiv) and H 2 O 2 (30%, 0.1 mL, 1.3 mmol, 20.0 equiv). After the addition was complete, the mixture was stirred at 60 ° C for 2 h, then diluted with water (100 mL) and extracted with EtOAc (150 mL × 2). The combined organic layer was washed with brine (150 mL), dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by preparative HPLC to give 5-amino-3-(4-ethoxy-8-fluoro-2-phenylquinoline-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide as a white solid (340.2 mg, 43%), LRMS (M+H + )m / z: calculated: 476.2, found: 476.2. 1 H NMR (DMSO-d 6,400MHz)δ8.32(d,2H),7.99(d,1H),7.67(s,1H),7.52-7.60(m,4H),6.34(s,2H),5.21(s ,1H),4.49-4.53(m,3H),2.54-2.60(m,2H),2.35-2.41(m,2H),1.54(t,3H),1.34(s,3H).

[0513] Example 34: Preparation of 5-amino-3-(8-fluoro-4-methoxy-2-phenylquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide

[0514]

[0515] MeONa (1.7 g, 30.1 mmol, 2.0 equiv) was added to a solution of 4,7-dibromo-8-fluoro-2-phenylquinoline (6 g, 15.5 mmol, 1.0 equiv) in MeOH (100 mL). The mixture was stirred at 70 ° C for 15 h. The mixture was concentrated under vacuum, diluted with water (100 mL) and extracted with EtOAc (150 mL X 2). The combined organic layers were washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give 7-bromo-8-fluoro-4-methoxy-2-phenylquinoline (4.5 g, 88.2%) as a white solid. LRMS (M+H + )m / z: calculated: 332.0, found: 332.0.

[0516]

[0517] 7-Bromo-8-fluoro-4-methoxy-2-phenylquinoline (2 g, 6.0 mmol, 1.0 eq), DPPP (1 g, 2.4 mmol, 0.4 eq) and Pd(OAc) were added. 2(270mg, 1.2mmol, 0.2 eq) TEA (9.6mL, 30mmol, 5.0 eq) was added to a solution of DMSO / MeOH (50mL / 50mL). The mixture was stirred at 80°C for 15h under CO (1atm), then the reaction mixture was diluted with water (100mL) and extracted with EtOAc (100mL X 3). The combined organic layers were washed with brine (100mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give 8-fluoro-4-methoxy-2-phenylquinoline-7-carboxylic acid methyl ester (1.3g, 72.2%) as a white solid. LRMS (M+H + )m / z: calculated: 312.1, found: 312.2.

[0518]

[0519] To methyl 8-fluoro-4-methoxy-2-phenylquinoline-7-carboxylate (1.3 g, 4.1 mmol, 1.0 equiv) was dissolved in MeOH (30 mL) and H 2 To the solution in 4% 4-nitropropene (10 mL) was added NaOH (501 mg, 12.3 mmol, 3.0 equiv). The mixture was stirred at 50 ° C for 15 h, then concentrated under vacuum and diluted with water (60 mL). The mixture was adjusted to pH 2 with 37% aqueous HCl. The resulting mixture was stirred for 5 min, filtered and dried to give 8-fluoro-4-methoxy-2-phenylquinoline-7-carboxylic acid (1.1 g, 90.2%) as a white solid, LRMS (M+H + )m / z: calculated: 298.1, found: 298.2.

[0520]

[0521] To a solution of 8-fluoro-4-methoxy-2-phenylquinoline-7-carboxylic acid (1.1 g, 3.7 mmol, 1.0 equiv) in DCM (30 mL) was added (COCl) at 0 °C. 2 (0.7 mL, 18.5 mmol, 5.0 equiv) and DMF (5 drops). The mixture was stirred at room temperature for 7 h and then concentrated under vacuum to give 8-fluoro-4-methoxy-2-phenylquinoline-7-carbonyl chloride (1.3 g, about 100%) as a yellow solid, which was used directly in the next step. LRMS (M+H + ) m / z: calcd: 312.1, found: 312.2 in MeOH.

[0522]

[0523] To a solution of 8-fluoro-4-methoxy-2-phenylquinoline-7-carbonyl chloride (1.3 g, 4.1 mmol, 1.0 equiv) in THF (30 mL) was added malononitrile (817 mg, 12.3 mmol, 3.0 equiv) and DIEA (3.5 mL, 20.5 mmol, 5.0 equiv). The mixture was stirred at room temperature for 3 h, then concentrated and diluted with water (20 mL). The resulting mixture was extracted with EtOAc (50 mL x 2). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH=20 / 1, v / v) to give 2-(8-fluoro-4-methoxy-2-phenylquinoline-7-carbonyl) malononitrile as a yellow oil (1.2 g, 82.9%), LRMS (M+H + )m / z: calculated: 346.1, found: 346.2.

[0524]

[0525] To a solution of 2-(8-fluoro-4-methoxy-2-phenylquinoline-7-carbonyl)malononitrile (1.2 g, 3.4 mmol, 1.0 equiv) in THF (30 mL) was added Me 2 SO 4 The product was stirred for 3 hours at 80 ° C. The mixture was concentrated under vacuum, diluted with water (20 mL) and extracted with EtOAc (50 mL × 2). The combined organic layer was washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA = 2 / 1, v / v) to give 2- ((8-fluoro-4-methoxy-2-phenylquinoline-7-yl) (methoxy) methylene) malononitrile as a yellow oil (800 mg, 66.6%), LRMS (M + H + )m / z: calculated: 360.1, found: 360.2.

[0526]

[0527] To a solution of 2-((8-fluoro-4-methoxy-2-phenylquinolin-7-yl)(methoxy)methylene)malononitrile (800 mg, 2.2 mmol, 1.0 equiv) and (1s, 3s)-3-hydrazino-1-methylcyclobutane-1-ol (384 mg, 3.3 mmol, 1.5 equiv) in MeOH (20 mL) was added TEA (3.4 mL, 17.2 mmol, 8.0 equiv) at room temperature. The reaction mixture was stirred at 90 ° C for 2 h, and then the mixture was concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=2 / 1, v / v) to give 5-amino-3-(8-fluoro-4-methoxy-2-phenylquinolin-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (500 mg, 50.9%) as a white solid. LRMS(M+H + )m / z: calculated: 444.2, found: 444.3.

[0528]

[0529] At room temperature, 5-amino-3-(8-fluoro-4-methoxy-2-phenylquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (500 mg, 1.12 mmol, 1.0 equiv) and K 2 CO 3 To a stirred solution of (467 mg, 3.36 mmol, 3.0 equiv) in DMSO (5 mL) was added H 2 O 2 (30%, 1.3mL, 11.2mmol, 10.0 equivalents). The mixture was stirred at 60 ° C for 2h, then diluted with water (100mL) and extracted with EtOAc (150mL×2). The combined organic layer was washed with brine (150mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by preparative HPLC to give 5-amino-3-(8-fluoro-4-methoxy-2-phenylquinolin-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide (374mg, 72.4%) as a white solid. LRMS (M+H + )m / z: calculated value: 462.2, found value: 462.2, 1 H NMR (DMSO-d 6,400MHz)δ8.33(d,2H),7.98(d,1H),7.68(s,1H),7.52-7.59(m,4H),6.32(s,2H),5.19(s ,1H),4.45-4.50(m,1H),4.21(s,3H),2.55-2.60(m,2H),2.36-2.40(m,2H),1.33(s,3H).

[0530] Example 35: Preparation of 5-amino-3-(8-fluoro-2-(2-fluorophenyl)-4-methoxyquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide

[0531]

[0532] To a solution of 3-bromo-2-fluoroaniline (50 g, 264.6 mmol, 1.0 equiv) in toluene (800 mL) was added ethyl 3-(2-fluorophenyl)-3-oxopropanoate (55.6 g, 264.6 mmol, 1.0 equiv) and p-toluenesulfonic acid (4.6 g, 26.5 mmol, 0.1 equiv). The reaction mixture was stirred at reflux for 3 h and then concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=10 / 1, v / v) to give ethyl 3-((3-bromo-2-fluorophenyl)imino)-3-(2-fluorophenyl)propanoate (8.4 g, 8.4%) as a yellow oil. LRMS (M+H + )m / z: calculated: 381.0, found: 381.1.

[0533]

[0534] A mixture of ethyl 3-((3-bromo-2-fluorophenyl)imino)-3-(2-fluorophenyl)propanoate (8.4 g, 22.1 mmol, 8.4%) and EATON reagent was stirred at 80° C. for 3 h. The mixture was then cooled to room temperature, poured into ice and treated with Na 2 CO 3 The aqueous solution was adjusted to pH 12-13. The aqueous layer was extracted with EtOAc (200 mL x 2). The combined organic layers were washed with brine (100 mL) and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give 7-bromo-8-fluoro-2-(2-fluorophenyl)quinoline-4(1H)-one (9.4 g, about 100%) as a yellow solid. LRMS (M+H + )m / z: calculated: 336.0, found: 336.1.

[0535]

[0536] 7-Bromo-8-fluoro-2-(2-fluorophenyl)quinolin-4(1H)-one (9.4 g, 27.9 mmol, 1.0 equiv), POBr 3 A mixture of 4-(24.1 g, 83.9 mmol, 3.0 equiv) and MeCN (200 mL) was stirred at reflux for 15 h. The mixture was cooled to room temperature and poured into ice and washed with Na 2 CO 3 The aqueous solution was adjusted to pH 12-13. The aqueous layer was extracted with EtOAc (200 mL x 2). The combined organic layers were washed with brine (100 mL) and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=2 / 1, v / v) to give 4,7-dibromo-8-fluoro-2-(2-fluorophenyl)quinoline (14.7 g, about 100%) as a yellow solid. LRMS (M+H + )m / z: calculated: 399.9, found: 401.0.

[0537]

[0538] A mixture of 4,7-dibromo-8-fluoro-2-(2-fluorophenyl)quinoline (14.7 g, 36.8 mmol, 1.0 equiv), MeONa (6.0 g, 110.5 mmol, 3.0 equiv) and MeOH (200 mL) was stirred at reflux for 15 h. The mixture was then concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=2 / 1, v / v) to give 7-bromo-8-fluoro-2-(2-fluorophenyl)-4-methoxyquinoline (10.8 g, 83.7%) as a yellow solid. LRMS (M+H + )m / z: calculated: 350.0, found: 350.0.

[0539]

[0540] To 7-bromo-8-fluoro-2-(2-fluorophenyl)-4-methoxyquinoline (10.8 g, 30.9 mmol, 1.0 eq), DPPP (5.1 g, 12.3 mmol, 0.4 eq) and Pd(OAc) was added. 2(1.4g, 6.2mmol, 0.2 equivalent) TEA (21.3mL, 154.3mmol, 5.0 equivalent) was added to a solution in DMSO / MeOH (200mL / 300mL). Under CO (1atm), the mixture was stirred at 80°C for 15h, then the reaction mixture was diluted with water (2000mL) and extracted with EtOAc (500mL X 3). The combined organic layer was washed with brine (300mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 8-fluoro-2-(2-fluorophenyl)-4-methoxyquinoline-7-carboxylic acid methyl ester (10.5g, about 100%) as a yellow solid. LRMS (M+H + )m / z: calculated: 330.1, found: 330.1.

[0541]

[0542] To methyl 8-fluoro-2-(2-fluorophenyl)-4-methoxyquinoline-7-carboxylate (10.5 g, 31.9 mmol, 1.0 equiv) was dissolved in MeOH (100 mL) and H 2 D (30 mL) was added with NaOH (1.9 g, 47.8 mmol, 1.5 eq). The mixture was stirred at 80 °C for 15 h, concentrated under vacuum, diluted with water (60 mL) and adjusted to pH 2 with 37% aqueous HCl. The resulting mixture was stirred for 5 min, filtered and concentrated under vacuum to give 8-fluoro-2-(2-fluorophenyl)-4-methoxyquinoline-7-carboxylic acid (9.9 g, 98%) as a white solid, LRMS (M+H + )m / z: calculated: 316.1, found: 316.0.

[0543]

[0544] To a solution of 8-fluoro-2-(2-fluorophenyl)-4-methoxyquinoline-7-carboxylic acid (9.9 g, 31.4 mmol, 1.0 equiv) in DCM (100 mL) was added (COCl) at -78 °C. 2 (13.3 mL, 157.1 mmol, 5.0 eq) and DMF (0.25 mL, 3.1 mmol, 0.1 eq). The mixture was stirred at room temperature for 7 h and then concentrated under vacuum to give 8-fluoro-2-(2-fluorophenyl)-4-methoxyquinoline-7-carbonyl chloride as a yellow solid (12.5 g, about 100.0%), which was used directly in the next step. LRMS (M+H +) m / z: Calculated: 330.1, found: 330.1 in MeOH.

[0545]

[0546] To a solution of 8-fluoro-2-(2-fluorophenyl)-4-methoxyquinoline-7-carbonyl chloride (12.5 g, 37.5 mmol, 1.0 equiv) in THF (100 mL) was added malononitrile (2.5 g, 37.5 mmol, 1.0 equiv) and DIEA (19.6 mL, 112.6 mmol, 3.0 equiv). The mixture was stirred at room temperature for 2 h, then concentrated and diluted with water (100 mL). The resulting mixture was extracted with EtOAc (150 mL x 2). The combined organic layers were washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH=50 / 1, v / v) to give 2-(8-fluoro-2-(2-fluorophenyl)-4-methoxyquinoline-7-carbonyl)malononitrile as a yellow oil (11.7 g, 86%), LRMS (M+H + )m / z: calculated: 364.1, found: 364.0.

[0547]

[0548] To a solution of 2-(8-fluoro-2-(2-fluorophenyl)-4-methoxyquinoline-7-carbonyl)malononitrile (11.7 g, 32.2 mmol, 1.0 equiv) in THF (200 mL) was added Me 2 SO 4 The mixture was stirred at 80 ° C for 3 h, concentrated under vacuum, diluted with water (100 mL) and extracted with EtOAc (150 mL × 2). The combined organic layer was washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 2-((8-fluoro-2-(2-fluorophenyl)-4-methoxyquinolin-7-yl)(methoxy)methylene)malononitrile as a yellow oil (7.1 g, 58.5%), LRMS (M+H + )m / z: calculated: 378.1, found: 378.1.

[0549]

[0550] To a solution of 2-((8-fluoro-2-(2-fluorophenyl)-4-methoxyquinolin-7-yl)(methoxy)methylene)malononitrile (1.1 g, 2.9 mmol, 1.0 equiv) and (1s,3s)-3-hydrazino-1-methylcyclobutane-1-ol (406 mg, 3.5 mmol, 1.2 equiv) in MeOH (50 mL) was added TEA (3.2 mL, 23.3 mmol, 8.0 equiv) at room temperature. The reaction mixture was stirred at 80 °C for 2 h and then concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=2 / 1, v / v) to give 5-amino-3-(8-fluoro-2-(2-fluorophenyl)-4-methoxyquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (760 mg, 55.1%) as a yellow solid, LRMS (M+H + )m / z: calculated: 462.2, found: 462.4.

[0551]

[0552] To a stirred solution of 5-amino-3-(8-fluoro-2-(2-fluorophenyl)-4-methoxyquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (760 mg, 1.6 mmol, 1.0 equiv) in DMSO (50 mL) was added K 2 CO 3 (1.1 g, 8.2 mmol, 5.0 equiv) and H 2 O 2 (30%, 3.7mL, 33.0mmol, 20.0 equivalents). After the addition was complete, the mixture was stirred at 60 ° C for 3h, then diluted with water (100mL) and extracted with EtOAc (150mL X 2). The combined organic layer was washed with brine (150mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by preparative HPLC to give 5-amino-3-(8-fluoro-2-(2-fluorophenyl)-4-methoxyquinoline-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide as a white solid (340.2mg, 43%). LRMS (M+H + )m / z: calculated: 480.2, found: 480.1. 1 H NMR (DMSO-d 6,400MHz)δ7.99-8.05(m,2H),7.55-7.62(m,2H),7.47(d,1H),7.38-7.43(m,2H),6.32(s,2H),5 .19(s,1H),4.44-4.49(m,1H),4.14(s,3H),2.54-2.60(m,2H),2.35-2.41(m,2H),1.33(s,3H).

[0553] Example 36: Preparation of 5-amino-3-(4-ethoxy-2-phenylquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide

[0554]

[0555] To a solution of 7-bromo-4-chloroquinoline (45 g, 185.6 mmol, 1.0 eq.) in MeOH (500 mL) was added NaOEt (37.8 g, 556.7 mmol, 3.0 eq.). The mixture was stirred at 70 °C for 15 h. The mixture was concentrated under vacuum, diluted with water (100 mL) and extracted with EtOAc (150 mL x 2). The combined organic layers were washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 7-bromo-4-ethoxyquinoline (40 g, 85.1%) as a white solid. LRMS (M+H + )m / z: calculated: 252.0, found: 252.0.

[0556]

[0557] 7-Bromo-4-ethoxyquinoline (40 g, 159.3 mmol, 1.0 eq), DPPP (26.3 g, 63.7 mmol, 0.4 eq) and Pd(OAc) were added. 2 (7.2g, 31.8mmol, 0.2 eq) TEA (110.3mL, 796.8mmol, 5.0 eq) was added to a solution in DMSO / MeOH (500mL / 500mL). The mixture was stirred at 80°C for 15h under CO (1atm), then the reaction mixture was diluted with water (300mL) and extracted with EtOAc (300mL X 3). The combined organic layers were washed with brine (300mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give 4-ethoxyquinoline-7-carboxylic acid methyl ester (25g, 67.5%) as a white solid. LRMS (M+H +)m / z: calculated: 232.1, found: 232.2.

[0558]

[0559] To a stirred solution of methyl 4-ethoxyquinoline-7-carboxylate (25 g, 99.6 mmol, 1.0 eq) in DCM (500 mL) was added m-CPBA (51.5 g, 298.8 mmol, 3.0 eq) at room temperature. The mixture was stirred at room temperature for 12 h, then poured into ice and concentrated by adding saturated Na 2 CO 3 The aqueous solution was adjusted to pH 13 and extracted with DCM (500 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under vacuum to give 4-ethoxy-7-(methoxycarbonyl)quinoline 1-oxide (36 g, >100%) as a yellow oil. LRMS (M+H + )m / z: calculated: 248.1, found: 248.1.

[0560]

[0561] To a solution of 4-ethoxy-7-(methoxycarbonyl)quinoline 1-oxide (36 g, 145.7 mmol, 1.0 equiv) in DCM (1000 mL) was added POBr at 0 °C. 3 (54.4 g, 189.5 mmol, 1.3 eq) and DMF (5.7 mL, 72.9 mmol, 0.5 eq). The mixture was stirred at 40 °C for 15 h, then poured into ice and washed with saturated Na 2 CO 3 The aqueous solution was adjusted to pH 13 and extracted with DCM (500 mL x 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give methyl 2-bromoquinoline-7-carboxylate (16 g, 47.9%, 2 steps) as a yellow solid, LRMS (M+H + )m / z: calculated: 310.0, found: 310.0.

[0562]

[0563] To a solution of methyl 2-bromo-4-ethoxyquinoline-7-carboxylate (16 g, 51.6 mmol, 1.0 equiv) in dioxane (300 mL) were added phenylboronic acid (12.6 g, 103.2 mmol, 2.00 equiv), Pd(PPh 3 ) 4(6.0 g, 5.1 mmol, 0.1 eq.) and Cs 2 CO 3 (33.6 g, 103.2 mmol, 2.0 equiv.). The mixture was stirred at 120 ° C for 2 h, then concentrated under vacuum and diluted with water (200 mL), extracted with EtOAc (250 mL × 2). The combined organic layer was washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA = 5 / 1, v / v) to give 4-ethoxy-2-phenylquinoline-7-carboxylic acid methyl ester (14 g, 88.6%) as a white solid. LRMS (M + H + )m / z: calculated: 308.1, found: 308.1.

[0564]

[0565] To methyl 4-ethoxy-2-phenylquinoline-7-carboxylate (14 g, 45.6 mmol, 1.0 equiv) was dissolved in MeOH (300 mL) and H 2 To the solution in 4% 4-nitropropane-2-yl quinoline-7-carboxylic acid (50 mL) was added NaOH (2.7 g, 68.4 mmol, 1.5 eq). The mixture was stirred at 50 °C for 6 h, then concentrated under vacuum and diluted with water (100 mL), and 37% HCl was added to adjust to pH 2. The resulting mixture was stirred for 5 min, filtered and dried to give 4-ethoxy-2-phenylquinoline-7-carboxylic acid (12 g, about 100%) as a white solid, LRMS (M+H + )m / z: calculated: 294.1, found: 294.1.

[0566]

[0567] To a solution of 4-ethoxy-2-phenylquinoline-7-carboxylic acid (12 g, 40.9 mmol, 1.0 eq.) in DCM (200 mL) was added (COCl) at -78 °C. 2 (10.4 mL, 122.9 mmol, 3.0 equiv) and DMF (0.1 mL). The mixture was stirred at room temperature for 1 h and then concentrated under vacuum to give 4-ethoxy-2-phenylquinoline-7-carbonyl chloride as a yellow solid (15 g, about 100.0%), LRMS (M+H + ) m / z: Calculated: 308.1, found: 308.1 in MeOH.

[0568]

[0569] In an ice bath, malononitrile (3.2 g, 48.2 mmol, 1.0 equiv) and DIEA (19.9 mL, 144.7 mmol, 3.0 equiv) were added to a solution of 4-ethoxy-2-phenylquinoline-7-carbonyl chloride (15 g, 48.2 mmol, 1.0 equiv) in THF (400 mL). The mixture was stirred at room temperature for 3 h, then concentrated under vacuum and diluted with water (200 mL). The resulting mixture was extracted with EtOAc (300 mL X 2). The combined organic layers were washed with brine (300 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH=50 / 1, v / v) to give 2-(4-ethoxy-2-phenylquinoline-7-carbonyl) malononitrile as a yellow oil (9 g, 62%), LRMS (M+H + )m / z: calculated: 342.1, found: 342.1.

[0570]

[0571] To a solution of 2-(4-ethoxy-2-phenylquinoline-7-carbonyl)malononitrile (3 g, 8.8 mmol, 1.0 eq.) in THF (100 mL) was added MeOH at room temperature. 2 SO 4 The mixture was stirred at 80 ° C for 3 h, then concentrated under vacuum, diluted with water (200 mL) and extracted with (500 mL X2). The combined organic layer was washed with brine (500 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 2-((4-ethoxy-2-phenylquinoline-7-yl)(methoxy)methylene)malononitrile as a yellow oil (1 g, 32%), LRMS (M+H + )m / z: calculated: 356.1, found: 356.1.

[0572]

[0573] At room temperature, 2-((4-ethoxy-2-phenylquinolin-7-yl)(methoxy)methylene)malononitrile (150 mg, 0.42 mmol, 1.0 equiv) and (1s, 3s)-3-hydrazino-1-methylcyclobutane-1-ol (73.5 mg, 0.63 mmol, 1.5 equiv) were added TEA (0.5 mL, 3.4 mmol, 8.0 equiv) in a solution of MeOH (50 mL). The reaction mixture was stirred at 90 ° C for 2 h, and the mixture was concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 5-amino-3-(4-ethoxy-2-phenylquinolin-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (120 mg, 64%) as a yellow solid. LRMS(M+H + )m / z: calculated: 440.2, found: 440.2.

[0574]

[0575] At room temperature, 5-amino-3-(4-ethoxy-2-phenylquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (120 mg, 0.27 mmol, 1.0 equiv) and K 2 CO 3 To a stirred solution of (113.3 mg, 0.82 mmol, 3.0 equiv) in DMSO (20 mL) was added H 2 O 2 (30%, 0.6mL, 5.5mmol, 20.0 equivalents). After the addition was complete, the reaction mixture was stirred at 60 ° C for 2h. Water (50mL) was added and the mixture was extracted with EtOAc (50mL × 2). The organic extract was washed with brine (100mL), dried over anhydrous sodium sulfate, filtered, concentrated under vacuum and purified by preparative HPLC to give 5-amino-3-(4-ethoxy-2-phenylquinoline-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide (14.1mg, 11%) as a white solid. LRMS (M+H + )m / z: calculated: 458.2, found: 458.2. 1 H NMR (DMSO-d 6,400MHz)δ8.29(d,2H),8.18(d,1H),8.12(d,1H),7.69(dd,1H),7.50-7.58(m,4H),6.31(s,2H), 5.20(s,1H),4.43-4.52(m,3H),2.59-2.64(m,2H),2.36-2.41(m,2H),1,53(t,3H),1.34(s,3H).

[0576] Example 37: Preparation of 5-amino-3-(2-(2-fluorophenyl)quinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide

[0577]

[0578] 7-Bromoquinoline (20 g, 96.6 mmol, 1.0 eq), DPPP (8.0 g, 19.3 mmol, 0.2 eq) and Pd(OAc) were added. 2 To a solution of (2.1 g, 9.7 mmol, 0.1 eq) in DMSO / MeOH (300 mL / 300 mL) was added TEA (40 mL, 289.8 mmol, 3.0 eq). The mixture was stirred at 120 °C for 15 h under CO (5 atm) and then concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give quinoline-7-carboxylic acid methyl ester (16.4 g, 91.1%) as a yellow solid. LRMS (M+H + )m / z: calculated: 188.1, found: 188.0.

[0579]

[0580] To a stirred solution of quinoline-7-carboxylic acid methyl ester (16.4 g, 87.7 mmol, 1.0 eq) in DCM (300 mL) was added m-CPBA (22.7 g, 131.6 mmol, 1.5 eq) at room temperature. The mixture was stirred at room temperature for 2 h, then poured into ice and concentrated by adding saturated Na 2 CO 3 The aqueous solution was adjusted to pH 13 and extracted with DCM (500 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under vacuum to give 7-(methoxycarbonyl)quinoline 1-oxide (17.5 g, 98.3%) as a yellow oil. LRMS (M+H + )m / z: calculated: 204.1, found: 204.1.

[0581]

[0582] To a solution of 7-(methoxycarbonyl)quinoline 1-oxide (17.5 g, 86.2 mmol, 1.0 equiv) in DCM (500 mL) was added POBr at -78 °C. 3 (32.1 g, 112.1 mmol, 1.3 eq) and DMF (3.3 mL, 43.1 mmol, 0.5 eq). The mixture was stirred at room temperature for 2 h, then poured into ice and stirred by adding saturated Na 2 CO 3 The aqueous solution was adjusted to pH 13 and extracted with DCM (500 mL x 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give methyl 2-bromoquinoline-7-carboxylate (17.2 g, 75.4%) as a yellow solid, LRMS (M+H + )m / z: calculated: 266.0, found: 266.0. 1 H NMR (DMSO-d 6 ,400MHz)δ8.50(s,1H),8.45(d,1H),8.12-8.21(m,2H),8.86(d,1H),3.95(s,3H).

[0583]

[0584] To a solution of methyl 2-bromoquinoline-7-carboxylate (12 g, 45.2 mmol, 1.0 equiv) in dioxane (300 mL) were added (2-fluorophenyl)boronic acid (12.7 g, 90.5 mmol, 2.0 equiv), Pd(PPh 3 ) 4 (2.6 g, 2.2 mmol, 0.05 eq) and Cs 2 CO 3 (29.5 g, 90.4 mmol, 2.0 equiv.). The mixture was stirred at 120 ° C for 1 h, then concentrated under vacuum and diluted with water (100 mL), extracted with EtOAc (150 mL × 2). The combined organic layer was washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give 2-(2-fluorophenyl)quinoline-7-carboxylic acid methyl ester (12.8 g, about 100%) as a white solid. LRMS (M+H + )m / z: calculated: 282.1, found: 282.1.

[0585]

[0586] To methyl 2-(2-fluorophenyl)quinoline-7-carboxylate (12.8 g, 45.6 mmol, 1.0 equiv) was dissolved in MeOH (200 mL) and H 2 To a solution in 4% 4-nitropropene (30 mL) was added NaOH (2.7 g, 68.3 mmol, 1.5 eq). The mixture was stirred at room temperature for 15 h, then concentrated under vacuum and diluted with water (60 mL), and 37% HCl was added to adjust to pH = 2. The resulting mixture was stirred for 5 min, filtered and concentrated under vacuum to give 2-(2-fluorophenyl)quinoline-7-carboxylic acid (10.7 g, 88.5%) as a white solid, LRMS (M+H + )m / z: calculated: 268.1, found: 268.1.

[0587]

[0588] To a solution of 2-(2-fluorophenyl)quinoline-7-carboxylic acid (10.7 g, 40.1 mmol, 1.0 equiv) in DCM (200 mL) was added (COCl) at -78 °C. 2 (3.4 mL, 42.1 mmol, 5.0 equiv) and DMF (5 drops). The mixture was stirred at room temperature for 7 h and then concentrated under vacuum to give 2-(2-fluorophenyl)quinoline-7-carbonyl chloride as a yellow solid (12.6 g, about 100.0%). LRMS (M+H + ) m / z: Calculated: 282.1, found: 282.1 in MeOH.

[0589]

[0590] In an ice bath, malononitrile (2.9 g, 44.5 mmol, 1.0 equivalent) and DIEA (23.3 mL, 133.7 mmol, 3.0 equivalent) were added to a solution of 2-(2-fluorophenyl)quinoline-7-carbonyl chloride (12.7 g, 44.6 mmol, 1.0 equivalent) in THF (200 mL). The mixture was stirred at room temperature for 3 h, then concentrated and diluted with water (120 mL). The resulting mixture was extracted with EtOAc (350 mL x 2). The combined organic layers were washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH=50 / 1, v / v) to give 2-((2-(2-fluorophenyl)quinolin-7-yl)(hydroxy)methylene)malononitrile as a yellow oil (14.7 g, about 100%), LRMS (M+H +)m / z: calculated: 316.1, found: 316.1.

[0591]

[0592] To a solution of 2-((2-(2-fluorophenyl)quinolin-7-yl)(hydroxy)methylene)malononitrile (14.7 g, 46.7 mmol, 1.0 equiv) in THF (300 mL) was added MeOH at room temperature. 2 SO 4 The mixture was stirred at 80 ° C for 3 h, then concentrated under vacuum and diluted with water (120 mL), extracted with EtOAc (250 mL X 2). The combined organic layer was washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 2-((2-(2-fluorophenyl)quinoline-7-yl)(methoxy)methylene)malononitrile as a yellow oil (5 g, 33%). LRMS (M+H + )m / z: calculated: 330.1, found: 330.1.

[0593]

[0594] To a solution of 2-((2-(2-fluorophenyl)quinolin-7-yl)(methoxy)methylene)malononitrile (100 mg, 0.30 mmol, 1.0 equiv) and 3-hydrazino-1-methylcyclobutan-1-ol (52.9 mg, 0.46 mmol, 1.5 equiv) in MeOH (50 mL) was added TEA (0.4 mL, 2.4 mmol, 8.0 equiv) at room temperature. The reaction mixture was stirred at 90° C. for 2 h, then the mixture was concentrated under vacuum and purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 5-amino-3-(2-(2-fluorophenyl)quinolin-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (40 mg, 32%) and 5-amino-3-(2-(2-fluorophenyl)quinolin-7-yl)-1-((1r, 3r)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (45 mg, 36%) as a yellow solid. LRMS (M+H + )m / z: calculated: 414.2, found: 414.3.

[0595]

[0596] At room temperature, 5-amino-3-(2-(2-fluorophenyl)quinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (40 mg, 0.096 mmol, 1.0 equiv) and K 2 CO 3 To a stirred solution of (40.1 mg, 0.29 mmol, 3.0 equiv) in DMSO (20 mL) was added H 2 O 2 (30%, 0.2mL, 1.9mmol, 20.0 equivalents). After the addition was complete, the reaction mixture was stirred at 60 ° C for 1h. The mixture was diluted with water (80mL) and the mixture was extracted with EtOAc (200mL). The organic extract was washed with brine (100mL), dried over anhydrous sodium sulfate and purified by preparative HPLC to give 5-amino-3-(2-(2-fluorophenyl)quinoline-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide (11.8mg, 33%) as a white solid. LRMS (M+H + )m / z: calculated: 432.2, found: 432.2. 1 H NMR (DMSO-d 6 ,400MHz)δ8.50(d,1H),8.22(s,1H),8.05-8.10(m,2H),7.94(d,1H),7.82(d,1H),7.55-7.59(m,1H),7.37-7 .43(m,2H),6.29(s,2H),5.19(s,1H),4.42-4.51(t,1H),2.59-2.65(m,2H),2.36-2.42(m,2H),1.35(s,3H).

[0597] Example 38: Preparation of 5-amino-3-(2-(2-bromophenyl)quinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide

[0598]

[0599] To a solution of methyl 2-bromoquinoline-7-carboxylate (3.1 g, 11.7 mmol, 1.0 equiv) in dioxane (300 mL) were added (2-bromophenyl)boronic acid (4.7 g, 23.4 mmol, 2.0 equiv), Pd(PPh 3 ) 4 (68.0 mg, 0.059 mmol, 0.05 equiv) and Cs 2 CO 3The product was stirred for 4 h at 120 ° C and then concentrated under vacuum. The resulting residue was diluted with water (100 mL) and extracted with EtOAc (150 mL × 2). The combined organic layer was washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give 2-(2-bromophenyl)quinoline-7-carboxylic acid methyl ester (2.8 g, 70%) as a white solid. LRMS (M+H + )m / z: calculated: 342.0, found: 342.1.

[0600]

[0601] To methyl 2-(2-bromophenyl)quinoline-7-carboxylate (2.8 g, 8.2 mmol, 1.0 equiv) was dissolved in MeOH (200 mL) and H 2 To a solution in 4% 4-bromophenyl quinoline-7-carboxylic acid (2.6 g, 97%), NaOH (492 mg, 12.3 mmol, 1.5 eq.) was added. The mixture was stirred at 50 °C for 2 h, then concentrated under vacuum and diluted with water (20 mL), and 37% HCl was added to adjust to pH = 2. The resulting mixture was stirred for 5 min, filtered and concentrated under vacuum to give 2-(2-bromophenyl)quinoline-7-carboxylic acid (2.6 g, 97%) as a white solid. LRMS (M+H + )m / z: calculated: 328.0, found: 328.0.

[0602]

[0603] To a solution of 2-(2-bromophenyl)quinoline-7-carboxylic acid (2.6 g, 7.9 mmol, 1.0 equiv) in DCM (50 mL) was added (COCl) at -78 °C. 2 (499 mg, 39.6 mmol, 5.0 equiv) and DMF (5 drops). The mixture was stirred at room temperature for 7 h and then concentrated under vacuum to give crude 2-(2-bromophenyl)quinoline-7-carbonyl chloride as a yellow solid (4 g, about 100%), LRMS (M+H + ) m / z: Calculated: 342.0, found: 342.1 in MeOH.

[0604]

[0605] In an ice bath, malononitrile (523 mg, 7.92 mmol, 1.0 equiv) and DIEA (3.06 g, 23.7 mmol, 3.0 equiv) were added to a solution of 2-(2-bromophenyl)quinoline-7-carbonyl chloride (4 g crude, 7.92 mmol, 1.0 equiv) in THF (50 mL). The mixture was stirred at room temperature for 2 h and then concentrated. The residue was diluted with water (100 mL). The resulting mixture was extracted with EtOAc (150 mL X 2). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH=50 / 1, v / v) to give 2-((2-(2-bromophenyl)quinoline-7-yl)(hydroxy)methylene)malononitrile as a yellow oil (3.4 g, 70%), LRMS (M+H + )m / z: calculated: 376.0, found: 376.1.

[0606]

[0607] To a solution of 2-((2-(2-bromophenyl)quinolin-7-yl)(hydroxy)methylene)malononitrile (3.4 g crude, 7.92 mmol, 1.0 eq.) in THF (100 mL) was added MeOH at room temperature. 2 SO 4 To the mixture was added 4-(2-(2-bromophenyl)quinoline-7-yl)(methoxy)methylene)malononitrile (130 mg, 4%, 3 steps) of 1,2-dihydro-1,2-dihydro-2-pyridine-2-ol (2.0 g, 15.8 mmol, 2.0 equivalents) and DIEA (5.11 g, 39.6 mmol, 5.0 equivalents). The mixture was stirred at 80 ° C for 3 h and then concentrated under vacuum. The residue was diluted with water (100 mL) and extracted with EtOAc (150 mL X 2). The combined organic layer was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 2-((2-(2-bromophenyl)quinoline-7-yl)(methoxy)methylene)malononitrile as a yellow oil (130 mg, 4%, 3 steps), LRMS (M+H + )m / z: calculated: 390.0, found: 390.1.

[0608]

[0609] To a solution of 2-((2-(2-bromophenyl)quinolin-7-yl)(methoxy)methylene)malononitrile (130 mg, 0.33 mmol, 1.0 equiv) and 3-hydrazino-1-methylcyclobutane-1-ol (58 mg, 0.50 mmol, 1.5 equiv) in MeOH (50 mL) was added TEA (267 mg, 2.64 mmol, 8.0 equiv) at room temperature. The reaction mixture was stirred at 90 °C for 2 h, then the mixture was concentrated under vacuum and purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 5-amino-3-(2-(2-bromophenyl)quinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (90 mg, 57%) as a yellow solid. LRMS (M+H + )m / z: calculated: 474.1, found: 474.2.

[0610]

[0611] To 5-amino-3-(2-(2-bromophenyl)quinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (90 mg, 0.19 mmol, 1.0 equiv) and K 2 CO 3 To a stirred solution of (79 mg, 0.57 mmol, 3.0 equiv) in DMSO (10 mL) was added H 2 O 2 (30% in water, 430 mg, 3.8 mmol, 20.0 equivalents). After the addition was complete, at room temperature, the reaction mixture was stirred at 60 ° C for 1 h, then diluted with water (50 mL) and extracted with EtOAc (50 mL × 2). The combined organic layer was washed with brine (50 mL), dried over anhydrous sodium sulfate and purified by preparative HPLC to give 5-amino-3-(2-(2-bromophenyl)quinoline-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide (51 mg, 0.10 mmol, 55%) as a white solid. LRMS (M+H + )m / z: calculated: 492.1, found: 492.0. 1 H NMR (DMSO-d 6,400MHz)δ8.49(d,1H),8.19(s,1H),8.09(d,1H),7.74-7.85(m,3H),7.64(d,1H),7.56(td,1H),7.44(t d,1H),6.29(s,2H),5.19(s,1H),4.42-4.51(m,1H),2.59-2.65(m,2H),2.36-2.42(m,2H),1.34(s,3H).

[0612] Example 39: Preparation of 5-amino-3-(2-(4-fluorophenyl)quinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide

[0613]

[0614] To a solution of methyl 2-bromoquinoline-7-carboxylate (2 g, 7.5 mmol, 1.0 equiv) in dioxane (100 mL) were added (4-fluorophenyl)boronic acid (2.1 g, 15.1 mmol, 2.0 equiv), Pd(PPh 3 ) 4 (436.2 mg, 0.38 mmol, 0.05 eq) and Cs 2 CO 3 (11.1 g, 15.0 mmol, 2.0 equiv.). The mixture was stirred at 120 ° C for 1 h, then concentrated under vacuum and diluted with water (100 mL), and extracted with EtOAc (150 mL × 2). The combined organic layer was washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give 2-(4-fluorophenyl)quinoline-7-carboxylic acid methyl ester (1.5 g, 71.4%) as a white solid. LRMS (M+H + )m / z: calculated: 282.1, found: 282.1.

[0615]

[0616] To methyl 2-(4-fluorophenyl)quinoline-7-carboxylate (1.5 g, 5.3 mmol, 1.0 equiv) was dissolved in MeOH (100 mL) and H 2To the solution in 4% 4-fluorophenyl)quinoline-7-carboxylic acid (1.4 g, ca. 100%) was added NaOH (320.3 mg, 8.0 mmol, 1.5 eq). The mixture was stirred at room temperature for 15 h, then concentrated under vacuum and diluted with water (60 mL), and 37% HCl was added to adjust to pH 2. The resulting mixture was stirred for 5 min, filtered and concentrated under vacuum to give 2-(4-fluorophenyl)quinoline-7-carboxylic acid (1.4 g, ca. 100%) as a white solid, LRMS (M+H + )m / z: calculated: 268.1, found: 268.1.

[0617]

[0618] To a solution of 2-(4-fluorophenyl)quinoline-7-carboxylic acid (1.4 g, 5.2 mmol, 1.0 equiv) in DCM (100 mL) was added (COCl) at -78 °C. 2 (2.2 mL, 26.2 mmol, 5.0 equiv) and DMF (5 drops). The mixture was stirred at room temperature for 7 h and then concentrated under vacuum to give 2-(4-fluorophenyl)quinoline-7-carbonyl chloride as a yellow solid (2.3 g, about 100.0%), LRMS (M+H + ) m / z: Calculated: 282.1, found: 282.1 in MeOH.

[0619]

[0620] In an ice bath, malononitrile (301.1 mg, 4.6 mmol, 1.0 equiv) and DIEA (2.3 mL, 13.7 mmol, 3.0 equiv) were added to a solution of 2-(4-fluorophenyl)quinoline-7-carbonyl chloride (1.3 g, 4.6 mmol, 1.0 equiv) in THF (100 mL). The mixture was stirred at room temperature for 3 h, then concentrated and diluted with water (120 mL). The resulting mixture was extracted with EtOAc (350 mL X 2). The combined organic layers were washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH=50 / 1, v / v) to give 2-((2-(4-fluorophenyl)quinoline-7-yl)(hydroxy)methylene)malononitrile as a yellow oil (1.3 g, 86%), LRMS (M+H + )m / z: calculated: 316.1, found: 316.1.

[0621]

[0622] To a solution of 2-((2-(4-fluorophenyl)quinolin-7-yl)(hydroxy)methylene)malononitrile (1.3 g, 4.1 mmol, 1.0 equiv) in THF (70 mL) was added MeOH at room temperature. 2 SO 4 To the mixture was added 4-(2-(4-fluorophenyl)quinoline-7-yl)(methoxy)methylene)malononitrile (0.8 mL, 8.3 mmol, 2.0 equiv.) and DIEA (2.7 mL, 20.6 mmol, 5.0 equiv.). The mixture was stirred at 80 ° C for 3 h, then concentrated under vacuum and diluted with water (120 mL), and extracted with EtOAc (250 mL × 2). The combined organic layer was washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 2-((2-(4-fluorophenyl)quinoline-7-yl)(methoxy)methylene)malononitrile as a yellow oil (410 mg, 31.4%), LRMS (M+H + )m / z: calculated: 330.1, found: 330.1.

[0623]

[0624] To a solution of 2-((2-(4-fluorophenyl)quinolin-7-yl)(methoxy)methylene)malononitrile (230 mg, 0.70 mmol, 1.0 equiv) and (1s, 3s)-3-hydrazino-1-methylcyclobutane-1-ol (121.6 mg, 1.0 mmol, 1.5 equiv) in MeOH (50 mL) was added TEA (0.8 mL, 5.6 mmol, 8.0 equiv) at room temperature. The reaction mixture was stirred at 90 ° C for 2 h, and then the mixture was concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 5-amino-3-(2-(4-fluorophenyl)quinolin-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (140 mg, 48%) as a yellow solid. LRMS (M+H + )m / z: calculated: 414.2, found: 414.3.

[0625]

[0626] At room temperature, 5-amino-3-(2-(4-fluorophenyl)quinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (140 mg, 0.34 mmol, 1.0 equiv) and K 2 CO 3To a stirred solution of (140.1 mg, 1.0 mmol, 3.0 equiv) in DMSO (20 mL) was added H 2 O 2 (30%, 0.8mL, 6.8mmol, 20.0 equivalents). After the addition was complete, the reaction mixture was stirred at 60 ° C for 1h. The reaction was diluted with water (80mL) and extracted with EtOAc (200mL). The combined organic layer was washed with brine (100mL), dried over anhydrous sodium sulfate and purified by preparative HPLC to give 5-amino-3-(2-(4-fluorophenyl)quinoline-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide (34.4mg, 23%) as a white solid. LRMS (M+H + )m / z: calculated: 432.2, found: 432.2. 1 H NMR (DMSO-d 6 ,400MHz)δ8.49(d,1H),8.35-8.39(m,2H),8.16-8.20(m,2H),8.05(d,1H),7.77(dd,1H),7.36-7.43(m ,2H),6.30(s,2H),5.19(s,1H),4.42-4.51(m,1H),2.59-2.65(m,2H),2.36-2.42(m,2H),1.34(s,3H).

[0627] Example 40: Preparation of 5-amino-3-(2-(2-fluorophenyl)quinolin-7-yl)-1-((1r,3r)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide

[0628]

[0629] At room temperature, 5-amino-3-(2-(2-fluorophenyl)quinolin-7-yl)-1-((1r,3r)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (45 mg, 0.11 mmol, 1.0 equiv) and K 2 CO 3 To a stirred solution of (40.1 mg, 0.29 mmol, 3.0 equiv) in DMSO (10 mL) was added H 2 O 2(30%, 0.2mL, 2.2mmol, 20.0 equivalents). After the addition was complete, the reaction mixture was stirred at 60 ° C for 1h. Water (30mL) was added and the mixture was extracted with EtOAc (50mL). The organic extract was washed with brine (30mL), dried over anhydrous sodium sulfate and purified by preparative HPLC to give 5-amino-3-(2-(2-fluorophenyl)quinoline-7-yl)-1-((1r, 3r)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide (15mg, 0.034mmol, 32%) as a white solid. LRMS (M+H + )m / z: calculated: 432.2, found: 432.2. 1 H NMR (DMSO-d 6 ,400MHz)δ8.50(d,1H),8.22(s,1H),8.05-8.10(m,2H),7.94(dd,1H),7.82(d,1H),7.55-7.59(m,1 H),7.37-7.43(m,2H),6.27(s,2H),4.98(s,1H),4.92-4.96(m,1H),2.39-2.55(m,4H),1.35(s,3H).

[0630] Example 41: Preparation of 5-amino-3-(2-(3-fluorophenyl)quinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide

[0631]

[0632] To a solution of methyl 2-bromoquinoline-7-carboxylate (6 g, 22.6 mmol, 1.0 equiv) in dioxane (100 mL) were added (3-fluorophenyl)boronic acid (6.3 g, 45.3 mmol, 2.0 equiv), Pd(PPh 3 ) 4 (1.3 g, 1.1 mmol, 0.05 equiv and Cs 2 CO 3 (14.7 g, 45.2 mmol, 2.0 equiv.). The mixture was stirred at 120 ° C for 1 h, then concentrated under vacuum and diluted with water (100 mL), and extracted with EtOAc (150 mL × 2). The combined organic layer was washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give 2-(3-fluorophenyl)quinoline-7-carboxylic acid methyl ester (2.2 g, 35%) as a white solid. LRMS (M+H +)m / z: calculated: 282.1, found: 282.1.

[0633]

[0634] To methyl 2-(3-fluorophenyl)quinoline-7-carboxylate (2.2 g, 7.8 mmol, 1.0 equiv) was dissolved in MeOH (100 mL) and H 2 To the solution in 4% 4-nitropropene (10 mL) was added NaOH (469.8 mg, 11.7 mmol, 1.5 eq). The mixture was stirred at room temperature for 15 h, then concentrated under vacuum and diluted with water (60 mL), and 37% HCl was added to adjust to pH 2. The resulting mixture was stirred for 5 min, filtered and concentrated under vacuum to give 2-(3-fluorophenyl)quinoline-7-carboxylic acid (1.4 g, 62%) as a white solid, LRMS (M+H + )m / z: calculated: 268.1, found: 268.1.

[0635]

[0636] To a solution of 2-(3-fluorophenyl)quinoline-7-carboxylic acid (1.4 g, 5.2 mmol, 1.0 equiv) in DCM (100 mL) was added (COCl) at -78 °C. 2 (2.2 mL, 26.2 mmol, 5.0 equiv) and DMF (5 drops). The mixture was stirred at room temperature for 7 h and then concentrated under vacuum to give 2-(3-fluorophenyl)quinoline-7-carbonyl chloride as a yellow solid (2.0 g, about 100.0%), LRMS (M+H + ) m / z: Calculated: 282.1, found: 282.1 in MeOH.

[0637]

[0638] In an ice bath, malononitrile (463.2 mg, 7.0 mmol, 1.0 equiv) and DIEA (3.7 mL, 21.1 mmol, 3.0 equiv) were added to a solution of 2-(3-fluorophenyl)quinoline-7-carbonyl chloride (2 g, 7.0 mmol, 1.0 equiv) in THF (100 mL). The mixture was stirred at room temperature for 3 h, then concentrated and diluted with water (120 mL). The resulting mixture was extracted with EtOAc (350 mL X2). The combined organic layers were washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH=50 / 1, v / v) to give 2-((2-(3-fluorophenyl)quinoline-7-yl)(hydroxy)methylene)malononitrile as a yellow oil (1.0 g, 66%), LRMS (M+H + )m / z: calculated: 316.1, found: 316.1.

[0639]

[0640] To a solution of 2-((2-(3-fluorophenyl)quinolin-7-yl)(hydroxy)methylene)malononitrile (1.0 g, 3.2 mmol, 1.0 equiv) in THF (70 mL) was added MeOH at room temperature. 2 SO 4 To the mixture was added 4-(2-(3-fluorophenyl)quinoline-7-yl)(methoxy)methylene)malononitrile (0.6 mL, 6.3 mmol, 2.0 equiv.) and DIEA (2.7 mL, 15.9 mmol, 5.0 equiv.). The mixture was stirred at 80 ° C for 3 h, then concentrated under vacuum and diluted with water (120 mL), extracted with EtOAc (250 mL × 2). The combined organic layers were washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 2-((2-(3-fluorophenyl)quinoline-7-yl)(methoxy)methylene)malononitrile as a yellow oil (100 mg, 10%), LRMS (M+H + )m / z: calculated: 330.1, found: 330.1.

[0641]

[0642] To a solution of 2-((2-(3-fluorophenyl)quinolin-7-yl)(methoxy)methylene)malononitrile (100 mg, 0.30 mmol, 1.0 equiv) and (1s,3s)-3-hydrazino-1-methylcyclobutane-1-ol (52.9 mg, 0.46 mmol, 1.5 equiv) in MeOH (50 mL) was added TEA (0.4 mL, 2.4 mmol, 8.0 equiv) at room temperature. The reaction mixture was stirred at 85 °C for 2 h, then the mixture was concentrated under vacuum and purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 5-amino-3-(2-(3-fluorophenyl)quinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (50 mg, 40%) as a yellow solid. LRMS (M+H + )m / z: calculated: 414.2, found: 414.3.

[0643]

[0644] At room temperature, 5-amino-3-(2-(3-fluorophenyl)quinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (50 mg, 0.12 mmol, 1.0 equiv) and K 2 CO 3 (50.1 mg, 0.36 mmol, 3.0 equiv) was added to a solution of H 2 O 2 (30%, 0.3mL, 2.4mmol, 20.0 equivalents). After the addition was complete, the reaction mixture was stirred at 60 ° C for 1h. The mixture was diluted with water (80mL) and extracted with EtOAc (200mL). The combined organic layer was washed with brine (100mL), dried over anhydrous sodium sulfate and purified by preparative HPLC to give 5-amino-3-(2-(3-fluorophenyl)quinoline-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide (21.3mg, 44%) as a white solid. LRMS (M+H + )m / z: calculated: 432.2, found: 432.1. 1 H NMR (DMSO-d 6,400MHz)δ8.52(d,1H),8.21-8.24(m,2H),8.16(d,1H),8.11(d,1H),8.07(d,1H),7.79(dd,1H),7.60-7.64(m,1H), 7.35-7.39(m,1H),6.30(s,2H),5.19(s,1H),4.42-4.51(m,1H),2.59-2.65(m,2H),2.36-2.42(m,2H),1.34(s,3H).

[0645] Example 42: Preparation of 5-amino-3-(8-fluoro-4-hydroxy-2-phenylquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide

[0646]

[0647] To a stirred solution of 5-amino-3-(8-fluoro-4-methoxy-2-phenylquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide (60 mg, 0.13 mmol, 1.0 equiv) in ACN (3 mL) was added TMSI (42 mg, 0.39 mmol, 3.0 equiv) and NaI (20 mg, 0.39 mmol, 3.0 equiv). 2 Under 4% saturation, the reaction mixture was stirred at 80 ° C for 16h. The mixture was diluted with water (10mL) and extracted with EtOAc (20mL × 3). The combined organic layer was washed with brine (100mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by preparative HPLC to give 5-amino-3-(8-fluoro-4-hydroxy-2-phenylquinoline-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide (30mg, 51%) as a white solid. LRMS (M+H + )m / z: calculated: 448.2, found: 448.2. 1 H NMR(MeOD,400MHz)δ8.18(d,1H),7.85(t,2H),7.48-7.58(m,4H),6.69(brs ,1H),4.43-4.48(m,1H),2.73-2.79(m,2H),2.57-2.62(m,2H),1.46(s,3H).

[0648] Example 43: Preparation of 5-amino-3-(4-ethoxy-2-phenylquinolin-7-yl)-1-(3-oxocyclobutyl)-1H-pyrazole-4-carboxamide

[0649]

[0650] To a solution of 2-((4-ethoxy-2-phenylquinolin-7-yl)(methoxy)methylene)malononitrile (600 mg, 1.7 mmol, 1.0 equiv) in EtOH (50 mL) was added NH 2 NH 2 .H 2 O (810 mg, 16.9 mmol, 10.0 equiv). The reaction mixture was stirred at 90 ° C for 2 h, then concentrated under vacuum and diluted with water (20 mL). The reaction mixture was stirred for 5 min and filtered. The solid was dried to give 5-amino-3-(4-ethoxy-2-phenylquinoline-7-yl)-1H-pyrazole-4-carbonitrile (520 mg, 86%) as a yellow solid, LRMS (M+H + )m / z: calculated: 356.1, found: 356.2.

[0651]

[0652] In N 2 To a stirred solution of 5-amino-3-(4-ethoxy-2-phenylquinolin-7-yl)-1H-pyrazole-4-carbonitrile (420 mg, 1.18 mmol, 1.0 equiv) was dissolved concentrated H 2 SO 4 (5 mL). The reaction mixture was stirred at room temperature for 15 h. The reaction mixture was carefully added to water (100 mL) at 0 °C. Na 2 CO 3 To adjust the pH to 12-13, the mixture was then extracted with DCM (80 mL x 2). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give 5-amino-3-(4-ethoxy-2-phenylquinoline-7-yl)-1H-pyrazole-4-carboxamide (370 mg, 84%) as a white solid. LRMS (M+H + )m / z: calculated: 374.2, found: 374.2.

[0653]

[0654] To a solution of 5-amino-3-(4-ethoxy-2-phenylquinolin-7-yl)-1H-pyrazole-4-carboxamide (420 mg, 1.1 mmol, 1.0 eq) in DMF (10 mL) were added 3-bromocyclobutane-1-one (200.0 mg, 1.4 mmol, 1.2 eq) and K 2CO 3 (93.2mg, 0.68mmol, 0.6 equivalent). After the addition was completed, the mixture was stirred at room temperature for 2h. The reaction mixture was diluted with water (50mL) and extracted with EtOAc (50mL x 3). The combined organic layer was washed with brine (30mL x 2), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by preparative HPLC to obtain 5-amino-3-(4-ethoxy-2-phenylquinoline-7-yl)-1-(3-oxocyclobutyl)-1H-pyrazole-4-carboxamide (170mg, 34%). LRMS (M+H + )m / z: calculated: 442.2, found: 442.6. 1 H NMR (DMSO-d 6, 400MHz) δ8.28-8.31(m,2H),8.18(d,1H),8.14(d,1H),7.71(dd,1H),7.50-7.57(m ,4H),6.44(s,2H),5.12-5.16(m,1H),4.48(q,2H),3.59-3.62(m,4H),1.53(t,3H).

[0655] Example 44: Preparation of 5-amino-3-(4-(difluoromethoxy)-8-fluoro-2-phenylquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide

[0656]

[0657] To a solution of 5-amino-3-(8-fluoro-4-hydroxy-2-phenylquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide (15.0 mg, 0.033 mmol, 1.0 equiv) in DMF (10 mL) was added K 2 CO 3(9.3mg, 0.067mmol, 2.0 equivalents) and 2-chloro-2,2-difluoroacetic acid sodium (7.7mg, 0.05mmol, 1.5 equivalents). After the addition was completed, the mixture was stirred at 50 ° C for 1h. The reaction mixture was diluted with water (50mL) and extracted with EtOAc (50mL × 3). The combined organic layer was washed with brine (30mL × 2) and concentrated under vacuum. The resulting residue was purified by preparative HPLC to obtain 5-amino-3-(4-(difluoromethoxy)-8-fluoro-2-phenylquinoline-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide (2.5mg, 15.6%). LRMS (M+H + )m / z: calculated: 498.2, found: 498.1. 1 H NMR (DMSO-d 6, 400MHz) δ8.32(d,2H),7.95-7.98(m,2H),7.56-7.74(m,4H),6.31(s,2H),5.19 (s,1H),4.42-4.49(m,1H),2.55-2.61(m,2H),2.36-2.39(m,2H),1.33(s,3H).

[0658] Example 45: Preparation of 5-amino-3-(8-fluoro-4-methoxy-2-phenylquinolin-7-yl)-1-((1r,3r)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide

[0659]

[0660] To a solution of 2-((8-fluoro-4-methoxy-2-phenylquinolin-7-yl)(methoxy)methylene)malononitrile (500 mg, 1.39 mmol, 1.0 equiv) and 3-hydrazino-1-methylcyclobutane-1-ol (242 mg, 2.08 mmol, 1.5 equiv) in MeOH (15 mL) was added TEA (1.12 g, 11.1 mmol, 8.0 equiv) at room temperature. The reaction mixture was stirred at 90 ° C for 2 h and then concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=2 / 1, v / v) to give 5-amino-3-(8-fluoro-4-methoxy-2-phenylquinolin-7-yl)-1-((1r, 3r)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (100 mg, 16%) as a white solid. LRMS (M+H + )m / z: calculated: 444.2, found: 444.3.

[0661]

[0662] At room temperature, 5-amino-3-(8-fluoro-4-methoxy-2-phenylquinolin-7-yl)-1-((1r,3r)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (80 mg, 0.18 mmol, 1.0 equiv) and K 2 CO 3 To a stirred solution of (75 mg, 0.54 mmol, 3.0 equiv) in DMSO (3 mL) was added H 2 O 2 (30%, 203 mg, 1.8 mmol, 10.0 equiv). After the addition was complete, the mixture was stirred at 60 ° C for 2 h, then diluted with water (15 mL) and extracted with EtOAc (30 mL × 2). The combined organic layer was washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by preparative HPLC to give 5-amino-3-(8-fluoro-4-methoxy-2-phenylquinoline-7-yl)-1-((1r, 3r)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide (24 mg, 29%) as a white solid. LRMS (M+H + )m / z: calculated value: 462.2, found value: 462.2, 1 H NMR (DMSO-d 6, 400MHz) δ8.32-8.35(m,2H),7.98(d,1H),7.68(s,1H),7.52-7.59(m,4H),6.29(s, 2H),4.97(s,1H),4.94-4.96(m,1H),4.21(s,3H),2.40-2.50(m,4H),1.33(s,3H).

[0663] Example 46: Preparation of 5-amino-3-(2-(2-fluorophenyl)-4-methoxyquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide

[0664]

[0665] To a solution of methyl 2-bromo-4-methoxyquinoline-7-carboxylate (5.0 g, 16.9 mmol, 1.0 equiv) in dioxane (100 mL) were added (2-fluorophenyl)boronic acid (4.7 g, 33.9 mmol, 2.0 equiv), Pd(PPh 3 ) 4 (979 mg, 0.8 mmol, 0.05 eq) and Cs 2 CO3 (11.1 g, 33.9 mmol, 2.0 equiv.). The mixture was stirred at 120 ° C for 15 h, then concentrated under vacuum and diluted with water (100 mL), extracted with EtOAc (150 mL × 2). The combined organic layer was washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give methyl 2-(2-fluorophenyl)-4-methoxyquinoline-7-carboxylate (4.5 g, 86%) as a white solid. LRMS (M+H + )m / z: calculated: 312.1, found: 312.1.

[0666]

[0667] To methyl 2-(2-fluorophenyl)-4-methoxyquinoline-7-carboxylate (4.5 g, 14.5 mmol, 1.0 equiv) was dissolved in MeOH (100 mL) and H 2 To the solution in 4% 4-nitropropene (10 mL) was added NaOH (868.2 mg, 21.7 mmol, 1.5 eq). The mixture was stirred at 50 °C for 6 h, then concentrated under vacuum and diluted with water (100 mL), and 37% HCl was added to adjust to pH 2. The resulting mixture was stirred for 5 min, filtered and dried to give 2-(2-fluorophenyl)-4-methoxyquinoline-7-carboxylic acid (4 g, 93%) as a white solid, LRMS (M+H + )m / z: calculated: 298.1, found: 298.1.

[0668]

[0669] To a solution of 2-(2-fluorophenyl)-4-methoxyquinoline-7-carboxylic acid (4 g, 13.5 mmol, 1.0 equiv) in DCM (100 mL) was added (COCl) at -78 °C. 2 (3.4 mL, 40.4 mmol, 3.0 equiv) and DMF (0.1 mL). The mixture was stirred at room temperature for 1 h and then concentrated under vacuum to give 2-(2-fluorophenyl)-4-methoxyquinoline-7-carbonyl chloride as a yellow solid (5 g, about 100.0%), LRMS (M+H + ) m / z: Calculated: 312.1, found: 312.1 in MeOH.

[0670]

[0671] In an ice bath, malononitrile (1.0 g, 15.8 mmol, 1.0 equiv) and DIEA (8.3 mL, 47.6 mmol, 3.0 equiv) were added to a solution of 2-(2-fluorophenyl)-4-methoxyquinoline-7-carbonyl chloride (5.0 g, 15.9 mmol, 1.0 equiv) in THF (200 mL). The mixture was stirred at room temperature for 3 h, then concentrated under vacuum and diluted with water (200 mL). The resulting mixture was extracted with EtOAc (300 mL x 2). The combined organic layers were washed with brine (300 mL), dried over anhydrous sodium sulfate, dried and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH=50 / 1, v / v) to give 2-((2-(2-fluorophenyl)-4-methoxyquinolin-7-yl)(hydroxy)methylene)malononitrile as a yellow oil (10.0 g, 100%), LRMS (M+H + )m / z: calculated: 346.1, found: 346.1.

[0672]

[0673] To a solution of 2-((2-(2-fluorophenyl)-4-methoxyquinolin-7-yl)(hydroxy)methylene)malononitrile (3.1 g, 9.0 mmol, 1.0 equiv) in THF (100 mL) was added MeOH at room temperature. 2 SO 4 The mixture was stirred at 80 ° C for 3 h, then concentrated under vacuum and diluted with water (200 mL), extracted with EtOAc (500 mL × 2). The combined organic layer was washed with brine (500 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 2-((2-(2-fluorophenyl)-4-methoxyquinoline-7-yl)(methoxy)methylene)malononitrile as a yellow oil (1.2 g, 37%), LRMS (M+H + )m / z: calculated: 360.1, found: 360.1.

[0674]

[0675] To a solution of 2-((2-(2-fluorophenyl)-4-methoxyquinolin-7-yl)(methoxy)methylene)malononitrile (1.2 g, 3.3 mmol, 1.0 equiv) and (1s, 3s)-3-hydrazino-1-methylcyclobutane-1-ol (581.6 mg, 5.0 mmol, 1.5 equiv) in MeOH (80 mL) was added TEA (3.7 mL, 26.7 mmol, 8.0 equiv) at room temperature. The reaction mixture was stirred at 80 ° C for 2 h and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 5-amino-3-(2-(2-fluorophenyl)-4-methoxyquinolin-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (1.2 g, 75%) as a yellow solid. LRMS(M+H + )m / z: calculated: 444.2, found: 444.2.

[0676]

[0677] At room temperature, 5-amino-3-(2-(2-fluorophenyl)-4-methoxyquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (1.2 g, 2.7 mmol, 1.0 equiv) and K 2 CO 3 To a stirred solution of (1.1 g, 8.1 mmol, 3.0 equiv) in DMSO (50 mL) was added H 2 O 2 (30%, 6.1mL, 54.2mmol, 20.0 equivalents). After the addition was completed, the reaction mixture was stirred at room temperature for 15h. Water (150mL) was added and the mixture was extracted with EtOAc (150mL x 2). The organic extract was washed with brine (100mL), dried over anhydrous sodium sulfate, filtered and concentrated. The resulting residue was purified by preparative HPLC to give 5-amino-3-(2-(2-fluorophenyl)-4-methoxyquinoline-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide (720mg, 60%) as a white solid. LRMS (M+H + )m / z: calculated: 462.2, found: 462.2. 1 H NMR (DMSO-d 6,400MHz) δ8.20(d,1H),8.14(d,1H),7.99-8.04(m,1H),7.77(dd,1H),7.53-7.59(m,1H),7.37-7.42(m,3H),6 .29(s,2H),5.20(s,1H),4.44-4.49(m,1H),4.12(s,3H),2.59-2.64(m,2H),2.36-2.41(m,2H),1.34(s,3H).

[0678] Example 47: Preparation of 5-amino-3-(2-(2-fluorophenyl)-4-methoxyquinolin-7-yl)-1-((1r,3r)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide

[0679]

[0680] To a solution of 2-((2-(2-fluorophenyl)-4-methoxyquinolin-7-yl)(methoxy)methylene)malononitrile (100 mg, 0.28 mmol, 1.0 equiv) and 3-hydrazino-1-methylcyclobutane-1-ol (48.5 mg, 0.42 mmol, 1.5 equiv) in MeOH (15 mL) was added TEA (225.1 mg, 2.2 mmol, 8.0 equiv) at room temperature. The reaction mixture was stirred at 90 ° C for 2 h and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=2 / 1, v / v) to give 5-amino-3-(2-(2-fluorophenyl)-4-methoxyquinolin-7-yl)-1-(3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (100 mg, 81%) as a white solid. LRMS (M+H + )m / z: calculated: 444.2, found: 444.3.

[0681]

[0682] At room temperature, 5-amino-3-(2-(2-fluorophenyl)-4-methoxyquinolin-7-yl)-1-(3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (100 mg, 0.22 mmol, 1.0 equiv) and K 2 CO 3 To a stirred solution of (30 mg, 0.66 mmol, 3.0 equiv) in DMSO (3 mL) was added H 2 O 2(30%, 248 mg, 2.2 mmol, 10.0 equiv). The mixture was stirred at 60 ° C for 1 h, then diluted with water (15 mL) and extracted with EtOAc (30 mL × 2). The combined organic layer was washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by preparative HPLC to give 5-amino-3-(2-(2-fluorophenyl)-4-methoxyquinoline-7-yl)-1-((1r, 3r)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide (20 mg, 0.043 mmol, yield 20%) as a white solid. LRMS (M+H + )m / z: calculated value: 462.2, found value: 462.3, 1 H NMR (DMSO-d 6 ,400MHz)δ8.19(d,1H),8.13(d,1H),8.01(td,1H),7.76(dd,1H),7.53-7.59(m,1H),7.37-7.41( m,3H),6.26(s,2H),4.97(s,1H),4.91-4.96(m,1H),4.12(s,3H),2.38-2.54(m,4H),1.35(s,3H).

[0683] Examples 48 and 49: Preparation of 5-amino-3-(2-(3-fluorophenyl)-4-methoxyquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide and 5-amino-3-(2-(3-fluorophenyl)-4-methoxyquinolin-7-yl)-1-((1r,3r)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide

[0684]

[0685] To a solution of methyl 2-bromo-4-methoxyquinoline-7-carboxylate (4.0 g, 13.6 mmol, 1.0 equiv) in dioxane (100 mL) were added (3-fluorophenyl)boronic acid (3.8 g, 27.1 mmol, 2.0 equiv), Pd(PPh 3 ) 4 (783.7 mg, 0.7 mmol, 0.05 eq) and Cs 2 CO 3(8.8 g, 27.1 mmol, 2.0 equiv). The mixture was stirred at 120 ° C for 15 h, then concentrated under vacuum, diluted with water (100 mL) and extracted with EtOAc (150 mL × 2). The combined organic layer was washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA = 5 / 1, v / v) to give 2- (3-fluorophenyl) -4-methoxyquinoline -7- carboxylic acid methyl ester (1.9 g, 45%) as a yellow solid. LRMS (M + H + )m / z: calculated: 312.1, found: 312.1.

[0686]

[0687] To methyl 2-(3-fluorophenyl)-4-methoxyquinoline-7-carboxylate (1.9 g, 6.1 mmol, 1.0 equiv) was dissolved in MeOH (100 mL) and H 2 To the solution in 4% 4-nitropropene (10 mL) was added NaOH (366.6 mg, 9.1 mmol, 1.5 eq). The mixture was stirred at 50 °C for 6 h, then concentrated under vacuum and diluted with water (20 mL), and 37% HCl was added to adjust to pH 2. The resulting mixture was stirred for 5 min, filtered and dried to give 2-(3-fluorophenyl)-4-methoxyquinoline-7-carboxylic acid (1.4 g, 78%) as a white solid, LRMS (M+H + )m / z: calculated: 298.1, found: 298.1.

[0688]

[0689] To a solution of 2-(3-fluorophenyl)-4-methoxyquinoline-7-carboxylic acid (800 mg, 2.7 mmol, 1.0 equiv) in DCM (50 mL) was added (COCl) at -78 °C. 2 (0.7 mL, 8.1 mmol, 3.0 equiv) and DMF (0.1 mL). The mixture was stirred at room temperature for 1 h and concentrated under vacuum to give 2-(3-fluorophenyl)-4-methoxyquinoline-7-carbonyl chloride as a yellow solid (848 mg, about 100.0%), LRMS (M+H + ) m / z: Calculated: 312.1, found: 312.1 in MeOH.

[0690]

[0691] In an ice bath, malononitrile (177.7 mg, 2.7 mmol, 1.0 equiv) and DIEA (1.4 mL, 8.1 mmol, 3.0 equiv) were added to a solution of 2-(3-fluorophenyl)-4-methoxyquinoline-7-carbonyl chloride (848 mg, 2.7 mmol, 1.0 equiv) in THF (50 mL). The mixture was stirred at room temperature for 3 h, then concentrated under vacuum and diluted with water (100 mL). The resulting mixture was extracted with EtOAc (100 mL x 2). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH=50 / 1, v / v) to give 2-((2-(3-fluorophenyl)-4-methoxyquinolin-7-yl)(hydroxy)methylene)malononitrile as a yellow oil (600 mg, 64.6%), LRMS (M+H + )m / z: calculated: 346.1, found: 346.1.

[0692]

[0693] To a solution of 2-((2-(3-fluorophenyl)-4-methoxyquinolin-7-yl)(hydroxy)methylene)malononitrile (600 mg, 1.7 mmol, 1.0 equiv) in THF (50 mL) was added Me 2 SO 4 The mixture was stirred at 80 ° C for 3 h, then concentrated under vacuum and diluted with water (100 mL), extracted with EtOAc (100 mL × 2). The combined organic layer was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 2-((2-(3-fluorophenyl)-4-methoxyquinoline-7-yl)(methoxy)methylene)malononitrile as a yellow oil (200 mg, 32%), LRMS (M+H + )m / z: calculated: 360.1, found: 360.1.

[0694]

[0695] To a solution of 2-((2-(3-fluorophenyl)-4-methoxyquinolin-7-yl)(methoxy)methylene)malononitrile (200 mg, 0.56 mmol, 1.0 equiv) and 3-hydrazino-1-methylcyclobutane-1-ol (96.9 mg, 0.84 mmol, 1.5 equiv) in MeOH (80 mL) was added TEA (0.6 mL, 4.5 mmol, 8.0 equiv) at room temperature. The reaction mixture was stirred at 80 °C for 2 h, then concentrated under vacuum and purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 5-amino-3-(2-(3-fluorophenyl)-4-methoxyquinolin-7-yl)-1-(3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (128.0 mg, 50%) as a yellow solid. LRMS (M+H + )m / z: calculated: 444.2, found: 444.2.

[0696]

[0697] At room temperature, 5-amino-3-(2-(3-fluorophenyl)-4-methoxyquinolin-7-yl)-1-((1r,3r)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (120 mg, 0.27 mmol, 1.0 equiv) and K 2 CO 3 To a stirred solution of (112 mg, 0.81 mmol, 3.0 equiv) in DMSO (5 mL) was added H 2 O 2 (30%, 612mg, 5.4mmol, 20.0 equivalents). After addition was completed, the reaction mixture was stirred at room temperature for 15h. Water (50mL) was added and the mixture was extracted with EtOAc (50mL x 2). The organic extract was washed with brine (50mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by preparative HPLC to obtain 5-amino-3-(2-(3-fluorophenyl)-4-methoxyquinoline-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide (25.5mg, 50%) and 5-amino-3-(2-(3-fluorophenyl)-4-methoxyquinoline-7-yl)-1-((1r, 3r)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide (22mg, 18%) as a white solid.

[0698] 5-amino-3-(2-(3-fluorophenyl)-4-methoxyquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide: LRMS (M+H+ )m / z: calculated: 462.2, found: 462.3. 1 H NMR (DMSO-d 6 ,400MHz)δ8.13-8.21(m,4H),7.73(dd,1H),7.63(s,1H),7.57-7.62(m,1H),7.34-7.38(m,1H),6.29(s ,2H),5.20(s,1H),4.44-4.49(m,1H),4.20(s,3H),2.59-2.64(m,2H),2.36-2.41(m,2H),1.34(s,3H).

[0699] 5-amino-3-(2-(3-fluorophenyl)-4-methoxyquinolin-7-yl)-1-((1r,3r)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide: LRMS (M+H + )m / z: calculated: 462.2, found: 462.3. 1 H NMR (DMSO-d 6 ,400MHz)δ8.13-8.21(m,4H),7.73(dd,1H),7.63(s,1H),7.57-7.62(m,1H),7.34-7.3 8(m,1H),6.27(s,2H),4.92-4.98(m,2H),4.20(s,3H),2.38-2.54(m,4H),1.35(s,3H).

[0700] Example 50: Preparation of 5-amino-3-(8-fluoro-2-(2-fluorophenyl)-4-methoxyquinolin-7-yl)-1-((1r,3r)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide

[0701]

[0702] To a solution of 2-((8-fluoro-2-(2-fluorophenyl)-4-methoxyquinolin-7-yl)(methoxy)methylene)malononitrile (1.1 g, 2.9 mmol, 1.0 eq) and 3-hydrazino-1-methylcyclobutane-1-ol (406 mg, 3.5 mmol, 1.2 eq) in MeOH (50 mL) was added TEA (3.2 mL, 23.3 mmol, 8.0 eq) at room temperature. The reaction mixture was stirred at 80 °C for 2 h and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=2 / 1, v / v) to give 5-amino-3-(8-fluoro-2-(2-fluorophenyl)-4-methoxyquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (240 mg, 18%) as a yellow solid, LRMS (M+H + )m / z: calculated: 462.2, found: 462.4.

[0703]

[0704] To a stirred solution of 5-amino-3-(8-fluoro-2-(2-fluorophenyl)-4-methoxyquinolin-7-yl)-1-((1r,3r)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (220 mg, 0.48 mmol, 1.0 equiv) in DMSO (6 mL) was added K 2 CO 3 (331 mg, 2.4 mmol, 5.0 equiv) and H 2 O 2 (30%, 1.1 g, 9.6 mmol, 20.0 equivalents). After the addition was complete, the mixture was stirred at 60 ° C for 2 h, then diluted with water (20 mL) and extracted with EtOAc (50 mL X2). The combined organic layer was washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by preparative HPLC to give 5-amino-3-(8-fluoro-2-(2-fluorophenyl)-4-methoxyquinoline-7-yl)-1-((1r, 3r)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide as a white solid (135 mg, 59%), LRMS (M+H + )m / z: calculated: 480.2, found: 480.3. 1 H NMR (DMSO-d 6,400MHz)δ7.99-8.05(m,2H),7.55-7.62(m,2H),7.47(d,1H),7.38-7.43(m,2H),6.29 (s,2H),4.98(s,1H),4.92-4.97(m,1H),4.14(s,3H),2.38-2.51(m,4H),1.33(s,3H).

[0705] Examples 51 and 52: Preparation of 5-amino-3-(6-fluoro-4-methoxy-2-phenylquinolin-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide and 5-amino-3-(6-fluoro-4-methoxy-2-phenylquinolin-7-yl)-1-((1r, 3r)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide

[0706]

[0707] 3- bromo-4-fluoroaniline (13.0 g, 68.4 mmol, 1.0 equiv) and 5- (methoxymethylene) -2,2- dimethyl -1,3- dioxane -4,6- dione (12.7 g, 132.2 mmol, 1.0 equiv) in dioxane (200 mL) mixture. The mixture was stirred at 120 ° C for 1 h, then cooled to room temperature and diluted with PE (500 mL). The precipitate was filtered to obtain 5- (((3- bromo-4-fluorophenyl) amino) methylene) -2,2- dimethyl -1,3- dioxane -4,6- dione (21 g, 88%) as a yellow solid.

[0708]

[0709] 5-(((3-bromo-4-fluorophenyl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione (21 g, 61.2 mmol, 1.0 equiv) and Ph 2 O (250mL) was stirred at 240°C for 1 h. The mixture was cooled to room temperature and diluted with PE (200mL), and the precipitate was filtered to give 7-bromo-6-fluoroquinolin-4-ol and 5-bromo-6-fluoroquinolin-4-ol (11.6 g, 79%) as brown solids. LRMS (M+H+) m / z: calculated: 242.0, found: 242.1.

[0710]

[0711] To a solution of 7-bromo-6-fluoroquinolin-4-ol and 5-bromo-6-fluoroquinolin-4-ol (11.6 g, 48.1 mmol, 1.0 eq.) in toluene (120 mL) was added POCl 3 (9.2 mL, 96.2 mmol, 2 eq.) The mixture was stirred at 100 °C for 1 h, then poured into ice and washed with saturated Na 2 CO 3 The aqueous solution was adjusted to pH 13 and extracted with DCM (500 mL x 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give 7-bromo-4-chloro-6-fluoroquinoline (5.5 g, 50.0%) as a yellow solid, LRMS (M+H+) m / z: calculated: 259.9, found: 260.0. 1 H NMR (DMSO-d 6 ,400MHz) δ8.86(d,1H),8.52(d,1H),8.03(d,1H),7.85(d,1H).

[0712]

[0713] MeONa (789.2 mg, 14.6 mmol, 2.0 equiv) was added to a solution of 7-bromo-4-chloro-6-fluoroquinoline (1.9 g, 7.3 mmol, 1.0 equiv) in MeOH (80 mL). The mixture was stirred at 40 ° C for 15 h, then concentrated under vacuum, diluted with water (100 mL) and extracted with EtOAc (150 mL × 2). The combined organic layers were washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give 7-bromo-6-fluoro-4-methoxyquinoline (850 mg, 50%) as a white solid. LRMS (M+H + )m / z: calculated: 256.0, found: 256.0.

[0714]

[0715] To 7-bromo-6-fluoro-4-methoxyquinoline (850 mg, 3.3 mmol, 1.0 eq), DPPP (547.2 mg, 1.3 mmol, 0.4 eq) and Pd(OAc) was added. 2(148.8mg, 0.66mmol, 0.2 eq) TEA (2.3mL, 16.6mmol, 5.0 eq) was added to a solution of DMSO / MeOH (50mL / 50mL). The mixture was stirred at 80°C for 15h under CO (1atm), then the reaction mixture was diluted with water (100mL) and extracted with EtOAc (100mL X 3). The combined organic layers were washed with brine (100mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give 6-fluoro-4-methoxyquinoline-7-carboxylic acid methyl ester (468mg, 61%) as a white solid. LRMS (M+H + )m / z: calculated: 236.1, found: 236.2.

[0716]

[0717] A mixture of methyl 6-fluoro-4-methoxyquinoline-7-carboxylate (468 mg, 2.0 mmol, 1.0 eq) and hydrogen peroxide (0.9 mL of a 30% solution, 0.34 mol, 4.0 eq) AcOH (20 mL) was stirred at 90 °C for 15 h, then concentrated in vacuo to give 6-fluoro-4-methoxy-7-(methoxycarbonyl)quinoline 1-oxide (400 mg, 80%) as a yellow solid. LRMS (M+H + )m / z: calculated: 252.1, found: 252.2.

[0718]

[0719] To a solution of 6-fluoro-4-methoxy-7-(methoxycarbonyl)quinoline 1-oxide (400 mg, 1.6 mmol, 1.0 equiv) in DCM (80 mL) was added POBr at 0 °C. 3 (594.5 mg, 2.1 mmol, 1.3 eq) and DMF (2 drops). The mixture was stirred at room temperature for 15 h, then poured into ice and washed with saturated Na 2 CO 3 The aqueous solution was adjusted to pH 13 and extracted with DCM (100 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give methyl 2-bromo-6-fluoro-4-methoxyquinoline-7-carboxylate (124.7 mg, 24%) as a yellow solid, LRMS (M+H + )m / z: calculated: 314.0, found: 314.0.

[0720]

[0721] To a solution of methyl 2-bromo-6-fluoro-4-methoxyquinoline-7-carboxylate (125 mg, 0.40 mmol, 1.0 equiv) in dioxane (30 mL) were added phenylboronic acid (97.4 mg, 0.80 mmol, 2.0 equiv), Pd(PPh 3 ) 4 (46.2 mg, 0.04 mmol, 0.1 eq) and Cs 2 CO 3 (260.4mg, 0.80mmol, 2.0 equivalents). The mixture was stirred at 120 ° C for 5h, then concentrated under vacuum and diluted with water (50mL), extracted with EtOAc (50mL × 2). The combined organic layer was washed with brine (50mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give 6-fluoro-4-methoxy-2-phenylquinoline-7-carboxylic acid methyl ester (100mg, 80%) as a yellow solid. LRMS (M+H + )m / z: calculated: 312.1, found: 312.1.

[0722]

[0723] To methyl 6-fluoro-4-methoxy-2-phenylquinoline-7-carboxylate (100 mg, 0.32 mmol, 1.0 equiv) in MeOH (50 mL) and H 2 To a solution of 4-nitro-2-nitro-1-yl-2-nitro-2-ol (10 mL) was added NaOH (19.3 mg, 0.48 mmol, 1.5 eq). The mixture was stirred at 50 °C for 6 h, then concentrated under vacuum and diluted with water (20 mL), and 37% HCl was added to adjust to pH = 2. The resulting mixture was stirred for 5 min, filtered and dried to give 6-fluoro-4-methoxy-2-phenylquinoline-7-carboxylic acid (100 mg, 100%) as a yellow solid, LRMS (M+H + )m / z: calculated: 298.1, found: 298.1.

[0724]

[0725] To a solution of 6-fluoro-4-methoxy-2-phenylquinoline-7-carboxylic acid (100 mg, 0.33 mmol, 1.0 equiv) in DCM (50 mL) was added (COCl) at -78 °C. 2(0.1 mL, 1.0 mmol, 3.0 equiv) and DMF (2 drops). The mixture was stirred at room temperature for 1 h and then concentrated under vacuum to give 6-fluoro-4-methoxy-2-phenylquinoline-7-carbonyl chloride as a yellow solid (120 mg, about 100.0%), LRMS (M+H + ) m / z: Calculated: 312.1, found: 312.1 in MeOH.

[0726]

[0727] In an ice bath, malononitrile (25.1 mg, 0.38 mmol, 1.0 equiv) and DIEA (0.2 mL, 1.1 mmol, 3.0 equiv) were added to a solution of 6-fluoro-4-methoxy-2-phenylquinoline-7-carbonyl chloride (120 mg, 0.38 mmol, 1.0 equiv) in THF (20 mL). The mixture was stirred at room temperature for 3 h, then concentrated under vacuum and diluted with water (100 mL). The resulting mixture was extracted with EtOAc (100 mL X 2). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH=50 / 1, v / v) to give 2-(6-fluoro-4-methoxy-2-phenylquinoline-7-carbonyl) malononitrile as a yellow oil (91 mg, 70%), LRMS (M+H + )m / z: calculated: 346.1, found: 346.1.

[0728]

[0729] To a solution of 2-(6-fluoro-4-methoxy-2-phenylquinoline-7-carbonyl)malononitrile (91 mg, 0.26 mmol, 1.0 equiv) in THF (30 mL) was added MeOH at room temperature. 2 SO 4 To the mixture was added 4-(6-fluoro-4-methoxy-2-phenylquinoline-7-yl)(methoxy)methylene)malononitrile (66.5 mg, 0.53 mmol, 2.0 equiv.) and DIEA (0.2 mL, 0.8 mmol, 3.0 equiv.). The mixture was stirred at 80 ° C for 3 h, then concentrated under vacuum and diluted with water (50 mL), extracted with EtOAc (50 mL × 2). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 2-((6-fluoro-4-methoxy-2-phenylquinoline-7-yl)(methoxy)methylene)malononitrile as a yellow oil (50 mg, 53%), LRMS (M+H +)m / z: calculated: 360.1, found: 360.1.

[0730]

[0731] To a solution of 2-((6-fluoro-4-methoxy-2-phenylquinolin-7-yl)(methoxy)methylene)malononitrile (50 mg, 0.14 mmol, 1.0 equiv) and 3-hydrazino-1-methylcyclobutane-1-ol (24.2 mg, 0.21 mmol, 1.5 equiv) in MeOH (30 mL) was added TEA (0.2 mL, 1.1 mmol, 8.0 equiv) at room temperature. The reaction mixture was stirred at 80 °C for 2 h, then the mixture was concentrated under vacuum and purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 5-amino-3-(6-fluoro-4-methoxy-2-phenylquinolin-7-yl)-1-(3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (20.0 mg, 32.7%) as a yellow solid. LRMS (M+H + )m / z: calculated: 444.2, found: 444.2.

[0732]

[0733] At room temperature, 5-amino-3-(6-fluoro-4-methoxy-2-phenylquinolin-7-yl)-1-(3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (20 mg, 0.045 mmol, 1.0 equiv) and K 2 CO 3 To a stirred solution of (18.6 mg, 0.14 mmol, 3.0 equiv) in DMSO (20 mL) was added H 2 O 2 (30%, 0.1mL, 0.9mmol, 20.0 equivalents). After addition was completed, the reaction mixture was stirred at room temperature for 15h. The mixture was diluted with water (50mL) and extracted with EtOAc (50mL × 2). The combined organic layer was washed with brine (50mL), dried over anhydrous sodium sulfate and concentrated under vacuum. The resulting residue was purified by preparative HPLC to obtain 5-amino-3-(6-fluoro-4-methoxy-2-phenylquinoline-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide (2.2mg, 11%) and 5-amino-3-(6-fluoro-4-methoxy-2-phenylquinoline-7-yl)-1-((1r, 3r)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide (4.2mg, 12%) as a white solid.

[0734] 5-amino-3-(6-fluoro-4-methoxy-2-phenylquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide: LRMS (M+H + )m / z: calculated: 462.2, found: 462.1. 1 H NMR (DMSO-d 6 ,400MHz)δ8.31(d,2H),8.07(d,1H),7.82(d,1H),7.63(s,1H),7.51-7.59(m,3H),6.28(s ,2H),4.44-4.49(m,1H),4.20(s,3H),2.59-2.64(m,2H),2.36-2.41(m,2H),1.34(s,3H). 19 FNMR (DMSO-d 6 ,377MHz)δ-115.5(s,1F).

[0735] 5-amino-3-(6-fluoro-4-methoxy-2-phenylquinolin-7-yl)-1-((1r,3r)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide: LRMS (M+H + )m / z: calculated: 462.2, found: 462.1. 1 H NMR (DMSO-d 6 ,400MHz)δ8.31(d,2H),8.07(d,1H),7.82(d,1H),7.63(s,1H),7.51-7.59(m,3H ),6.25(s,2H),4.92-4.97(m,1H),4.20(s,3H),2.38-2.51(m,4H),1.33(s,3H). 19 F NMR (DMSO-d 6 ,377MHz)δ-115.5(s,1F).

[0736] Example 53: Preparation of 5-amino-3-(4-(difluoromethoxy)-2-phenylquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide

[0737]

[0738] To a solution of 5-amino-3-(4-hydroxy-2-phenylquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide (40.0 mg, 0.09 mmol, 1.0 equiv) in DMF (10 mL) was added K2 CO 3 (25.6mg, 0.18mmol, 2.0 equivalents) and 2-chloro-2,2-difluoroacetic acid sodium (21.6mg, 0.14mmol, 1.5 equivalents). The mixture was stirred at 50 ° C for 1h. The reaction mixture was diluted with water (50mL) and extracted with EtOAc (50mL x 3). The combined organic layer was washed with brine (30mL x 2) and concentrated under vacuum. The resulting residue was purified by preparative HPLC to give 5-amino-3-(4-(difluoromethoxy)-2-phenylquinoline-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide (1.8mg, 5%). LRMS (M+H + )m / z: calculated: 480.2, found: 480.1. 1 H NMR (400MHz, DMSO) δ8.29.8.32(m,2H),8.24(d,1H),8.16(d,1H),7.84-7.90(m,2H),7.54-7.93(m,3 H),6.28(s,2H),5.21(s,1H),4.44-4.49(m,1H),2.57-2.68(m,2H),2.32-2.41(m,2H),1.34(s,3H).

[0739] Example 54: Preparation of 5-amino-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-3-(2-phenylquinazolin-7-yl)-1H-pyrazole-4-carboxamide

[0740]

[0741] To methyl 2-chloroquinazoline-7-carboxylate (1.0 g, 4.5 mmol, 1.0 equiv) was added in DME / EtOH / H 2 Phenylboronic acid (823.5 mg, 6.8 mmol, 1.5 equiv), Pd(PPh 3 ) 2 Cl 2 (315.9 mg, 0.45 mmol, 0.1 eq) and K 2 CO 3(1.8 g, 13.5 mmol, 3.0 equiv.). The mixture was stirred at 120 ° C for 15 h. The mixture was diluted with water (50 mL) and extracted with EtOAc (50 mL × 3). The combined organic layer was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH = 10 / 1, v / v) to give 2-phenylquinazoline-7-carboxylic acid (500 mg, 44.2%) as a yellow solid. LRMS (M + H + )m / z: calculated: 251.1, found: 251.1.

[0742]

[0743] To a solution of 2-phenylquinazoline-7-carboxylic acid (500 mg, 2.0 mmol, 1.0 equiv) in DCM (10 mL) was added (COCl) at -78 °C. 2 (0.9 mL, 10.0 mmol, 5.0 equiv) and DMF (2 drops). The mixture was stirred at room temperature for 2 h and then concentrated under vacuum to give 2-phenylquinazoline-7-carbonyl chloride as a yellow solid (500 mg, about 100.0%). LRMS (M+H + ) m / z: Calculated: 265.1, found: 265.1 in MeOH.

[0744]

[0745] In an ice bath, malononitrile (250.8 mg, 3.8 mmol, 2.0 equiv) and DIEA (1.0 mL, 5.7 mmol, 3.0 equiv) were added to a solution of 2-phenylquinazoline-7-carbonyl chloride (500 mg, 1.9 mmol, 1.0 equiv) in THF (10 mL). The mixture was stirred at room temperature for 2 h, then concentrated and diluted with water (20 mL). The resulting mixture was extracted with EtOAc (30 mL X 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH=10 / 1, v / v) to give 2-(hydroxy(2-phenylquinazoline-7-yl)methylene)malononitrile as a yellow oil (400 mg, 71.9%). LRMS (M+H + )m / z: calculated: 299.1, found: 299.1.

[0746]

[0747] To a solution of 2-(hydroxy(2-phenylquinazolin-7-yl)methylene)malononitrile (400 mg, 1.3 mmol, 1.0 equiv) in THF (10 mL) was added Me 2 SO 4 The product was stirred for 3 hours at 80 ° C. and then concentrated under vacuum, diluted with water (20 mL) and extracted with EtOAc (30 mL × 2). The combined organic layer was washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=1 / 1, v / v) to give 2-(methoxy(2-phenylquinazolin-7-yl)methylene)malononitrile as a yellow oil (200 mg, 47.8%). LRMS (M+H + )m / z: calculated: 313.1, found: 313.1.

[0748]

[0749] A mixture of 2-(methoxy(2-phenylquinazolin-7-yl)methylene)malononitrile (200 mg, 0.64 mmol, 1.0 equiv), (1s,3s)-3-hydrazine-1-methylcyclobutane-1-ol (111.2 mg, 0.96 mmol, 1.5 equiv) and TEA (0.4 mL, 1.92 mmol, 3.0 equiv) in 5.0 mL of EtOH was stirred at 80 °C for 2 h. The mixture was concentrated and the resulting residue was purified by column chromatography on silica gel (DCM / MeOH=10 / 1, v / v) to give 5-amino-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-3-(2-phenylquinazolin-7-yl)-1H-pyrazole-4-carbonitrile as a yellow oil (150 mg, 59.3%). LRMS (M+H + )m / z: calculated: 397.2, found: 397.2.

[0750]

[0751] To a solution of 5-amino-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-3-(2-phenylquinazolin-7-yl)-1H-pyrazole-4-carbonitrile (50 mg, 0.13 mmol, 1.0 equiv) in DMSO (3.0 mL) was added K 2 CO 3 (54 mg, 0.39 mmol, 3.0 equiv) and H 2 O 2(1mL). After the addition was completed, the mixture was stirred at 60 ° C for 1h. Water (20mL) was added and the mixture was extracted with EtOAc (50mL × 3). The combined organic layer was washed with brine (30mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by preparative HPLC to give 5-amino-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-3-(2-phenylquinazoline-7-yl)-1H-pyrazole-4-carboxamide as a white solid (8.0mg, 15.4%). LRMS (M+H + )m / z: calculated: 415.2, found: 415.2. 1 H NMR (DMSO-d 6 ,400MHz)δ9.71(s,1H),8.58-8.60(m,2H),8.18-8.20(d,2H),7.92-7.95(m,1H),7.56-7.59(m,3H ),6.26(s,2H),5.19(s,1H),4.45-4.49(m,1H),2.59-2.67(m,2H),2.37-2.41(m,2H),1.34(s,3H).

[0752] Example 55: Preparation of 5-amino-3-(5-fluoro-4-methoxy-2-phenylquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide

[0753]

[0754] A mixture of 3-bromo-5-fluoroaniline (5.0 g, 26.4 mmol, 1.0 equiv) and 5-(methoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione (4.9 g, 26.4 mmol, 1.0 equiv) in dioxane (100 mL) was stirred at 120 ° C for 1 h. The mixture was cooled to room temperature and diluted with PE (100 mL). The precipitate was filtered to give 5-(((3-bromo-5-fluorophenyl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione (8.2 g, >100%) as a yellow solid. LRMS (M+H + )m / z: calculated: 344.0, found: 286.0, 304.1.

[0755]

[0756] 5-(((3-bromo-5-fluorophenyl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione (8.2 g, 23.9 mmol, 1.0 equiv) and Ph 2 O (100mL) and the mixture was stirred at 240 ° C for 1h. The mixture was cooled to room temperature and diluted with PE (100mL). The precipitate was filtered to obtain a mixture of 7-bromo-5-fluoroquinoline-4-ol and 5-bromo-7-fluoroquinoline-4-ol (4.5g, 78%) as a brown solid. LRMS (M+H+) m / z: calculated value: 242.0, found value: 242.1.

[0757]

[0758] To a solution of 7-bromo-5-fluoroquinolin-4-ol and 5-bromo-7-fluoroquinolin-4-ol (4.5 g, 18.7 mmol, 1.0 eq.) in toluene (120 mL) was added POCl 3 (5.7 g, 37.3 mmol, 2 eq.) The mixture was stirred at 100 °C for 1 h, then poured into ice and washed with saturated Na 2 CO 3 The aqueous solution was adjusted to pH 13 and extracted with DCM (500 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give 7-bromo-4-chloro-5-fluoroquinoline and 5-bromo-4-chloro-7-fluoroquinoline (3.9 g, 79%) as yellow solids, LRMS (M+H+) m / z: calculated: 259.9, found: 260.0.

[0759]

[0760] A mixture of 7-bromo-4-chloro-5-fluoroquinoline and 5-bromo-4-chloro-7-fluoroquinoline (3.1 g, 12 mmol, 1.0 eq.) and MeONa (970 mg, 18 mmol, 1.5 eq.) in MeOH (50 mL) was stirred at 40 °C for 1 h. LCMS showed that the reaction was complete. The reaction was purified by H 2 O (50 mL) and extracted with EtOAc (50 mL x 3). The combined organic layers were purified by Na 2 SO 4 The residue was dried, filtered and concentrated in vacuo. The obtained residue was purified by column chromatography on silica gel (PE / EtOAc=10 / 1, v / v) to give 7-bromo-5-fluoro-4-methoxyquinoline and 5-bromo-7-fluoro-4-methoxyquinoline as yellow oil (2.4 g, 80%). LRMS (M+H +)m / z: calculated: 256.0, found: 256.0.

[0761]

[0762] 7-Bromo-5-fluoro-4-methoxyquinoline and 5-Bromo-7-fluoro-4-methoxyquinoline (2.4 g, 9.4 mmol, 1.0 eq), DPPP (780 mg, 1.8 mmol, 0.2 eq) and Pd(OAc) were added. 2 (210.6 mg, 0.94 mmol, 0.1 eq.) TEA (3.8 mL, 28.2 mmol, 3.0 eq.) was added to a solution of DMSO / MeOH (20 mL / 20 mL). The mixture was stirred at 80 ° C for 15 h under CO (5 atm) and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=10 / 1, v / v) to give 5-fluoro-4-methoxyquinoline-7-carboxylic acid methyl ester and 7-fluoro-4-methoxyquinoline-5-carboxylic acid methyl ester (1.8 g, 72%) as yellow oils. LRMS (M+H + )m / z: calculated: 236.1, found: 236.1.

[0763]

[0764] To a stirred solution of methyl 5-fluoro-4-methoxyquinoline-7-carboxylate and methyl 7-fluoro-4-methoxyquinoline-5-carboxylate (1.8 g, 7.7 mmol, 1.0 eq) in DCM (20 mL) was added m-CPBA (1.9 g, 11.5 mmol, 1.5 eq) at room temperature. The mixture was stirred at room temperature for 12 h, then poured into ice and concentrated by adding saturated Na 2 CO 3 The aqueous solution was adjusted to pH 13 and extracted with DCM (30 mL x 3). The combined organic layers were dried over sodium sulfate and concentrated under vacuum to give a mixture of 5-fluoro-4-methoxy-7-(methoxycarbonyl)quinoline 1-oxide and 7-fluoro-4-methoxy-5-(methoxycarbonyl)quinoline 1-oxide (1.5 g, 78.9%) as a yellow oil. LRMS (M+H + )m / z: calculated: 252.1, found: 252.1.

[0765]

[0766] To a solution of 5-fluoro-4-methoxy-7-(methoxycarbonyl)quinoline 1-oxide and 7-fluoro-4-methoxy-5-(methoxycarbonyl)quinoline 1-oxide (1.5 g, 5.9 mmol, 1.0 equiv) in DCM (20 mL) was added POBr at -78 °C. 3 (2.2 g, 7.8 mmol, 1.3 eq) and DMF (2.3 mL, 2.9 mmol, 0.5 eq). The mixture was stirred at 45 °C for 15 h, then poured into ice and stirred for 15 min by adding saturated Na 2 CO 3 The aqueous solution was adjusted to pH 13 and extracted with DCM (30 mL x 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give methyl 2-bromo-5-fluoro-4-methoxyquinoline-7-carboxylate (600 mg, 31.6%) as a yellow solid. LRMS (M+H + )m / z: calculated: 314.0, found: 314.0. 1 HNMR (DMSO-d 6 ,400MHz) δ8.16(s,1H),7.66(dd,1H),7.37(s,1H),4.07(s,3H),3.94(s,3H).

[0767]

[0768] To a solution of methyl 2-bromo-5-fluoro-4-methoxyquinoline-7-carboxylate (600 mg, 1.9 mmol, 1.0 equiv) in dioxane (10 mL) were added phenylboronic acid (467.7 mg, 3.8 mmol, 2.00 equiv), Pd(PPh 3 ) 4 (219 mg, 0.19 mmol, 0.1 eq) and Cs 2 CO 3 (1.8 g, 5.7 mmol, 3.0 equiv.). The mixture was stirred at 80 ° C for 5 h, then concentrated under vacuum and diluted with water (100 mL), and extracted with EtOAc (150 mL × 2). The combined organic layer was washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA = 5 / 1, v / v) to give 5-fluoro-4-methoxy-2-phenylquinoline-7-carboxylic acid methyl ester (410 mg, 68.3%) as a white solid. LRMS (M + H + )m / z: calculated: 312.1, found: 312.1.

[0769]

[0770] To methyl 5-fluoro-4-methoxy-2-phenylquinoline-7-carboxylate (410 mg, 1.3 mmol, 1.0 equiv) was dissolved in MeOH (6.0 mL) and H 2 To a solution in 4% 4-nitropropene (2.0 mL) was added NaOH (80 mg, 2.0 mmol, 1.5 eq). The mixture was stirred at 50 °C for 15 h, then concentrated under vacuum and diluted with water (50 mL). 37% HCl was added to adjust to pH 2. The resulting mixture was stirred for 5 min, filtered and concentrated under vacuum to give 5-fluoro-4-methoxy-2-phenylquinoline-7-carboxylic acid (350 mg, 89.7%) as a white solid. LRMS (M+H + )m / z: calculated: 298.1, found: 298.1.

[0771]

[0772] To a solution of 5-fluoro-4-methoxy-2-phenylquinoline-7-carboxylic acid (350 mg, 1.2 mmol, 1.0 equiv) in DCM (10 mL) was added (COCl) at 0 °C. 2 (0.6 mL, 6.0 mmol, 5.0 equiv) and DMF (2 drops). The mixture was stirred at room temperature for 2 h and then concentrated under vacuum to give 5-fluoro-4-methoxy-2-phenylquinoline-7-carbonyl chloride as a yellow solid (340 mg, 91.9%). LRMS (M+H + ) m / z: Calculated: 312.1, found: 312.1 in MeOH.

[0773]

[0774] In an ice bath, malononitrile (145.2 mg, 2.2 mmol, 2.0 equiv) and DIEA (0.6 mL, 3.3 mmol, 3.0 equiv) were added to a solution of 5-fluoro-4-methoxy-2-phenylquinoline-7-carbonyl chloride (340 mg, 1.1 mmol, 1.0 equiv) in THF (10 mL). The mixture was stirred at room temperature for 2 h, then concentrated and diluted with water (20 mL). The resulting mixture was extracted with EtOAc (30 mL X 3). The combined organic layers were washed with brine (40 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH=10 / 1, v / v) to give 2-(5-fluoro-4-methoxy-2-phenylquinoline-7-carbonyl) malononitrile as a yellow oil (350 mg, 94.1%). LRMS (M+H+ )m / z: calculated: 346.1, found: 346.1.

[0775]

[0776] To a solution of 2-(5-fluoro-4-methoxy-2-phenylquinoline-7-carbonyl)malononitrile (350 mg, 1.0 mmol, 1.0 equiv) in THF (10 mL) was added MeOH at room temperature. 2 SO 4 The mixture was stirred at 80 ° C for 3 h, then concentrated under vacuum, diluted with water (20 mL) and extracted with EtOAc (30 mL × 2). The combined organic layer was washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give 2-((5-fluoro-4-methoxy-2-phenylquinoline-7-yl)(methoxy)methylene)malononitrile as a yellow oil (130 mg, 36.1%). LRMS (M+H + )m / z: calculated: 360.1, found: 360.1.

[0777]

[0778] To a solution of 2-((5-fluoro-4-methoxy-2-phenylquinolin-7-yl)(methoxy)methylene)malononitrile (130 mg, 0.36 mmol, 1.0 equiv) in EtOH (5.0 mL) was added (1s, 3s)-3-hydrazine-1-methylcyclobutane-1-ol (63 mg, 0.54 mmol, 1.5 equiv) and TEA (1.4 mL, 10.1 mmol, 3.0 equiv). The reaction mixture was stirred at 80 °C for 2 h, then concentrated under vacuum and purified by column chromatography on silica gel (DCM / MeOH=10 / 1, v / v) to give 5-amino-3-(5-fluoro-4-methoxy-2-phenylquinolin-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile as a yellow oil (100 mg, 62.5%). LRMS(M+H + )m / z: calculated: 444.2, found: 444.2.

[0779]

[0780] To a stirred solution of 5-amino-3-(5-fluoro-4-methoxy-2-phenylquinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (100 mg, 0.22 mmol, 1.0 equiv) in DMSO (3.0 mL) was added K 2 CO 3 (93.4 mg, 0.66 mmol, 3.0 equiv) and H 2 O 2 (2.0mL). After the addition was completed, the mixture was stirred at 60 ° C for 2h. Water (20mL) was added and the mixture was extracted with EtOAc (50mL × 3). The combined organic layer was washed with brine (30mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by preparative HPLC to give 5-amino-3-(5-fluoro-4-methoxy-2-phenylquinoline-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide as a white solid (76.0mg, 73.1%). LRMS (M+H + )m / z: calculated: 462.2, found: 462.2. 1 H NMR (DMSO-d 6 ,400MHz)δ8.30-8.32(m,2H),8.00-8.01(d,1H),7.52-7.59(m,4H),7.42-7.45(d,1H),6.25(s,2H ),5.20(s,1H),4.50-4.59(m,1H),4.16(s,3H),2.58-2.63(m,2H),2.35-2.40(m,2H),1.33(s,3H).

[0781] Example 56: Preparation of 5-amino-3-(8-fluoro-2-(2-fluorophenyl)quinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide

[0782]

[0783] A mixture of 2-fluorobenzaldehyde (5.0 g, 40.3 mmol, 1.0 equiv) and 2-(triphenyl-phosphinilidene)acetaldehyde (12.3 g, 40.3 mmol, 1.0 equiv) in toluene (50.0 mL) was stirred at 80° C. for 4 h. The mixture was concentrated under vacuum and the resulting residue was purified by column chromatography on silica gel (DCM / MeOH=10 / 1, v / v) to give (E)-3-(2-fluorophenyl)acrolein as a yellow oil (3.9 g, 65%).

[0784]

[0785] A mixture of (E)-3-(2-fluorophenyl)acrolein (3.9 g, 26 mmol, 1.0 eq.), 3-bromo-2-fluoroaniline (4.9 g, 26 mmol, 1.0 eq.) in toluene (40.0 mL) and 6N HCl (40 mL) was heated to reflux for 40 h. The mixture was concentrated and the residue was purified by H 2 O (50 mL). The mixture was washed with saturated NaHCO 3 Adjust to pH 13 and extract with EtOAc (50 mL x 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give 7-bromo-8-fluoro-2-(2-fluorophenyl)quinoline as a yellow oil (3.1 g, 37.3%). LRMS (M+H + )m / z: calculated: 320.0, found: 320.0.

[0786]

[0787] To 7-bromo-8-fluoro-2-(2-fluorophenyl)quinoline (3.1 g, 9.7 mmol, 1.0 eq), DPPF (799 mg, 1.9 mmol, 0.2 eq) and Pd(OAc) was added. 2 To a solution of (217.6 mg, 0.97 mmol, 0.1 eq) in DMSO / MeOH (30 mL / 30 mL) was added TEA (3.9 mL, 29.1 mmol, 3.0 eq). The mixture was stirred at 80 ° C for 20 h under CO (5 atm) and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=10 / 1, v / v) to give 8-fluoro-2-(2-fluorophenyl)quinoline-7-carboxylic acid methyl ester (960 mg, 33.1%) as a yellow solid. LRMS (M+H + )m / z: calculated: 300.1, found: 300.1.

[0788]

[0789] To methyl 8-fluoro-2-(2-fluorophenyl)quinoline-7-carboxylate (960 mg, 3.2 mmol, 1.0 equiv) was dissolved in MeOH (6.0 mL) and H 2To the solution in 4% 4-nitropropene (2.0 mL) was added NaOH (192.6 mg, 4.8 mmol, 1.5 eq). The mixture was stirred at 50 °C for 15 h, then concentrated under vacuum and diluted with water (50 mL). 37% HCl was added to adjust to pH 2. The resulting mixture was stirred for 5 min, filtered and concentrated under vacuum to give 8-fluoro-2-(2-fluorophenyl)quinoline-7-carboxylic acid (800 mg, 87.4%) as a white solid. LRMS (M+H + )m / z: calculated: 286.1, found: 286.1.

[0790]

[0791] To a solution of 8-fluoro-2-(2-fluorophenyl)quinoline-7-carboxylic acid (800 mg, 2.8 mmol, 1.0 equiv) in DCM (10 mL) was added (COCl) at 0 °C. 2 (1.4 mL, 14 mmol, 5.0 equiv) and DMF (2 drops). The mixture was stirred at room temperature for 2 h and concentrated under vacuum to give 8-fluoro-2-(2-fluorophenyl)quinoline-7-carbonyl chloride as a yellow solid (800 mg, 94.1%). LRMS (M+H + ) m / z: calcd: 300.1, found: 300.1 in MeOH.

[0792]

[0793] In an ice bath, malononitrile (348.5 mg, 5.2 mmol, 2.0 equiv) and DIEA (1.4 mL, 7.8 mmol, 3.0 equiv) were added to a solution of 8-fluoro-2-(2-fluorophenyl)quinoline-7-carbonyl chloride (800 mg, 2.6 mmol, 1.0 equiv) in THF (10 mL). The mixture was stirred at room temperature for 2 h, then concentrated and diluted with water (20 mL). The resulting mixture was extracted with EtOAc (30 mL×3). The combined organic layers were washed with brine (40 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (DCM / MeOH=10 / 1, v / v) to give 2-(8-fluoro-2-(2-fluorophenyl)quinoline-7-carbonyl)malononitrile as a yellow oil (300 mg, 34.1%). LRMS (M+H + )m / z: calculated: 334.1, found: 334.1.

[0794]

[0795] To a solution of 2-(8-fluoro-2-(2-fluorophenyl)quinoline-7-carbonyl)malononitrile (300 mg, 0.9 mmol, 1.0 equiv) in THF (10 mL) was added Me 2 SO 4 The mixture was stirred at 80 ° C for 3 h, then concentrated under vacuum, diluted with water (20 mL) and extracted with EtOAc (30 mL × 2). The combined organic layer was washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=5 / 1, v / v) to give 2-((8-fluoro-2-(2-fluorophenyl)quinoline-7-yl)(methoxy)methylene)malononitrile as a yellow oil (90 mg, 28.8%). LRMS (M+H + )m / z: calculated: 348.1, found: 348.1.

[0796]

[0797] To a solution of 2-((8-fluoro-2-(2-fluorophenyl)quinolin-7-yl)(methoxy)methylene)malononitrile (90 mg, 0.26 mmol, 1.0 equiv) in EtOH (5.0 mL) was added (1s, 3s)-3-hydrazine-1-methylcyclobutane-1-ol (64 mg, 0.39 mmol, 1.5 equiv) and TEA (0.1 mL, 0.78 mmol, 3.0 equiv). The reaction mixture was stirred at 80 °C for 2 h, then concentrated under vacuum and purified by column chromatography on silica gel (DCM / MeOH=10 / 1, v / v) to give 5-amino-3-(8-fluoro-2-(2-fluorophenyl)quinolin-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile as a yellow oil (100 mg, 90.1%). LRMS(M+H + )m / z: calculated: 432.2, found: 432.2.

[0798]

[0799] To a solution of 5-amino-3-(8-fluoro-2-(2-fluorophenyl)quinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carbonitrile (100 mg, 0.23 mmol, 1.0 equiv) in DMSO (3.0 mL) was added K 2 CO 3(94.2 mg, 0.69 mmol, 3.0 equiv) and H 2 O 2 (2.0mL). After the addition was complete, the mixture was stirred at 60 ° C for 2h. The reaction was diluted with water (50mL) and extracted with EtOAc (30mL × 3). The combined organic layer was washed with brine (30mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by preparative HPLC to give 5-amino-3-(8-fluoro-2-(2-fluorophenyl)quinoline-7-yl)-1-((1s, 3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide as a white solid (13.4mg, 12.9%). LRMS (M+H + )m / z: calculated: 450.2, found: 450.2. 1 H NMR (DMSO-d 6 ,400MHz)δ8.57-8.59(d,1H),8.02-8.09(m,2H),7.90-7.92(d,1H),7.44-7.67(m,2H),7.39-7.41(m, 2H),6.31(s,2H),5.18(s,1H),4.45-4.49(m,1H),2.50-2.60(m,2H),2.36-2.40(m,2H),1.33(s,3H).

[0800] Example 57: Preparation of 5-amino-3-(8-fluoro-2-(pyridin-2-yl)quinolin-7-yl)-1-((1s,3s)-3-hydroxy-3-methylcyclobutyl)-1H-pyrazole-4-carboxamide

[0801]

[0802] 3-Bromo-2-fluoroaniline (50.0 g, 0.26 mol, 1.0 eq.), sodium 3-nitrobenzenesulfonate (105.3 g, 0.47 mol, 1.8 eq.) and propane-1,2,3-triol (66.9 g, 0.73 mol, 2.8 eq.) were added in H 2 Concentrated H 2 SO 4(105.5mL). The mixture was stirred at 150 ° C for 2h. The mixture was poured into ice water and acidified to pH 14 with 5N sodium hydroxide aqueous solution. The mixture was extracted with EtOAc (300mL X 3). The combined organic layer was washed with brine (300mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EtOAc=5 / 1, v / v) to give 7-bromo-8-fluoroquinoline (26.0g, 43.3%) as a yellow solid. LRMS (M+H + )m / z: calculated: 226.0, found: 226.0.

[0803]

[0804] To 7-bromo-8-fluoroquinoline (26.0 g, 0.12 mol, 1.0 eq), DPPP (9.5 g, 23.1 mmol, 0.2 eq) and Pd(OAc) was added. 2 (2.7 g, 0.012 mol, 0.1 eq.) TEA (49.0 mL, 0.36 mol, 3.0 eq.) was added to a solution of DMSO / MeOH (260 mL / 260 mL). The mixture was stirred at 80 ° C for 15 h under CO (5 atm) and then concentrated under vacuum. The resulting residue was purified by column chromatography on silica gel (PE / EA=10 / 1, v / v) to give 8-fluoroquinoline-7-carboxylic acid methyl ester (11.2 g, 47.5%) as a yellow oil. LRMS (M+H + )m / z: calculated: 206.1, found: 206.1.

[0805]

[0806] To a stirred solution of methyl 8-fluoroquinoline-7-carboxylate (6.5 g, 31.7 mmol, 1.0 eq) in DCM (80 mL) was added m-CPBA (8.17 g, 47.6 mmol, 1.5 eq) at room temperature. The mixture was stirred at room temperature for 12 h, then poured into ice and concentrated by adding saturated Na 2 CO 3 The aqueous solution was adjusted to pH 13 and extracted with DCM (100 mL x 3). The combined organic layers were dried over sodium sulfate and concentrated under vacuum to give 8-fluoro-7-(methoxycarbonyl)quinoline 1-oxide (6.3 g, 90%) as a yellow oil. LRMS (M+H + )m / z: calculated: 222.1, found: 222.1.

[0807]

[0808] To a solution of 8-fluoro-7-(methoxycarbonyl)quinoline 1-oxide (3.1 g, 14.0 mmol, 1.0 equiv) in DCM (30 mL) was added POBr at -78 °C. 3 (5.2 g, 18.2 mmol, 1.3 eq) and DMF (0.5 mL, 7.0 mmol, 0.5 eq). The mixture was stirred at 45 °C for 15 h, then poured into ice and washed with saturated Na 2 CO 3 The aqueous solution was adjusted to pH 13 and extract...

Claims

1. A compound or a pharmaceutically acceptable salt or solvate thereof having a structure of formula (I): in, X is optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl; L is a bond or optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl or optionally substituted heterocyclylalkyl; R 2 is an optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl; wherein the optional substituent of the optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl is selected from cyano, halo, hydroxy, azido, amino, nitro, -CO2H, -S(O)-R 10 、-SR 10 、-S(O)2-R 10 , optionally substituted C1-C6 alkoxy, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted (heterocyclyl)-O-, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted C2-C6 alkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, -N(R 11 2. -CO-R 10 、-CO2-R 10 、-CON(R 11 )2.-NR 11 CO-R 10 、-NR 11 CO2-R 10 、-SO2N(R 11 )2, -C(=NR 12 )-N(R 11 )2.-NR 11 CO-N(R 10 )2 or -NR 11 SO2-N(R 10 )2; X 3 Is N or CR 3 ; X 4 Is N or CR 4 ; X 5 Is N or CR 5 ; X 6 Is N or CR 6 ; X 8 Is N or CR 8 ; R 3 , R 4 , R 5 , R 6 and R 8 are independently selected from hydrogen, cyano, halo, hydroxy, azido, amino, nitro, -CO2H, -S(O)-R 10 、-SR 10 、-S(O)2-R 10 , optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted C2-C6 alkenyl, optionally substituted heterocyclyl, -N(R 11 2. -CO-R 10 、-CO2-R 10 、-CON(R 11 )2.-NR 11 CO-R 10 、-NR 11 CO2-R 10 、-SO2N(R 11 )2, -C(=NR 12 )-N(R 11 )2.-NR 11 CO-N(R 10 )2 and -NR 11 SO2-N(R 10 )2; Each R 10 independently selected from optionally substituted C1-C6 alkyl, optionally substituted C3-C8 carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl and optionally substituted heteroaryl; Each R 11 independently selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; R 12 is H or optionally substituted C1-C6 alkyl; R 9 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 carbocyclyl or optionally substituted C4-C10 carbocyclylalkyl; wherein R 9 and L or R 9 and X may be taken together with any intervening atoms to form an optionally substituted heterocyclyl ring.

2. The compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein X 3 is N and X 4 Yes CR 4 .

3. The compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein X 3 Yes CR 3 And X 4 It is N.

4. The compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein X 3 Yes CR 3 And X 4 Yes CR 4 .

5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt or solvate thereof, wherein L is a bond.

6. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt or solvate thereof, wherein X is an optionally substituted C3-C7 cycloalkyl group.

7. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt or solvate thereof, wherein X is an optionally substituted C4 cycloalkyl group.

8. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt or solvate thereof, wherein X is an optionally substituted heterocyclic group.

9. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt or solvate thereof, wherein X is an optionally substituted piperidine or pyrrolidine.

10. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt or solvate thereof, wherein X is an optionally substituted piperidin-4-yl.

11. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt or solvate thereof, wherein X is an optionally substituted C1-C8 alkyl group.

12. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt or solvate thereof, wherein L is an optionally substituted cycloalkyl group.

13. The compound according to claim 12, or a pharmaceutically acceptable salt or solvate thereof, wherein X is an optionally substituted C3-C7 cycloalkyl group.

14. The compound according to claim 12, or a pharmaceutically acceptable salt or solvate thereof, wherein X is an optionally substituted heterocyclic group.

15. The compound according to claim 12, or a pharmaceutically acceptable salt or solvate thereof, wherein X is an optionally substituted C1-C8 alkyl group.

16. The compound according to claim 12, or a pharmaceutically acceptable salt or solvate thereof, wherein X is an optionally substituted C4-C10 cycloalkylalkyl group.

17. The compound according to claim 12, or a pharmaceutically acceptable salt or solvate thereof, wherein X is an optionally substituted heterocyclylalkyl group.

18. A compound according to any one of claims 1, 3, 4 or 5-17, or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 It's H.

19. A compound according to any one of claims 1, 2, 4 or 5-17, or a pharmaceutically acceptable salt or solvate thereof, wherein R 4 It's H.

20. A compound according to any one of claims 1, 2, 4 or 5-17, or a pharmaceutically acceptable salt or solvate thereof, wherein R 4 is an optionally substituted C1-C4 alkoxy group.

21. A compound as claimed in any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein X 8 It is N.

22. The compound according to any one of claims 1 to 20, or a pharmaceutically acceptable salt or solvate thereof, wherein X 8 Yes CR 8 .

23. The compound of claim 22 or a pharmaceutically acceptable salt or solvate thereof, wherein R8 It's H.

24. The compound of claim 22 or a pharmaceutically acceptable salt or solvate thereof, wherein R 8 It's a halogen.

25. The compound of claim 24 or a pharmaceutically acceptable salt or solvate thereof, wherein R 8 It's F.

26. A compound as claimed in any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein R 9 It's H.

27. A compound as claimed in any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is an optionally substituted aryl group.

28. The compound of claim 27 or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is optionally substituted phenyl.

29. The compound of claim 27 or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is phenyl substituted by at least one halogen.

30. A compound according to any one of claims 1 to 26, or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is an optionally substituted heteroaryl.

31. The compound of claim 30 or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is an optionally substituted pyridine.

32. A compound as claimed in any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein X 6 It is N.

33. A compound as described in any one of claims 1 to 31, or a pharmaceutically acceptable salt or solvate thereof, wherein X 6 Yes CR 6 .

34. The compound of claim 33 or a pharmaceutically acceptable salt or solvate thereof, wherein R 6 It's H.

35. A compound as claimed in any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein X 5 It is N.

36. A compound as described in any one of claims 1 to 34, or a pharmaceutically acceptable salt or solvate thereof, wherein X 5 Yes CR 5 .

37. The compound of claim 36 or a pharmaceutically acceptable salt or solvate thereof, wherein R5 It's H.

38. A compound or a pharmaceutically acceptable salt or solvate thereof having the structure of a compound provided in Table 1A or Table 1B.

39. A pharmaceutical composition comprising a compound according to any one of claims 1 to 38 or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable excipient.

40. A method for preparing a pharmaceutical composition, comprising mixing a compound according to any one of claims 1 to 38 or a pharmaceutically acceptable salt or solvate thereof with a pharmaceutically acceptable carrier.

41. A compound as claimed in any one of claims 1 to 38, or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of the human or animal body.

42. A compound as claimed in any one of claims 1 to 38 or a pharmaceutically acceptable salt or solvate thereof for use in a method of treating cancer or a neoplastic disease.

43. Use of a compound as claimed in any one of claims 1 to 38 or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for treating cancer or a neoplastic disease.

44. A method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of any one of claims 1-38, or a pharmaceutically acceptable salt or solvate thereof.

45. A method of treating cancer in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound as described in any one of claims 1-38, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

46. ​​A compound according to any one of claims 1 to 38, or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treating an autoimmune disease.

47. Use of a compound according to any one of claims 1 to 38 or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for treating an autoimmune disease.

48. A method of treating an autoimmune disease in a patient in need thereof, comprising administering to the patient a compound of any one of claims 1-38, or a pharmaceutically acceptable salt or solvate thereof.

49. A method of treating an autoimmune disease in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound as described in any one of claims 1-38, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

50. A compound according to any one of claims 1 to 38, or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treating thyroid eye disease.

51. Use of a compound as described in any one of claims 1 to 38 or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for treating thyroid eye disease.

52. A method of treating thyroid eye disease in a patient in need thereof, comprising administering to the patient a compound as described in any one of claims 1-38, or a pharmaceutically acceptable salt or solvate thereof.

53. A method of treating thyroid eye disease in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound as described in any one of claims 1-38, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.